JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

№ 06 (142) 2017

  • Уважаемые читатели!
    Уже стало традицией один из номеров нашего журнала посвящать проблеме полиморбидности, которая становится основной в современной медицине. Вопросы по этой теме широко обсуждаются в медицинской литературе, на конференциях, съездах и круглых столах. Передовая статья нашего номера отражает проблему кардио-дигестивных ассоциаций, наиболее часто встречающихся в практике терапевта, кардиолога и гастроэнтеролога. Также представлены алгоритмы своевременной диагностики и подбор адекватного комплексного лечения при сочетанной патологии сердечно-сосудистой системы и желудочно-кишечного тракта.
    Раздел «Клиническая гастроэнтерология» открывает оригинальная работа наших коллег из Твери проф. Джулай Г. С. с соавторами, посвященная изучению качественных и количественных характеристик микробиоценоза полости рта и эзофагогастродуоденальной зоны. В статье показано, что у больных ГЭРБ, ассоциированной с дуоденогастроэзофагеальным рефлюксом, имеют место патомикробиоценозы верхних отделов пищеварительного тракта с участием условно-патогенных микроорганизмов, которые обладают факторами патогенности и цитотоксичностью, что и определяет хронический характер воспалительных изменений в слизистых оболочках.
    Нередко объектом изучения становится сочетание гастроэнтерологической патологии с заболеваниями сердечно-сосудистой системы, что нашло отражение в работе авторов из Перми (Кравцовой Т. Ю., Заривчацкого М. Ф., Алеевой Н. Г., Блинова С. А., Репина В. Н., Вачегиной О. М., Голдобиной Г. В.), которые показали, что сочетание активации свертывающей системы крови в утренние часы с избыточным утренним подъемом систолического АД у больных артериальной гипертонией на фоне язвенной болезни 12-перстной кишки, осложнившейся острым кровотечением, может стать важнейшим и предрасполагающим фактором развития грозных сердечно-сосудистых катастроф: внезапной смерти, инсульта и/или инфаркта миокарда.
    Статья сотрудников Ижевской государственной медицинской академии Вахрушева Я. М. и Бусыгиной М. С. посвящена подробному изучению вегетативного статуса, личностной и ситуативной тревожности и качества жизни у больных язвенной болезнью желудка и двенадцатиперстной кишки и сопутствующей хронической дуоденальной недостаточностью.
    В статье Плоскиревой А. А. из Центрального НИИ эпидемиологии очень подробно изложены результаты собственных многолетних наблюдений, показывающие особенности клинических проявлений ротавирусной инфекции и ее сочетанных форм (с норовирусной инфекцией, сальмонеллезом и антибиотик-ассоциированной диареей) у детей.
    Интересную работу представили Харитонова Л. А., Атаянц О. К., Шашель В. А. и Клещенко Е. И. (Российский научно-исследовательский медицинский университет им. Н. И. Пирогова, Кубанский государственный медицинский университет и Детская краевая клиническая больница, Краснодар), в которой авторы показали, что у детей с врожденными пороками сердца чаще выявляются эрозивно-язвенные болезни, у детей с малыми аномалиями сердца – поверхностные гастродуодениты, рефлюксные нарушения. На морфофункциональное состояние верхних отделов пищеварительного тракта у детей с такой патологией сердца оказывает влияние хроническая гипоксия.
    Следующие две статьи посвящены современным генетическим исследованиям. Группа авторов Н. П. Денисенко, Д. А. Сычев, Ж. М. Сизова, Е. А. Гришина, К. А. Рыжикова, Ж. А. Созаева представили собственные результаты по изучению взаимосвязи носительства полиморфного маркера C 3435T гена ABCB 1 и клинических особенностей больных язвенной болезнью желудка и двенадцатиперстной кишки, принимающих ИПП. Показана также, что у пациентов с язвенной болезнью желудка и двенадцатиперстной кишки Московских ЛПУ отмечается высокая распространенность полиморфизма C 3435T гена ABCB 1. Наши коллеги из Харьковского национального медицинского университета Пасиешвили Л. М., Железнякова Н. М., Пасиешвили Т. М. изучали полиморфизм гена эндотелиальной NO-синтазы (eNOS) у больных гастроэзофагеальной рефлекторной болезнью (ГЭРБ) в сочетании с ожирением. В статье показано, что течение ГЭРБ в большинстве случаев происходит на фоне изменений в полиморфизме данного гена.
    В статье Д. Р. Акберовой, С. А. Кошкина, А. Х. Одинцовой и Д. И. Абдулганиевой проведена комплексная оценка кишечной проницаемости у пациентов с аутоиммунным гепатитом и синдромом перекреста. Наши коллеги Мнацаканян М. Г., Погромов А. П., Дюкова Г. М., Тащян О. В. из Первого МГМУ им. И. М. Сеченова в своей работе отразили гендерные и возрастные различия в показателях психического и физического компонентов здоровья у больных с синдромом раздраженного кишечника. Интересную совместную работу по изучению особенностей кишечной микробиоты у пациентов с язвенным колитом на основании метагеномного анализа представили коллективы авторов из Казани и Москвы (Н. А. Данилова, С. Р. Абдулхаков, Т. В. Григорьева, М. И. Маркелова, А. В. Павленко, А. В. Тяхт, В. Б. Дубинкина, Е. С. Кострюкова, А. К. Ларин, Л. О. Скородумова, А. И. Манолов, А. Х. Одинцова, Р. А. Абдулхаков).
    В статье в разделе Хирургическая гастроэнтерология авторы (А. А. Натальский, С. В. Тарасенко, О. В. Зайцев, О. Д. Песков, А. Ю. Богомолов, О. А. Кадыкова и И. В. Баконина) показали отдаленные результаты хирургического лечения больных, страдающих хроническим панкреатитом и подчеркнули, что данное заболевание является мультидисплинарной проблемой и требует внимания не только со стороны медицинских специалистов, но и длительного наблюдения психологов, социологов и социальных работников.
    Клинические исследования невозможны без основательного экспериментального базиса. Наша рубрика «Экспериментальная гастроэнтерология» представлена тремя работами. Авторы из Сибири Томова Т. А., Замощина Т. А., Федоруцева Е. Ю., Светлик М. В. выявили сезонные особенности влияния карбахола и Gly-Pro на секреторную функцию желудка у крыс с активно-поисковым, промежуточным и пассивно-оборонительным типами поведения в «открытом поле».
    Трубицина И. Е. с соавторами представили данные об определении ацетилхолина и холинестеразной активности в сыворотке крови пациентов с язвенной болезнью 12-перстной кишки, хроническим панкреатитом алкогольной этиологии и воспалительными заболеваниями кишечника (язвенный колит, болезнь Крона). В статье авторов из Санкт-Петербурга Торопова В. А., Шалаевой О. Н., Рощиной Е. К., Вахитова Т. Я., Ситкина С. И. приведены результаты по выявлению генов бактериоцинов у пробиотических штаммов Lactobacillus acidophilus Д № 75 и Lactobacillus acidophilus Д № 76, входящих в состав БАД «Витафлор».
    Нам представляются полезными как для начинающих врачей, так и для опытных специалистов лекция наших коллег из Кыргызстана (Сабировой А. И., Мамытовой А. Б., Сабирова И. С., Муркамилова И. Т.), посвященная проблеме состояния жесткости артерий при метаболическом синдроме и генерализованном парадонтите и лекция Морозовой Т. Е., Андрущишиной Т. Б. Царева И. Л. (Первый МГМУ имени И. М. Сеченова), содержащая обзор современных рекомендаций по ведению больных с инфекцией Clostridium difficilе (Сd-И), риск развития которой возрастает у больных пожилого возраста, с различными сопутствующими заболеваниями.
    Обращаем ваше внимание на обзор Барышниковой Г. А., Чорбинской С. А. и Кудрявцевой Н. А., посвященный важной для практического врача проблеме – профилактике гастроэнтерологических осложнений на фоне применения кардиологических препаратов (антиагреганты, антикоагулянты, статины). Для обсуждения мы предлагаем статью авторов из Смоленска Афанасенкова Т. Е., Дубская Е. Е., Руссиянов В. В., посвященную проблеме целесообразности применения циклоферона у пациентов с хроническим эрозивным гастритом, ассоциированным с Helicobacter pylori и герпесвирусной инфекцией. Ждем ваших отзывов.
    В разделе «Клинические наблюдения» представлен клинический случай (авторы Борисенко Т. С., Гончар Н. В., Орлов А. В., Иванова Р. А., Конев А. И.) осложненного течения муковисцедоза у грудного ребенка с развитием синдрома псевдо-Барттера, отражающего трудности дифференциальной диагностики заболевания.
    Принципиально важным, с нашей точки зрения, является раздел «История медицины». Наши коллеги из Перми Палатова Л. Ф. и Нечаев О. И. очень подробно описали историю развития дифференциальной диагностики желтух в Пермском крае.
    Редакция журнала и авторы желают Вам приятного прочтения.


    Ответственный за выпуск номера редактор,

      профессор
      Комиссаренко И. А.
       

    1. Moscow state medical and dentistry University n. a. A. I. Evdokimov (Moscow, Russian Federation)

    Keywords:gastroesophageal reflux,angina,congestive heart failure,dilated cardiomyopathy,liver cirrhosis,polymorbidity,polypharmacy

    Abstract: In this review we discuss the problem of polymorbidity and polypharmacy in the elderly patient, particularly the mutual influence of cardiovascular and gastroenterological diseases, presents algorithms for timely diagnostics and adequate selection of treatment in combined pathology.

      1. Информационный бюллетень ВОЗ №317 Январь 2015 г.
      2. Лазебник Л. Б. Полиморбидность и старение. Новости медицины и фармации. 2007;1(205). URL: bttp://archive.today/smbi
      3. Лазебник Л. Б., Дроздов В. Н. Заболевания органов пищеварения у пожилых. М.: Анахарсис, 2003. - 208 с.
      4. Лазебник Л. Б., Машарова А. А., Бордин Д. С. и др. Многоцентровое исследование «Эпидемиология Гастроэзофагеальной Рефлюксной болезни в России» (МЭГРЕ): первые итоги // Экспер. клин. гастроэнтерол. - 2009. - № 6. - С. 4-12
      5. Погромов А. П., Шишлов А. Ю., Стремоухов А. А., Дымшиц М. А. Одновременное pH и ЭКГ-мониторирование у больных с кардиалгией // Клиническая медицина. - 2001. - № 5. С. 20-24.
      6. Таранченко Ю. В., Звенигородская Л. А. Особенности диагностики гастроэзофагеальной рефлюксной болезни у больных с сопутствующей ишемической болезнью сердца // Экспериментальная и клиническая гастроэнтерология. - 2003. - № 1. - С. 110-112.
      7. Шишлов А. Ю., Дымшиц М. А. Одновременное рН- и ЭКГ-мониторирование при гастроэзофагеальной рефлюксной болезни и ишемической болезни сердца. // Актуальные вопросы внутренней медицины и педагогики. Сб. научных тр. М. ИД «Русский врач», - 2000, - С. 132-136
      8. Сорока Н. Ф., Зыбалова Т. С. Роль активации цитокинов в развитии и прогрессировании хронической сердечной недостаточности // Медицинские новости. - 2003. -№ 1. - С. 12-15.
      9. Терещенко С. Н., Жиров И. В. Хроническая сердечная недостаточность и желудочно-кишечный тракт. Лечащий врач. № 2, 2004 г. C.22-24
      10. Медведев В. Н.,.Кораблин Н. И. Алкогольная болезнь печени: диагностика и лечение острого и хронического алкогольного гепатита. Consilium medicum. 2002,4,7:17-23
      11. Möller S, Henriksen JH. Cirrhotic cardiomyopathy.J Hepatol. 2010 Jul; 53(1): 179-90. Wong F. Cirrhotic cardiomyopathy. Hepatol Int (2009) 3: 294-304
      12. Braz J et al. Is hepatitis C virus a cause of idiopathic dilated cardiomyopathy? A systematic review of literature. Infect Dis. 2006 Jun;10(3):199-202.
      13. Комиссаренко И. А., Лазебник Л. Б., Колечкина И. А., Давыдова С. С. Хроническая сердечная недостаточность, артериальная гипертония, цирротическая кардиомиопатия. Возможности медикаментозной коррекции. «Медицинский совет», № 11, 2012, с. 38-43
      14. Голованова Е. В., Комиссаренко И. А. Поражения сердца при заболеваниях печени. Терапия, № 3 (3), 2015, с. 54-61
      15. Zubiaurre L et al. Cytomegalovirus hepatitis and myopericarditis. World J Gastroenterol. 2007 Jan 28;13(4):647-8
      16. Звенигородская Л. А. Метаболический синдром: основы патогенеза, исследования в будущем. Экспериментальная и клиническая гастроэнтерология. 2007, № 1, с. 5-7
      17. Перова Н. В., Метельская В. А., Оганов Р. Г. Метаболический синдром: патогенетические связи и направления коррекции, «Кардиология», № 3, 2001, стр. 4-9.
      18. Гриневич В. Б., Мехтиев С. Н., Ратников В. А., Латышева А. Я., Кравчук Ю. А. Язвенная болезнь и метаболический синдром (механизмы формирования, клинико-инструментальные проявления и подходы к терапии). - СПб, 2006. - 31 с.
      19. Ткаченко Е. И., Успенский Ю. П., Белоусова Л. Н., Петренко В. В. Неалкогольная жировая болезнь печени и метаболический синдром: единство патогенетических механизмов и подходов к лечению. Экспериментальная и клиническая гастроэнтерология, № 2, 2008, стр. 92-96
      20. Лазебник Л. Б. Гепатоцит и атеросклероз. Клиническая геронтология. Том 18, № 1-2, 2012, с. 3-9
      21. Драпкина О. М., Гацолаева Д. С., Ивашкин В. Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома. //Российские медицинские вести, 2010, том 15, 2. с. 72-78.
      22. Драпкина О. М., Ивашкин В. Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России. //Российский журнал гастроэнтерологии гепатологии, колопроктологии. 2014, том 24, 4. с. 32-38
      23. В. Т. Ивашкин В. Т., Драпкина О. М. Маев И. В. и др. Рапространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG2. //Российский журнал гастроэнтерологии гепатологии, колопроктологии. 2015, том 6, с. 31-41
      24. Подымова С. Д. Современный взгляд на патогенез и проблему лечения неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. - 2016. - № 5. - С. 74-82.
      25. Арутюнов Г. П. и др. Хроническая сердечная недостаточность: структурные и микробиологические изменения в толстой кишке // Терапевтический архив. - 2007. - № 2. - С. 31-37.
      26. Пермяков Н. К., Яковлев М. Ю., Лиходед В. Г., Конев Ю. В. Эндотоксининдуцированные повреждения эндотелия. Архив патологии. 1996,2, т. 58, 41-46
      27. Конев Ю. В. Системная эндотоксинемия и клинико-патогенетические особенности течения атеросклероза и ишемической болезни сердца в пожилом и старческом возрасте: автореферат дис. … доктора медицинских наук: 14.00.05 / Ин-т морфологии человека РАМН. - Москва, 1997. - 43 с.: ил. РГБ ОД, 9 98-5/1474-4
      28. Полещук Е. О. Усиление эффектов адреналина на деятельность сердца под влиянием эндотоксина кишечника // Новости медико-биологических наук. - 2010. - Т. 2, № 3. - С. 46-50.
      29. Конев Ю. В., Лазебник Л. Б. Роль эндотоксина кишечной микрофлоры в патогенезе атеросклероза. Терапия. - 2015. - № 2. С 19-27
      30. Арутюнов Г. П., Кафарская Л. И., Власенко В. К. Биоценоз кишечника и сердечно-сосудистый континуум. Сердечная недостаточность 2004; 5:224-9).
      31. Ebner N, Földes G, Schomburg L, Renko K, et al. Lipopolysaccharide responsiveness is an independent predictor of death in patients with chronic heart failure. J Mol Cell Cardiol. 2015 Oct;87:48-53. doi: 10.1016/j.yjmcc.2015.07.029
      32. Anker S. D., von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004; 90:464-70. 2.
      33. Lamblin N., Mouquet F., Hennache B. et al. High-sensitivity Creactive protein: potential adjunct forrisk stratification inpatients with stable congestive heartfailure.European Heart Journal 2005; 26:2245-50.
      34. Егорова Е. Н., Кузьмина М. И., Мазур В. В. и др. Динамика факторовсистемного воспаления и аминотерминального мозгового натрийуретического пропептида при лечении хронической сердечной недостаточности. Терапевтический архив 2011; 1:56-9.
      35. Петухов В. А. Липидный дистресс-синдром (методические рекомендации)/ под ред. акад. В. С. Савельева. - М.: МАКС Пресс, 2006. - 268 с.
      36. Кишечная микрофлора и ее возможная взаимосвязь с ожирением Новости мировой медицины. Ожирение и метаболизм, 2010, № 1. С 68. Gut microbiota and its possible relationship with obesity DiBaise J.K., Zhang H., Crowell M. D., Krajmalnik-Brown R., Decker G. A., Rittmann B. E. Mayo Clin Proc., 2008, Apr.; 83(4): 460-9
      37. Плотникова Е. Ю., Краснов О. А Метаболический синдром и кишечная микрофлора: что общего? экспериментальная и клиническая гастроэнтерология выпуск 112, № 12, 2014, с. 64-73
     


    Full text is published :
    Lazebnik L.B., Komissarenko I.A., Levchenko S.V. CARDIO DIGESTIVE ASSOCIATION. Experimental and Clinical Gastroenterology Journal. 2017;142(06):04-08
    Read & Download full text

    1. Tver State Medical University (Tver, Russian Federation)

    Keywords:microflora of the digestive tract,gastroesophageal reflux disease,duodenogastroesophageal reflux

    Abstract: Aim. The study of the qualitative and quantitative characteristics of microbiocenosis of the oral cavity and esophagogastroduodenal zone in patients with gastroesophageal reflux disease (GERD), associated with duodenogastroesophageal reflux (DGER) as a manifestation of biliary pathology. Materials and methods. In 83 GERD patients with symptoms of reflux esophagitis and DGER we studied the microbial landscape of the oral fluid and biopsy samples from visually unaltered sections of the mucosa of the lower third of the esophagus, antrum and duodenum by the classical bacteriological methods. Results. Biopsy specimens from the esophagogastroduodenal zone mucosa in patients with GERD indicated high content of staphylococci (92 %) and streptococci (85 %) in amount of from 4,8 to 6,1 lg CFU/g. Bacteria of the Enterobacteriaceae family were defined in 61 % of cases in an amount of 3,1-5,4 lg CFU/g. Fungi of the genus Candida were detected in 59 % of the samples in the amount of 104-107 CFU. Bacteria characterized by cytotoxic, hemolytic and lecithinase activity were often detected in comparison with healthy people. Conclusion. The study revealed pathological microbiocenosis of upper gastrointestinal tract with opportunistic pathogens presence with factors of pathogen and cytotoxicity in patients with GERD associated with DGER, that define chronic inflammatory changes in the mucous membranes.

      1. Лазебник Л. Б., Ткаченко Е. И., Абдулганиева Д. И. и соавт. Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helcobacter pylori заболеваний (V Московские соглашения). Гастроэнтерология Санкт-Петербурга. - 2015. - № 3-4. - С. 12-18.
      2. Hopper A. D. Improving the diagnosis and management of GORD in adults. Practitioner. - 2015. - № 259 (1781). - P. 27-32.
      3. Чернин В. В., Бондаренко В. М., Червинец В. М. и соавт. Helicobacter pylori как составная часть микробиоценоза микрофлоры эзофагогастродуоденальной зоны в норме и при патологии. Экспериментальная и клиническая гастроэнтерология. - 2011. - № 8. - С. 66-72.
      4. Джулай Г. С., Секарева Е. В., Червинец В. М. и соавт. Гастроэзофагеальная рефлюксная болезнь, ассоциированная с дуоденогастроэзофагеальным рефлюксом, у больных с билиарной патологией: особенности течения и микробного биоценоза эзофагогастродуоденальной зоны. Терапевтический архив. - 2014. - № 2. - С. 17-21.
      5. Маев И. В., Гуленченко Ю. С., Андреев Д. Н. и соавт. Дуоденогастроэзофагеальный рефлюкс: клиническое значение и подходы к терапии. Consilium Medicum. - 2014. - Т. 16, № 8. - С. 5-8.
      6. Самсонов А. А., Голубев Н. Н., Андреев Н. Г. и соавт. Подходы к диагностике и лечению гастроэзофагеальной рефлюксной болезни в сочетании с дуоденогастроэзофагеальным рефлюксом. Фарматека. - 2012. - № 10. - С. 10-15.
      7. Kahrilas P. J., Keefer L., Pandolfino J. E. Patients with refractory reflux symptoms: What do they have and how should they be managed. J. Neurogastroenterol. Motil. - 2015. - № 27 (9). - P. 1195-2001.
      8. Bredenoord A. J., Hemmink G. J.M., Smout A. J.P.M. Relationship between gastro-oesophageal reflux pattern and severity of mucosal damage. J. Neurogastroenterol. Motil. - 2009. - № 21 (8). - P. 807-812.
      9. Вёрткин А. Л. Коморбидность: история, современное представление, профилактика и лечение. Кардиоваскулярная терапия и профилактика. - 2015. - Т. 14, № 2. - С. 74-79.
      10. Ткаченко Е. И., Орешко Л. С., Ситкин С. И. Гастроэнтерология XXI века с позиций многомерной биологии. Гастроэнтерология Санкт-Петербурга. - 2012. - № 2-3. - С. 2-4.
     


    Full text is published :
    Dzhulay G.S., Mikhaylova E.S., Dzhulay T.E., Samoukina A.M. MICROBIOCENOSIS OF UPPER GASTROINTESTINAL TRACT IN PATIENTS WITH GASTROESOPHAGEAL REFL UX DISEASE, ASSOCIATED WITH BILIARY PATHOLOGY. Experimental and Clinical Gastroenterology Journal. 2017;142(06):09-14
    Read & Download full text

    1. FSBEI HE Academician Ye. A. Vagner PSMU MOH Russia (Perm, Russian Federation)

    Keywords:peptic duodenal ulcer,acute gastrointestinal bleeding,arterial hypertension,hemostasis,morning surge in blood pressure

    Abstract:A comparative evaluation of the «morning load» of blood pressure and the hemostatic system in patients with peptic duodenal ulcer associated with arterial hypertension after acute gastrointestinal bleeding had been done. The study included 45 patients with hypertension who underwent gastrointestinal bleeding and 63 patients with gastrointestinal bleeding without hypertension. The combination of the activation of blood coagulation in the morning with an excessive morning rise of systolic blood pressure in hypertensive patients with duodenal ulcer complicated by acute bleeding, may be an important and a predisposing factor for the development threatening cardiovascular events: sudden death, stroke and / or myocardial infarction.

      1. Артериальная гипертония и ассоциированные с ней заболевания/Под общ. ред. проф. А. В. Туева. - Пермь: Пресс-тайм, 2007. - 416 с.
      2. Вербицкий В. Г., Багненко С. Ф., Курыгин А. А. Желудочно-кишечные кровотечения язвенной этиологии. - СПб., Политехника, 2004. - 240 с.
      3. Лазебник Л. Б., Конев Ю. В., Ефремов Л. И. Полиморбидность в клинической практике: количественная и качественная оценка. Клиническая геронтология 2012; 1-2: 36-42.
      4. Лебедев Н. В., Климов А. Е., Петухов В. А. Повторный эндоскопический гемостаз как альтернатива хирургическому лечению больных с язвенными гастродуоденальными кровотечениями. Журнал: Хирургия. Журнал им. Н. И. Пирогова 2016; 6: 52-56.
      5. Лычев В. Г. Диагностика и лечение диссеминированного внутрисосудистого свертывания. - 2-е изд., перераб. и доп. - М.: Медицинская книга; Н.Н.: Изд-во НГМА, 2001. - 192 с. Михеева О. М. Язвенная болезнь у пожилых пациентов с артериальной гипертонией. Клиническая геронтология 2008; 1: 17-29.
      6. Михеева О. М. Язвенная болезнь у пожилых пациентов с артериальной гипертонией. Клиническая геронтология 2008; 1: 17-29.
      7. Остроумова О. Д., Смолярчук Е. А., Резникова К. У. Утренние подъемы артериального давления: клиническое значение, методики расчета, возможности коррекции препаратом Лодоз. Лечебное дело 2011; 3: 41-49.
      8. Трошкина А. А., Потешкина Н. Г. Артериальная гипертензия при коморбидной патологии, вопросы терапии. РМЖ 2015; 27: 1630-1632.
      9. Kaplan N. M. Morning surge in blood pressure. Circulation 1997; 96: 19-21.
      10. Slergio G. S., Vemmos K. N., Pliarchopoulou K. M. et al. Parallel morning and evening surge in stroke onset, blood pressure and physical activity. Stroke 2002; 33: 1480-1486.
     


    Full text is published :
    Kravtsova T.Yu., Zarivchatsky M.F., Aleeva N.G.. Blinov S.A. MORNING SURGE IN BLOOD PRESSURE AND HEMOSTASIS IN PATIENTS WITH ARTERIAL HYPERTENSON ASSOCIATED WITH PEPTIC DUODENAL ULCER AFTER ACUTE GASTROINTESTINAL BLEEDING. Experimental and Clinical Gastroenterology Journal. 2017;142(06):15-19
    Read & Download full text

    1. Izhevsk State Medical Academy (Izhevsk, Russian Federation)

    Keywords:ulcer stomach disease,chronic duodenal insufficiency,vegetative status,personal and situational anxiety,quality of life

    Abstract:Purpose. The aim of the study was to analyze the vegetative status, personal and situational anxiety and quality of life in patients with peptic ulcer disease with associated chronic duodenal insufficiency (CDI), as well as the contingency of their changes with indicators of the functional state of duodenum. Materials and methods. The complex study conducted 106 patients with ulcer disease with associated CDI (observation group) and 30 patients without CDI (group of comparison). Verification of ulcer disease was performed clinically and by fibrogastroduodenoscopic researches. In determination of chronic duodenal insufficiency there were used the cavitary manometry. We have studied motor performance of the stomach and gastroduodenal ulcer with a help of peripheral electrogastrograph EGG-4М. The study of the state of the autonomic nervous system was conducted by autonomic tone (AT), autonomic reactivity (AR) and software vegetative (SV). In determining the type of temperament was used the test Eysenck questionnaire, in the assessing of trait anxiety (TA) and situational anxiety (SA) - test questionnaire Spielberg Hanina. In definition of quality of life (QL) was performed by using the SF-36 questionnaire. Results. The majority of patients from observation group was haved sympathicotonia with enhanced indicators of SA and IN. The level of coefficient of correlation power of the stomach/ duodenum was reduced postprandial against the comparison group. The vegetative status of patients with gastric ulcer without CDI was characterized by eutoniya with high AR and normal SV. The vegetative status of patients with duodenal ulcer without CDI was characterized by parasympathikotoniya, reduced AR, excess SV. In the comparison group the levels of TA and SA were reduced in relation to the observation group, the levels of the coefficient of correlation power of the stomach / duodenum have normokinetic values. The patients with ulcer disease with associated CDI have significant changes in quality of life, manifested in the reduction of the mental and physical well-being. Conclusion. Chronic duodenal insufficiency in patients with ulcer disease have a functional character, resulting from infringements of the vegetative regulation and psycho-emotional status.

      1. Вахрушев Я. М. Изучение состояния нейрогормональных регуляторных систем при язвенной болезни и его клиническое значение. Механизмы функционирования висцеральных систем. Международная конференция, посвященная 75-летию со дня рождения А. М. Уголева. Тезисы докладов Санкт-Петербург, 2001, С. 60.
      2. Вахрушев, Я.М., Никишина Е. В. К вопросу о патогенезе эрозивных гастритов и дуоденитов. Клин. Медицина,1999, № 2, С. 28-31.
      3. Маев И. В., Самсонов А. А. «Хронический дуоденит», - Москва: ГОУ ВУНМЦ МЗ СР РФ, 2005.
      4. Ивашкин В. Т., Лапина Т. Л. «Рациональная фармокотерапия заболеваний органов пищеварения: для практикующих врачей», - Москва: Литтера, 2003.
      5. Григорьев П.Я., Яковенко Э. П. «Диагностика и лечение болезней органов пищеварения», - Москва: Медицина,1996.
      6. Волков В. С., Колесникова И. Ю. Дуоденогастральный рефлюкс и язвенная болезнь двенадцатиперстной кишки - расставим точки над “i”. Верхневолжский медицинский журнал,2010, Т. 8, № 1, с. 26-29.
      7. Мальцев С. В., Волгина С. Я. Особенности психовегетативного состояния при хроническом гастродуодените у детей старшего гинального возраста. Педиатрия,1996, N 4, с.38-42.
      8. Шептуллин А. А., Запруднов А. М. «Дуоденит. Малая медицинская энциклопедия в 6 томах», - Москва: Советская энциклопедия,1991.
      9. Бурчинский Г. И. Клинические варианты течения язвенной болезни.Клиническая медицин,1985, № 9, с. 66-71.
      10. Смирнова Г. О. «Переферическая электрогастроэнтерография в клинической практике». - Методические рекомендации.
      11. Колесникова, И. Ю. Почему не возникает язва двенадцатиперстной кишки у больных хроническим гастродуоденитом? Российские медицинские вести, 2012, Т. 17, № 3, с.69-72.
      12. Колесникова, И. Ю. Особенности дуоденогастрального рефлюкса при язвенной болезни двенадцатиперстной кишки и его динамика после эрадикации Helicobacter pylori. Экспериментальная и клиническая гастроэнтерология, 2011, № 5, с.16-19.
      13. Вахрушев Я. М., Бусыгина М. С. Особенности клинического течения язвенной болезни с сопутствующей дуоденальной недостаточностью. Архив внутренней медицины, 2016, т. 5,№ , с.30-36.
      14. Колесникова И. Ю., Беляева Г. С. Качество жизни и вегетативный статус больных язвенной болезнью.Терапевтический архив,2005,№ 2, с. 34-38.
     


    Full text is published :
    Vahrushev Yu.M., Busygina M.S. THE EVALUATION OF VEGETATIVE STATUS, PSYCHO-EMOTIONAL STATE AND QUALITY OF LIFE IN PATIENTS WITH ULCER STOMACH AND DUODENI DISEASE ASSOCIATED WITH CHRONIC DUODENAL INCUFFI CIENSY. Experimental and Clinical Gastroenterology Journal. 2017;142(06):20-25
    Read & Download full text

    1. Federal Budget Institution of Science “Central Research Institute of Epidemiology” of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance (Moscow, Russian Federation)

    Keywords:acute intestinal infections,children,the rotavirus infection

    Abstract:Acute intestinal infections (AII) are important for clinical practice. Many experts shows that there are the change in the etiological structure of AII in children. There is a dominance of pathogens of viral etiology, primarily rotavirus. However, in recent years there is growing importance of combined forms of viral AII. This requires the establishment of the characteristics of their clinical manifestations. In the article there are results of own long-term observations, showing the peculiarities of the clinical appearances of rotavirus infection and its combined form (with a norovirus infection, salmonellosis and antibioticassociated diarrhea) in children.

      1. Инфекционная заболеваемость в Российской Федерации за январь-декабрь 2015 года (по данным формы № 1 «Сведения об инфекционных и паразитарных заболеваниях») [Электронный ресурс]. - Режим доступа: http://www.rospotrebnadzor.ru/activities/statistical-materials/statictic_details.php? ELEMENT_ID=5525 - (дата обращения 10.02.2016).
      2. World Gastroenterology Organisation Global Guidelines Acute diarrhea in adults and children: a global perspective - February 2012 - URL: http://www.worldgastroenterology.org/ -Date of access: 24.08.2016.
      3. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2014 году: Государственный доклад. - М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. - 2015. - 206 с.
      4. Подколзин А. Т. Эпидемиологическая и клиническая характеристика острых кишечных инфекций вирусной этиологии в российской федерации / Подколзин Александр Тихонович/ / Автореферат дисс. на соиск. уч. ст. д. м.н. Москва - 2015 г. - 46 с.
      5. Rosefeldt, V. Viral etiology and incidence of acute gastroenteritis in young children attending day-care centres / Rosefeldt V., Vescari T., Pang X. L. / Pediatrics Infection Diseases // 2005, Vol. 24. - p. 962-965.
      6. Radlović, N. Acute Diarrhea in Children. / Radlović N, Leković Z, Vuletić B, Radlović V, Simić D. // Srp Arh Celok Lek. 2015 Nov-Dec;143(11-12):755-62. Review.
      7. Постановление Главного государственного санитарного врача Российской Федерации от 19 марта 2010 г. № 21 «О профилактике острых кишечных инфекций» // Российская газета. - 2010 (30 апреля). - С. 21.
      8. Милютина, Л. Н. Актуальные проблемы современных кишечных микст-инфекций у детей / Л. Н. Милютина, А. О. Голубев // Сборник докладов научной конференции «Инновационные технологии в области образования и медицины». Арад (Израиль), 2012. - С. 139-147.
      9. Петри, А. Наглядная медицинская статистика / А. Петри, К. Сэбин. - М.: ГЭОТАР-МЕД, 2010. - 169 с.
      10. Staat, M. A. Clinical presentations of rotavirus infection among hospitalized children / M. A. Staat, P. H. Azimi, T. Berke et al.// Pediatr Infect Dis J. -2002. - Vol.21(3). - P.221-227.
      11. Голубев А. О. Клинико-иммуноллогические особенности сочетанных сальмонеллезов у детей и иммунотерапия постинфекционного бактерионосительства: Автореф. дис. … канд. мед. наук. М. - 2013. 22 с.
      12. Sanderson, С. Global review of rotavirus morbidity and mortality data by age and region / Sanderson С., Clark А., Taylor D., Bolanos В. http://www.who.int/immunization/sage/meetings/2012/april/Sanderson_et_al_SAGE_April_rotavirus.pdf -Date of access: 24.08.2016.
      13. Анохин, В. А. Ротавирусная инфекция у детей: современные аспекты диагностики и лечения / В. А. Анохин, С. В. Халиуллина, О. И. Биккинина, К. В. Сушников // Практическая медицина. - 2009. - № 7 (39). - С. 41-45.
      14. Гречуха, М. Г. Галицкая, А. Г. Гайворонская, Л. С. Намазова-Баранова. Ротавирусная инфекция. Как действительно защитить детей от тяжелых гастроэнтеритов? // Педиатрическая фармакология. 2013; 10 (5): 14-17.
      15. Hashavya, S. Rotavirus-associated colitis in a six-month-old baby /Hashavya S, Wilscrhanski M, Averbuch D, Arbell D, Pappo O, Shteyer E.// Pediatr Int. 2010 Aug;52(4).
     


    Full text is published :
    Ploskireva A.A., ROTAVIRUS INFECTION IN CHILDREN AND ITS COMBINED FORMS. Experimental and Clinical Gastroenterology Journal. 2017;142(06):26-30
    Read & Download full text

    1. FDO FGBOU IN “Russian Research Medical University. Pirogov “of Ministry of Health of Russia (Moscow, Russian Federation)
    2. GBUZ “Children’s Regional Clinical Hospital” (Krasnodar, Russian Federation)
    3. FGBOU IN “Kuban State Medical University,” Health Ministry of Russia (Krasnodar, Russian Federation)

    Keywords:digestive tract,children,congenital heart defects,small anomalies of heart development

    Abstract:The results of the study of morpho-functional state of the upper gastrointestinal tract in children with congenital anomalies of the heart and small development. The study involved 324 child with congenital heart and small anomaly of development between the ages of 1 month to 15 years. Boys 170, girls 154 children were divided into groups: 138 children with congenital malformations, the second 186 children with minor heart anomalies. It was found that children with congenital frequently detected erosive and ulcerative diseases in children with small heart-surface anomalies gastroduodenitis, reflux disorders. On the morphological and functional state of the upper gastrointestinal traktau children with congenital anomalies of the heart and small influence the state of chronic hypoxia.

      1. Запруднов, А. М. Подростковая гастроэнтерология: болезнь начинается в детстве / А. М. Запруднов, К. И. Григорьев, Ю. А. Князев [и др.] // Врач. - 2003. - № 5. - С. 7-10.
      2. Калмыкова, А. С. Частота встречаемости артериальной гипертензии у подростков г. Ставрополя / А. С. Калмыкова, Э. М. Сариева // Актуальные проблемы педиатрии: матер. 15 Конгресса педиатров России. - 2011. - С. 773.
      3. Панова, И. В. Клинико-патогенетические особенности формирования хронического гастродуоденита в сочетании с гастроэзофагеальной рефлюксной болезнью у детей в I-III стадиях полового созревания: Дис. … д-р. мед. наук / И. В. Панова// Ростов-на-Дону, 2013. - 279 с.
      4. Володин, Н. Н. Неонатология: национальное руководство/под ред. Н. Н. Володина// М.: ГЭОТАР-Медиа. - 2009. - 848 с.
      5. Баранов, А. А. Детская гастроэнтерология. Избранные главы./А.А. Баранов, Е. В. Климанская, Г. В. Римарчук // М., 2002. - 592 с.
      6. Белоусов, Ю. В. Кардиологические аспекты детской гастроэнтерологии/ Матер. 14-го Конгресса детских гастроэнтерологов России. - М., 2006. - С. 50-51.
     


    Full text is published :
    Haritonova L.A., Atayants O.S., Shashel V.A., Kleschenko E.I. MORFOFUNKTSONALNYE FEATURES DIGESTIVE TRACT IN CHILDREN AND ADOLESCENTS WITH CONGENITAL AND DEVELOPMENTAL ABNORMALITIES SMALL HEART. Experimental and Clinical Gastroenterology Journal. 2017;142(06):31-33
    Read & Download full text

    1. Russian Medical Academy of Continuous Professional Education (Moscow, Russian Federation)
    2. I. M. Sechenov First Moscow State Medical University (Moscow, Russian Federation)

    Keywords:ABCB 1,P-glycoprotein,pharmacogenetics,proton pump inhibitor,omeprazole,peptic ulcer

    Abstract:Introduction. ABCB 1 gene localized on seventh chromosome encodes ABC-transporter P-glycoprotein. Proton pump inhibitors are known to be substrates of P-glycoprotein. Studies showed that C 3435T genetic polymorphism of ABCB 1 might influence proton pump inhibitors-based acid suppression and Helicobacter pylori eradication rates. From this point of view, studying the relation between C 3435T polymorphism of ABCB 1 and clinical and demographic features of peptic ulcer patients taking proton pump inhibitors may have clinical relevance. The aim of the study - to find the connection between C 3435T polymorphism of ABCB 1 and clinical and demographic features of patients with peptic ulcer taking omeprazole. Methods. Fifty peptic ulcer patients (19 men, 31 women), who were on treatment with omeprazole in Moscow clinics, aged 18-77 years (mean age 51.5±14.9 years) were enrolled. Six milliliters of venous blood were taken from patients in K2-EDTA tubes. C 3435T polymorphism of ABCB 1 gene was analyzed using real-time polymerase chain reaction (PCR). Results. CC genotype of ABCB 1 was found in 11 (22 %) patients, CT genotype - in 26 (52 %) patients, TT genotype - in 13 (26 %) patients. All genotypes were in Hardy-Weinberg equilibrium (p=0.77). There were no statistically significant differences in distribution of CC, CT, TT genotypes of ABCB 1 gene in patients depending on stomach or duodenum ulcer localization (6,8 %, 15,9 %, 9,1 % vs. 13,6 %, 34,1 %, 20,5 %, respectively), existence or absence of family history of peptic ulcer (14,3 %, 33,3 %, 9,6 % vs. 4,7 %, 23,8 %, 14,3 %, respectively), existence or absence of exacerbation after diagnosed peptic ulcer (14,8 %, 18,6 %, 3,7 % vs. 11,1 %, 37 %, 14,8 %, respectively), existence or absence of ulcer complications (15,1 %, 9,1 %, 9,1 % vs. 12,1 %, 45,5 %, 9,1 %, respectively), less than 1 cm or 1 cm and more ulcer according to gastroscopy (7,1 %, 28,6 %, 28,6 % vs. 7,1 %, 7,1 %, 21,5 %, respectively), less than 30 or 30 and more total score of GSRS scale (10 %, 30 %, 30 % vs. 5 %, 15 %, 10 %, respectively), Fisher’s Exact test, p>0.05. Conclusion. There is a high prevalence of C 3435T polymorphisms of ABCB 1 gene in peptic ulcer patients of Moscow region. There were no statistically significant differences between ABCB 1 genotype and clinical and demographic features of peptic ulcer patients.

      1. Jażdżyk M, Sałagacka A, Zebrowska M, Balcerczak M, Mirowski M, Balcerczak E. ABCB 1 expression in peptic ulcer patients and its connection with H. pylori Infection. Ann Clin Lab Sci. 2014; 44(3): 294-7.
      2. Higgins CF. Gottesman MM. Is the multidrug transporter a flippase? Trends Biochem Sci. 1992; 17: 18-21.
      3. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. CancerRes. 1970; 30(4): 1174-84.
      4. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986; 47(3): 381-9.
      5. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. BiochimBiophysActa. 1976; 455(1): 152-62.
      6. Inaba M, Kobayashi H, Sakurai Y, Johnson RK. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res. 1979; 39(6 Pt 1): 2200-3.
      7. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR 1 (P-glycoprotein): recent advances and clinical relevance. ClinPharmacolTher. 2004; 75(1): 13-33.
      8. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl AcadSci USA. 2000; 97: 3473-8.
      9. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W. Multidrug resistance polypeptide 1 (MDR 1, ABCB 1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005; 15(10): 693-704.
      10. Furuta T, Sugimoto M, Shirai N, et al. Effect of MDR 1 C 3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP2C 19 genotypes and 23S rRNA genotypes of H.pylori. Aliment PharmacolTher. 2007; 26: 693-703.
      11. Gawrońska-Szklarz B, Wrześniewska J, Starzyńska T, Pawlik A, Safranow K, Ferenc K, Droździk M. Effect of CYP2C 19 and MDR 1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection. Eur J Clin Pharmacol. 2005; 61: 375-379.
      12. Маев И. В., Кучерявый Ю. А., Андреев Д. Н. Причины неэффективности антигеликобактерной терапии. РЖГГК. 2013; 6: 62-72.
      13. Komoto C, Nakamura T, Sakaeda T, et al. MDR 1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug MetabPharmacokinet. 2006; 21(2): 126-32.
      14. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB 1 (MDR 1, multidrug resistance transporter) gene. Pharmacogenetics. 2003; 13(8): 481-94.
      15. Omar M, Crowe A, Parsons R, Ee H, Tay CY, Hughes J. P-glycoprotein expression in Helicobacter pylori-positive patients: the influence of MDR 1 C 3435T polymorphism. JDigDis. 2012; 13: 414-420.
      16. Babic Z, Svoboda-Beusan I, Kucisec-Tepes N, Dekaris D, Troskot R. Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. WorldJGastroenterol. 2005; 11: 2720-2725.
     


    Full text is published :
    Denisenko N.P., Sychev D.A., Sizova Zh.M., Grishina E.A. et al. ABCB 1 C 3435T POLYMORPHISM AND CLINICAL FEATURES OF PEPTIC ULCER PATIENTS TAKING PROTON PUMP INHIBITORS. Experimental and Clinical Gastroenterology Journal. 2017;142(06):34-39
    Read & Download full text

    1. Kharkiv national medical University (Kharkiv, Ukraine)

    Keywords:gastroesophageal reflux disease,obesity,pathogenesis,polymorphism of endothelial NO-synthase gene

    Abstract:The work describes the results of a study of gene endothelial NO-synthase (eNOS) polymorphism in patients with gastroesophageal reflex disease (GERD) combined with obesity. It is shown that even isolated GERD course occurs against changes in gene polymorphism. GERD and obesity in 48.8 % of cases occurs at a polymorphic variant of the eNOS gene (pathological genotype CC), that allows to speak about increased risk of endothelial and hemostatic disorders, in particular, the development of cardiac symptoms. These factors may contribute to the development of atypical forms of the disease, its progression and the appearance of complications.

      1. Бабак О. Я. Гастроэзофагеальная рефлюксная болезнь: от понимания механизмов заболевания к уменьшению клинических симптомов / О. Я. Баба, Е. В. Колесникова // Сучасна гастроентерологія.-2012.-№ 3.-С.32-35.
      2. Бордин Д. С. Алгоритм ведения больных гастроэзофагеальной рефлюксной болезнью / Д. С. Бородин // Человек и лекарство.-2011.-№ 2.-С.326-338.
      3. Гастроэзофагеальная рефлюксная болезнь / В. Т. Ивашкин, И. В. Маев, А. С. Трухманов / Клинические рекомендации.-М.,2013. - 22 с.
      4. Ивашкин В. Т. Эволюция представления о роли нарушений двигательной функции пищевода в патогенезе гастроэзофагеальной рефлюксной болезни / В. Т. Ивашкин, А. С. Трухманов // Рос. журнал гастроэнтер., гепатол., колопроктол.-2010.-№ 2.-С.13-19.
      5. Маев И. В. Гастроэзофагеальная рефлюксная болезнь: от патогенеза к терапевтическим аспектам / И. В. Маев, Д. И. Андреев, Д. Т. Дичева // Consilium medicum.-2013.-№ 15(8).-С.30-34.
      6. Мониторинг распространенности заболеваний внутренних органов на примере патологии пищеварительной системы / Т. П. Денисова, В. А. Шульдяков, Л. А. Тюльтяева // Саратовский научно-медицинский журнал.-2011.-Том 5, № 4.-С.772-776.
      7. Результаты многоцентрового исследования «Эпидемиология гастроэзофагеальной рефлюксной болезни в России» (МЭГРЭ)/ Л. Б. Лабезник, А. А. Машарова, Д. С. Бородин // Тер.архив.-2011.-№ 1.-С.5-25.
      8. Гастроэзофагеальная рефлюксная болезнь: пищеводные, внепищеводные проявления и коморбидность / Г. Д. Фадеенко, А. Е. Гриднев, Киев, «Здоровье Украины»,2014.-376 с.
      9. Abdominal visceral adipose tissue volume is associated with increased risk of erosive esophagitis in men and women / S. Y. Nam, I. J. Choi, K. H. Ryu // Gastroenterology.-2010.-№ 139.-P.1902-1911.
      10. Emerenziani S. Gastro-esophageal reflux disease and obesity, where is the linc? / S. Emerenziani, J. Woald // Gastroenterol.-2013.-№ 19(39).-p.6536-6539.
      11. Epidemiology of gastro-esophageal reflux disease: a systematic review / J. Dent, H. B. Ei-Serag, M. A. Wallander // Gut.-2005.-№ 54.-p.710-717.
      12. Symptom characteristics and psychosomatic profiles in different spectrum of gastroesophageal reflux disease / C. H. Lim, M. G. Choi, M/K.Baeg // Gut Liyer.-2014.-№ 8(2).-p.165-169.
      13. Visceral fat predominance is associated with erosive esophagitis in Japanese men with metabolic syndrome / J. R. Kramer, L. A. Fischbach, P. Richardson [et al.] // Clin. Gastroenterol. Hepatol.-2013. - № 11. - P. 373-381.
      14. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial / S. Singh, J. Lee, N. Gupta // Obesity.-2013.-№ 21.-p.284-290.
      15. Wu Y. W. Association of Esophageal Inflammation, Obesity and Gastroesophageal Reflux Disease: From FDG PET/CT Perspective / Y. W. Wu. P. H. Tseng, Y. Ch. Lee // PLoS One.-2014.-Vol.9.-№ 3.-p.147-165.
     


    Full text is published :
    Pasiyeshvili L.M., Zhelezniakova N.M., Pasiyeshvili T.M. GENETIC DETERMINANTS OF CARDIOVASCULAR RISK IN PATIENTS WITH GASTROESOPHAGEAL REFL UX DISEASE AND OBESITY. Experimental and Clinical Gastroenterology Journal. 2017;142(06):40-43
    Read & Download full text

    1. Kazan State Medical University (Kazan, Russian Federation)
    2. Kazan Federal University (Kazan, Russian Federation)
    3. Republican Clinical Hospital (Kazan, Russian Federation)

    Keywords:intestinal permeability,autoimmune hepatitis,overlap syndrome,lactulose/mannitol ratio,sucralose,triple sugar test

    Abstract:The article presented complex assessment of intestinal permeability in patients with autoimmune hepatitis (AIH) and overlap syndrome (OS). The study included 82 people: 26 patients with AIH, 26 - with OS and 30 healthy controls. All included into the study underwent a triple sugar test. There was increasing of small intestinal permeability in patients with AIH 0,11 [0,075; 0,18] (p<0,001) and OS 0,2 [0,088; 0,3] (p<0,001), comparing with control group 0,013 [0,01; 0,025]. In patients with cirrhosis, portal hypertension and liver failure intestinal permeability changes were more prominent - increasing small bowel and colonic permeability.

      1. Manns M. P. Diagnosis and Management of Autoimmune Hepatitis / M. P. Manns, A. J. Czaja, J. D. Gorham et al. // Hepatology. - №. 51(6). - C. 2193-2213.
      2. Boberg K. M. Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue / K. M. Boberg, R. W. Chapman, G. M. Hirschfield et al. // Journal of Hepatology. - 2011. - № 54 - С. 374-385.
      3. Ивашкин В. Т. Аутоиммунные заболевания печени в практике клинициста. / В. Т. Ивашкин, А. О. Буеверов // 2-е изд. М. Изд. дом «М-Вести». - 2011
      4. Czaja A. J. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis / A. J. Czaja // World Journal of Gastroenterology - 2016 - № 22(42) - С. 9257-9278.
      5. Lin R. Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis / R. Lin, L. Zhou, J. Zhang, et al. // Int J Clin Exp Pathol - 2015. - № 8(5). - С. 5153-5160.
      6. Liboredo J. C. Nutrition status and intestinal permeability in patients eligible for liver transplantation. / J. C. Liboredo, E. G. Vilela, M. L. Ferrari et al. // J Parenter Enteral Nutr. -2015. № 39. - С. 163-170.
      7. Swanson G. R. Is moderate red wine consumption safe in inactive inflammatory bowel disease? /Swanson G.R., Tieu V., Shaikh M., et al.// Digestion. - 2011. - № 84(3). - С. 238-244.
      8. Vilela E. G. Gut permeability to lactulose and mannitol differs in treated Crohn’s disease and celiac disease patients and healthy subjects/ Torres H. O., Ferrari M. L., Lima A. S. et al.// Braz J Med Biol Res. - 2008. - № 41(12). - С. 1105-1109.
      9. Camilleri M. Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion/ Camilleri M., Nadeau A., Lamsam J. et al.// Neurogastroenterol. Motil. - 2010. - № 22(1). - С. 15-26.
      10. Tsiaoussis G. I. Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications/ Tsiaoussis G. I., Assimakopoulos S. F., Tsamandas A. C. et al.// World J Hepatol. - 2015. - № 7(17). - С. 2058-2068.
     


    Full text is published :
    Akberova D.R., Koshkin S.A., Odintsova A.N., Abdulganieva D.I. ASSESSMENT OF THE INTESTINAL PERMEABILITY IN PATIENTS WITH AUTOIMMUNE HEPATITIS AND OVERLAP SYNDROME. Experimental and Clinical Gastroenterology Journal. 2017;142(06):44-47
    Read & Download full text

    1. I. M. Sechenov First Moscow State Medical University (Moscow, Russian Federation)

    Keywords:irritable bowel syndrome,quality of life,age,gender,type of IBS

    Abstract:Preamble and aim of the study: Irritable bowel syndrome (IBS) affects health-related quality of life (QоL). The purpose of this study is a comparative analysis of the mental and physical indicators of health conditions IBS patients depending on age, gender of patients and type of IBS. Materials and methods: In a specialized gastroenterology clinic 245 patients with IBS were investigated QoL using a questionnaire MOS SF-36. The analysis was conducted in 2 groups of patients with IBS: up to 45 years (n=125) from 45 years and older (n=120). The results of the study: IBS рatients have low rates of both physical and mental components health. With age significantly reduced QoL, due to the physical component health (PH), p<0.05. QoL by physical (FF), emotional (RE) and role functioning (RP), in the women older age subgroup is lower than in men, p<0.05. QoL indicators of IBS-C patients are lower than in IBS-D and IBS-CM patients, p<0.05. Conclusion: QOL in patients with IBS reduced in younger and older age, predominantly in women and with age even more reduced. IBS-C patients QoL is lower than at IBS-D and IBS-CM.

      1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. //Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.
      2. Михайлова Т. Л., Румянцев В. Г., Кольченко И. И. и соавт. Качество жизни больных с синдромом раздраженного кишечника. РЖГГК, 2002-6 - стр. 70-75.
      3. http://psylab.info
      4. Drossman DA. The functional gastrointestinal disorders and the Rome process. Gastroenterology. 2006; 130: 1377-1390.
      5. Коновалова Т. А. Оценка качества жизни больных синдромом раздраженного кишечника в Донецком регионе. Газета “новости медицины и фармации” Гастроэнтерология (358) 2011(тематический номер)
      6. Cho HS, Park JM, Lim CH et al. Anxiety, depression and quality of life in patients with irritable bowel syndrome. // Gut Liver. 2011;5:29-36.
      7. Mönnikes H. Quality of life in patients with irritable bowel syndrome. //J Clin Gastroenterol. 2011 Aug; 45 Suppl: S 98-101.
      8. Мнацаканян М. Г., Тащян О. В., Погромов А. П., Дюкова Г. М. Сравнительная характеристика ассоциированных симптомов у больных синдромом раздраженного кишечника разного возраста. // Журнал «Медицинский совет», 2015, № 7, стр. 72-77;
      9. Tang Y-R, Yang W-W, Liang M-L, et al. Age-related symptom and life quality changes in women with irritable bowel syndrome. // World J Gastroenterol. 2012;18(48):7175-7183.
      10. Phillips RJ, Walter GC, Powley TL. Age-related changes in vagal afferents innervating the gastrointestinal tract. // Auton Neurosci. 2010;153: 90-98.
      11. Simren M, Abrahamsson H, Svedlund J et al. Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. //Scand J Gastroenterol. 2001;36:545-552.
      12. Park JM, Choi MG, Kim YS et al. Quality of life of patients with irritable bowel syndrome in Korea. //Qual Life Res. 2009 May;18(4):435-46.
      13. Voci SC, Cramer KM. Gender-related traits, quality of life, and psychological adjustment among women with irritable bowel syndrome. //Qual Life Res. 2009;18(9):1169-76;
      14. Tang YR, Yang WW, Wang YL, Lin L. Sex differences in the symptoms and psychological factors that influence quality of life in patients with irritable bowel syndrome.// Eur J Gastroenterol Hepatol. 2012 Jun; 24(6): 702-7.
      15. Kwan AC, Hu WH, Chan YK et al. Prevalence of irritable bowel syndrome in Hong Kong.// J Gastroenterol Hepatol 2002; 17: 1180-1186;
      16. Lau EM, Chan FK, Ziea ET et al. Epidemiology of irritable bowel syndrome in Chinese. //Dig Dis Sci 2002; 47: 2621-262.
      17. Мнацаканян М. Г., Погромов А. П., Зуев В. М. и соавт. Синдром раздраженного кишечника у женщин репродуктивного и менопаузального возраста. //Журнал “Сеченовский вестник”, 2016, № 3(25), стр. 70-78
      18. Kanazawa M, Hongo M, Fukudo S. Visceral hypersensitivity in irritable bowel syndrome.// J Gastroenterol Hepatol. 2011 Apr;26 Suppl 3:119-21].
      19. Meleine M, Matricon J. Gender-related differences in irritable bowel syndrome: Potential mechanisms of sex hormones. //World J Gastroenterol 2014; 20(22): 6725-6743.
      20. Björkman I, Jakobsson Ung E, Ringström G1 et al. More similarities than differences between men and women with irritable bowel syndrome. //Neurogastroenterol Motil. 2015 Jun;27(6):796-804;
      21. Naliboff BD, Kim SE, Bolus R et al. Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. // Am J Gastroenterol. 2012;107(3):451-9.
      22. Eriksson EM, Andren KI, Eriksson HT, Kurlberg GK. Irritable bowel syndrome subtypes differ in body awareness, psychological symptoms and biochemical stress markers.// World J Gastroenterol. 2008;14:4889-4896. doi: 10.3748/wjg.14.4889.
      23. Si JM, Wang LJ, Chen SJ et al. Irritable bowel syndrome consulters in Zhejiang province: the symptoms pattern, predominant bowel habit subgroups and quality of life.// World J Gastroenterol. 2004;10:1059-1064.
      24. Singh P1, Staller K1, Barshop K1 et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.// World J Gastroenterol. 2015 Jul 14;21(26):8103-9
      25. Jamali R, Jamali A, Poorrahnama M, et al. Evaluation of health related quality of life in irritable bowel syndrome patients.// Health Qual Life Outcomes 2012;10:12.
      26. Drossman D. A., Dumitrascu D. L. Rome III: New standard for functional gastrointestinal disorders // J. Gastrointestin. Liver Dis. 2006; 15: 237-241.
      27. Quigley E. M., Abdel-Hamid H., Barbara G., Bhatia S. J., Boeckxstaens G., de Giorgio R., Delvaux M., Drossman D. A., Foxx-Orenstein A. E., Guarner F. et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome // J Clin Gastroenterol. 2012; 46: 356-366.
     


    Full text is published :
    Mnatsakanyan M.G., Pogromov A.P., Dyukova G.M., Tashjian O.V. ANALYSIS OF GENDER AND AGE DIFF ERENCES IN THE QUALITY OF LIFE OF PATIENTS WITH IRRITABLE BOWEL SYNDROME. Experimental and Clinical Gastroenterology Journal. 2017;142(06):48-53
    Read & Download full text

    1. Kazan State Medical University (Kazan, Russian Federation)
    2. Kazan Federal University (Kazan, Russian Federation)
    3. Federal Research and Clinical Centre of Physical-Chemical Medicine (Moscow, Russian Federation)
    4. Moscow Institute of Physics and Technology (Moscow, Russian Federation)
    5. Republican Clinical Hospital of the Ministry of Healthcare of the Republic of Tatarstan (Kazan, Russian Federation)

    Keywords:intestinal microbiota,ulcerative colitis,inflammatory bowel diseasesmetagenome

    Abstract:The aim of the study was to evaluate the representation of the microbial community in patients with ulcerative colitis. Materials and methods. The study included 46 patients with ulcerative colitis (25 men and 21 women, aged 42,4±13.8 years, duration of the disease - 5,42 ±8.21 years). Results of sequencing of ulcerative colitis patients stool samples as well as samples from 96 healthy volunteers were used for analysis. Whole genome sequencing was carried out on the SOLiD 5500W platform (LifeTechnologies, FosterCity, CA, USA). Results. Metagenomic analysis allowed us to detect 29 classes of bacteria, including: 73 families, 154 genera, 437 species of microbes in intestinal microbiota of patients with ulcerative colitis. The prokaryotic part of microbiota formed 99.5 % (98,2 % - Bacteria, 1,8 % - Archaea), viruses - 0.5 %, eukaryotes - 0,004 % of all intestinal microbiota. Taxonomic analysis revealed changes in the relative representation of bacterial families: we observed decrease in Lachnospiraceae, Rikenellaceae, Acidaminococcaceae, Enterococcaceae, Desulfovibrionaceae, Verrucomicrobiaceae, Clostridiaceae and increase in Enterobacteriaceae. Only the number of Escherichia genus, particularly Escherichia coli species was significantly abundant among the members of Enterobacteriaceae family. In ulcerative colitis patients the fraction of Escherichia was (3,74±8,01)% which was greater than in the control group (1,49±of 5.23)%, whereas the fraction of Clostridium (1,15±3,35)% was significantly lower in patients with ulcerative colitis than in the control group (2,33±4,26)%. The alpha-diversity index which characterizes richness of the microbial community was decreased in stool samples of patients with ulcerative colitis in comparison with the control group. Conclusions. The metagenomics analysis revealed significant changes in intestinal microbiota in ulcerative colitis patients comparing with the control group.

      1. Li KY, Wei JP, Gao SY, et al. Fecal microbiota in pouchitis and ulcerative colitis. World Journal of Gastroenterology. 2016; 22(40):8929-8939. doi: 10.3748/wjg.v22.i40.8929
      2. Presley LL, Ye J, Li X, et al. Host-microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosal-luminal interface. Inflamm Bowel Dis. 2012 Mar; 18(3):409-417. doi: 10.1002/ibd.21793.
      3. Ganji L, Alebouyeh M, Shirazi MH, et al. Dysbiosis of fecal microbiota and high frequency of Citrobacter, Klebsiella spp., and Actinomycetes in patients with irritable bowel syndrome and gastroenteritis. Gastroenterol Hepatol Bed Bench. 2016 Autumn; 9(4):325-330.
      4. Vrakas S, Mountzouris KC, Michalopoulos G, et al. Intestinal Bacteria Composition and Translocation of Bacteria in Inflammatory Bowel Disease. PLoS One. 2017; 12(1): e0170034. doi:10.1371/ journal.pone.0170034
      5. Ситкин С. И., Вахитов Т. Я., Ткаченко Е. И. и соавт. Микробиота кишечника при язвенном колите и целиакии // Экспериментальная и клиническая гастроэнтерология. - 2017. - № 1(137). - С. 8-30.
      6. Лазебник Л. Б., Конев Ю. В. Новое понимание роли микробиоты в патогенезе метаболического синдрома. // Consilium Medicum. (Прил.). - 2014. - 08. - с. 77-82.
      7. Мечников И. И. Этюды оптимизма. М.: Наука, 1964. - 128 с.
      8. Nissle A. Explanations of the significance of colonic dysbacteria & the mechanism of action of E. coli therapy (mutaflor) Medizinische. 1959; 4:1017-1022.
      9. Quigley EMM. Gut Bacteria in Health and Disease. Gastroenterol Hepatol (NY). 2013 Sep.; 9(9):560-569.
      10. Bull MJ, Plummer NT. Part 1: The Human Gut Microbiome in Health and Disease. Integr Med (Encinitas). 2014 Dec; 13(6):17-22.
      11. Costello EK, Lauber CL, Hamady M, et al. Bacterial Community Variation in Human Body Habitats Across Space and Time. Science. 2009 Dec 18; 326(5960):1694-1697. doi: 10.1126/science.1177486.
      12. Qin J, Li R, Raes J, et al. A human gut microbial gene catalog established by metagenomic sequencing. Nature. 2010 Mar 4; 464(7285):59-65. doi: 10.1038/nature08821.
      13. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015; 37:47-55. doi: 10.1007/s00281-014-0454-4.
      14. Gill SR, Pop M, DeBoy R, et al. Metagenomic Analysis of the Human Distal Gut Microbiome. Science. 2006 Jun 2; 312(5778):1355-1359. doi: 10.1126/science.1124234.
      15. Tap J, Mondot S, Levenez F, et al. Towards the human intestinal microbiota phylogenetic core. Environ Microbiol. 2009 Oct; Vol. 11 (10):2574-84. doi: 10.1111/j.1462-2920.2009.01982.x.
      16. Mariat D, Firmesse O, Levenez F, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009 Jun 9; 9:123. doi: 10.1186/1471-2180-9-123.
      17. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol. 2009 Dec; 7(12):887-94. doi: 10.1038/nrmicro2245.
      18. Bringiotti R, Lerardi E, Lovero R, et al. Intestinal microbiota: The explosive mixture at the origin of inflammatory bowel disease? World J Gastrointest Pathophysiol. 2014 Nov 15; 5(4):550-559. doi: 10.4291/wjgp.v5.i4.550
      19. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut. 2008 Sep; 57 (9):1185-1191. doi: 10.1136/gut.2007.122143.
      20. Donaldson GP, Lee SM, Mazmanian SK. Gut biogeography of the bacterial microbiota. Nat Rev Microbiol. 2016 Jan.; 14 (1):20-32. doi: 10.1038/nrmicro3552.
      21. Petriz BA, Franco OL. Metaproteomics as a Complementary Approach to Gut Microbiota in Health and Disease. Front Chem. 2017 Jan 26; 5:4. doi: 10.3389/fchem.2017.00004.
      22. Yamashita T. Intestinal Immunity and Gut Microbiota in Atherogenesis. Journal of Atherosclerosis and Thrombosis. 2017; Vol. 24 No. 2:110-119. doi.org/10.5551/jat.38265
      23. Escobedo G, Lopez-Ortiz E, Torres-Castro I. Gut microbiota as a key player in triggering obesity, systemic inflammation and insulin resistance. Rev Investig Clin. 2014 Sep-Oct; 66(5):450-459.
      24. Xuyun H, Guang J, Wei J, Houkai L. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics. Int J Mol Sci. 2016 Mar; 17(3):300. doi: 10.3390/ijms17030300.
      25. Hua X, Goedert JJ, Pu A, et al. Allergy associations with the adult fecal microbiota: Analysis of the American Gut Project. EBioMedicine. 2015 Nov 27; 3:172-9. doi: 10.1016/j.ebiom.2015.11.038.
      26. Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: Microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2015 Nov; 42 (9):1051-63. doi: 10.1111/apt.13376.
      27. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Col of Nutrition. 2003 Feb; 22(1):56-63. doi: 10.1080/07315724.2003.10719276.
      28. Saez-Lara M.J., Gomez-Llorente C., Plaza-Diaz J., Gil A. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int. 2015; 2015:505878. doi: 10.1155/2015/505878.
      29. Ohkusa T. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol. 2002 Aug; 17 (8):849-53.
      30. Matsuoka K, Mizuno S, Hayashi A, et al. Fecal microbiota transplantation for gastrointestinal diseases. Keio J Med. 2014; 63(4):69-74. doi: 10.2302/kjm.2014-0006-RE.
      31. Ott SJ, et al. Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol. 2008; 103:643-648. doi:10.1111/j.1572-0241.2007.01592.x.
      32. Дубинкина В. Б., Тяхт А. В., Ильина Е. Н. и соавт. Метагеномный анализ таксономических и функциональных особенностей микробиоты кишечника у пациентов с синдромом алкогольной зависимости. // Биомедицинская химия. - 2015. - Т. 61 (Вып. 6). - С. 742-749.
      33. Michail S, Durbin M, Turner D, et al. Alterations in the gut microbiome of children with severe ulcerative colitis. Inflamm Bowel Dis. 2012 Oct; 18 (10):1799-808. doi: 10.1002/ibd.22860.
      34. Сафина Д. Д., Абдулхаков С. Р., Григорьева Т. В. и соавт. Влияние фармакотерапии на генетическое разнообразие биоценоза кишечника. // Гены & клетки. - 2015. - Том X, № 4. - С. 80-85.
      35. Khusnutdinova D, Grigoryeva T, Abdulkhakov S, Safina D. Gut Microbiome Shotgun Sequencing in Assessment of Microbial Community Changes Associated with H.pylori Eradication Therapy. BioNanoSci. 2016; Vol.6, Is.4:585-587. doi:10.1007/s12668-016-0285-y.
      36. Лоранская И. Д., Болдырева М. Н., Лаврентьева О. А., Мулухова Э. В. Пристеночная микрофлора кишечника. - М.: Прима принт, 2015. - 100 с.
      37. Ардатская М. Д. Синдром избыточного бактериального роста. - М.: Форте принт, 2011. - 56 с.
      38. Барсук А. Л., Сумина А. В. Практическое обоснование низкой диагностической ценности микробиологического исследования кала на дисбактериоз. // Вопросы диагностики педиатрии. - 2009. - № 2. - С. 7-11.
      39. Лоранская И. Д., Лаврентьева О. А. Функциональный анализ микробиоценоза желудочно-кишечного тракта // РМЖ. - 2011. - № 17. - С. 1057.
      40. Tyakht AV, Kostryukova ES, Popenko AS, et al. Human gut microbiota community structures in urban and rural populations in Russia. Nat Commun. 2013; 4:2469. doi: 10.1038/ncomms3469.
      41. Truong DT, Franzosa EA, Tickle TL, et al. MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nature Methods. 2015; 12:902-903. doi:10.1038/nmeth.3589.
      42. Human Microbiome Project (HMP) Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012 Jun 13; 486 (7402):207-14. doi: 10.1038/nature11234.
      43. Pilarczyk-Zurek M, Strus M, Piotr PA, Heczko B. The dual role of Escherichia coli in the course of ulcerative colitis. BMC Gastroenterol. 2016; 16:128. doi: 10.1186/s12876-016-0540-2.
      44. Dabard J, Bridonneau C, Phillipe C, et al. Fons Ruminococcin A, a New Lantibiotic Produced by a Ruminococcus gnavus Strain Isolated from Human Feces. Appl Environ Microbiol. 2001 Sep; 67(9):4111-8.
      45. Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012; Vol. 489 № 7415:220-230.
      46. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006 Feb; 55(2):205-211. doi: 10.1136/gut.2005.073817.
      47. Noor SO, Ridgway K, Scovell L, et al. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterology. 2010; 10:134. doi: 10.1186/1471-230X-10-134.
     


    Full text is published :
    Danilova N.A., Abdulkhakov S.R., Grigoryeva T.V., Markelova M.I. et al. CHANGES OF INTESTINAL MICROBIOTA IN PATIENTS WITH ULCERATIVE COLITIS. Experimental and Clinical Gastroenterology Journal. 2017;142(06):54-60
    Read & Download full text

    1. Ryazan State Medical University (Ryazan, Russian Federation)

    Keywords:chronic pancreatitis,long-term results,auto-aggressive behavior,social and psychological characteristics,quality of life

    Abstract:This article is devoted to studying the long-term results of surgical treatment of patients with chronic pancreatitis. Studied personality traits, social and psychological characteristics and the quality of life of patients with chronic pancreatitis. The results indicate that the disease is multidisplinarnoy problem and requires the attention not only on the part of health professionals, but also long-term observations of psychologists, sociologists and social workers.

      1. Jupp J., Fine D., Johnson p. D. The epidemiology and socioeconomic impact of chronic pancreatitis // Best Pract Res Clin Gastroenterol. 2010. Vol. 24, № 3. Р. 219-231.
      2. Натальский А. А., Тарасенко С. В., Песков О. Д. Проблема печеночной недостаточности в хирургии // Наука молодых - Eruditio juvenium. 2013. № 1. С. 59-71.
      3. Ивашкин В. Т., Маев И. В., Охлобыстин А. В., Кучерявый Ю. А., Трухманов А. С., Шептулин А. А., Шифрин О. С., Лапина Т. Л., Осипенко М. Ф., Симаненков В. И., Хлынов И. Б., Алексеенко С. А., Алексеева О. П., Чикунова М. В. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению хронического панкреатита // Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2014. Т. 24, № 4. С. 70-97.
      4. Global status report on alcohol and health / World Health Organization. Geneve: WHO, 2014. 375 p.
      5. Тарасенко С. В., Рахмаев Т. С., Песков О. Д., Копейкин А. А., Зайцев О. В., Соколова С. Н., Баконина И. В., Натальский А. А., Богомолов А. Ю., Кадыкова О. А. Классификационные критерии хронического панкреатита // Рос. мед.-биол. вестн. им. акад. И. П. Павлова. 2016. № 1. С. 91-97.
      6. Маев И. В., Кучерявый Ю. А., Андреев Д. Н., Дичева Д. Т., Гуртовенко И. Ю., Баева Т. А. Хронический панкреатит: новые подходы к диагностике и лечению: учебно-методическое пособие для врачей. Москва: ФКУЗ «ГКГ МВД России», 2014. 32 с.
      7. Сидоров П. И. Клиническая психология. Москва: ГЭОТАР-Медиа, 2008. 879 с.
      8. Евдокимова Е. М., Липатов В. А. Характеристика личностных особенностей у больных хроническим панкреатитом // Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2007. № 2. С. 20-30.
      9. Ширинская Н. В., Росляков А. Е., Ахмедов В. А., Минеев В. С. Психологический статус пациентов хроническим алкогольным и хроническим рецидивирующим панкреатитом // Сибирский журнал гастроэнтерологии и гепатологии. 2007. № 16-17. С. 188-189.
      10. Шитов Е. А., Меринов А. В., Шустов Д. И., Федотов И. А. Клиническая и суицидологическая характеристика больных алкогольной зависимостью с сопутствующим пограничным расстройством личности // Российский медико-биологический вестник имени академика И. П. Павлова. 2015. № 4. С. 87-90.
      11. Меринов А. В., Федотов И. А., Куликов С. О. Сравнение методов психотерапевтического лечения аутоагрессивного поведения // Академический журнал Западной Сибири. 2015. Т. 11, № 2 (57). С. 126-131.
      12. Баженова М. И. Особенности интегральной индивидуальности хронических соматических больных и их связь с отношением к болезни: автореферат дис. кандидата психологических наук. Пермь, 2007. 23 с.
      13. Гутнова С. К. Качество жизни больных при хроническом панкреатите // Вестник современной клинической медицины. 2010. Т. 3, прил. 1. С. 52.
      14. Липатов В. А., Евдокимова Е. М. Исследование депрессивных реакций у больных хроническим панкреатитом // Российский биомедицинский журнал. 2007. Т. 8. С. 161-168.
     


    Full text is published :
    Natalskiy A.A., Tarasenko S.V., Zaytsev O.V., Peskov O.D. et al. CHRONIC PANCREATITIS IS A MULTIDISCIPLINARY MEDICAL-SOCIAL PROBLEM. Experimental and Clinical Gastroenterology Journal. 2017;142(06):61-65
    Read & Download full text

    1. Siberian State Medical University, Ministry of Health of the Russian Federation (Tomsk, Russian Federation)
    2. Tomsk State Pedagogical University (Tomsk, Russian Federation)
    3. National Research Tomsk State University (Tomsk, Russian Federation)

    Keywords:season,the reactivity of the nervous system,open field,carbachol,glycylproline (Gly-Pro),gastric secretion,volume of juice,acidity,proteolytic activity

    Abstract:The aim of this study was to identify the effect of seasonal changes of carbachol and Gly-Pro on secretor function of the stomach in rats with actively-search behavior, intermediate and passive-defensive behavior in the “open field”. The experiment was carried out on male rats of Wistar, the reactivity of the nervous system was assessed during the winter and summer solstice. Rats were imposed ligature on the pyloric section of the stomach, after that carbachol, Gly-Pro and saline were injected in various combinations. In 45 minutes of secretion, rats were decapitateв, gastric juice was collected, and its volume, acidity and proteolytic activity were identified. Statistical procedures were performed using STATISTICA 8.0, used the criterion of Mann-Whitney, cluster analysis. When comparing rates of gastric secretion after administration of carbachol, assessed in summer and winter periods, certain specific secretion features were detected only in rats with the passive-defensive type. This group demonstrated the smaller volume and greater proteolytic activity of gastric juice in summer compared to winter. Greater variety of secretion features was identified in thegroups of rats receiving the peptide cholinomimetic depending on the reactivity of the nervous system and season. In the summer the introduction of сholinomimetiс and Gly-Pro were accompanied with decreasing proteolytic activity of gastric juice in the rats with active search behavior; decrease in the volume of secretion, and in rats with an intermediate type of behavior; increase in volume of juice and decreased digestive ability in rats with passive-defensive type of behavior. In winter Gly-Pro on the background of carbachol increased only the acidity of gastric juice in rats with active search behavior in the “indoor field”, without affecting the levels of gastric secretion of two other groups of animals. Thus specific response of the secretory cells of the rats’ stomach after administration of carbachol solely, and together with Gly-Pro are determined by the reactivity of the central nervous system of animals and season of the year.ons of psychologists, sociologists and social workers.

      1. Browning K. N., Travagli R. A. Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions. Comprehensive Physiology, 2014, vol. 4, no. 4, pp. 1339-1368.
      2. Мерденова Л. А., Созаева З. Ю., Хетагурова Л. Г. Мелатонин - межклеточный нейроэндокринный регулятор жизнедеятельности организма. // Владикавказский медико-биологический вестник, 2008, т. 8, № 14, с. 34-40.
      3. Мерденова Л. А., Созаева З. Ю., Хетагурова Л. Г. Мелатонин - межклеточный нейроэндокринный регулятор жизнедеятельности организма. // Владикавказский медико-биологический вестник, 2008, т. 8, № 14, с. 34-40.
      4. Фирсова Л. Д. Психологические реакции на болезнь и приверженность лечению. Экспериментальная и клиническая гастроэнтерология, 2013, № 8, с. 41-44.
      5. Van Oudenhove L., Crowell M. D., Drossman D. A. et al. Biopsychosocial Aspects of Functional Gastrointestinal Disorders. Gastroenterology, 2016, Feb 18. pii: S 0016-5085(16)00218-3. doi: 10.1053/j.gastro.2016.02.027.
      6. Merchant J. L. Tales from the crypts: regulatory peptides and cytokines in gastrointestinal homeostasis and disease. The Journal of clinical investigation, 2007, vol. 117, no. 1, pp. 6-12.
      7. Jékely G. Global view of the evolution and diversity of metazoan neuropeptide signaling. Proceedings of the National Academy of Sciences of the United States of America, 2013, vol. 110, no. 21, pp. 8702-8707.
      8. Бакаева З. В., Козлов И. Г., Сангаджиева А. Д. и соавт. Корреляционный анализ изменений экспрессии генов цитокинов и противоязвенных эффектов Pro-Gly-Pro и N-Acetyl- Pro-Gly-Pro в условиях экспериментальных моделей язвообразования. Доклады Академии наук, 2015, т. 465, № 5, с. 612.
      9. Томова Т. А., Замощина Т. А., Просекина Е. Ю., Светлик М. В. Влияние карбахолина (Gly-Pro) на секреторную функцию желудка в зависимости от реактивности ЦНС у крыс. Экспериментальная и клиническая фармакология, 2015, т. 78, № 3, с. 13-16.
      10. Каркищенко Н. Н., Грачев С. В. (ред.) Руководство по лабораторным животным и альтернативным моделям в биомедицинских исследованиях. - Москва: Профиль, 2010.
      11. Буреш Я., Бурешова О., Хьюстон Дж. Методики и основные эксперименты по изучению мозга и поведения. - Москва: Высш. шк., 1991.
      12. Мыш В. Г. Секреторная функция желудка и язвенная болезнь. - Новосибирск: Наука, 1987.
      13. Кривова Н. А., Дамбаев Г. Ц., Хитрихеев В. Е. Надэпителиальный слизистый слой желудочно-кишечного тракта и его функциональное значение. - Томск: МГП «РАСКО», 2002.
      14. Сергеев П. В., Шимановский Н. Л., Петров В. И. Рецепторы физиологически активных веществ. - Волгоград: Семь ветров, 1999.
      15. Humphrey P. A., Ruffolo R. R. et al. The IUPHAR compendium of receptor characterization and classification. - London: Cambridge, 1998.
      16. Майский В. В. (ред.) Фармакология, Ч. 1-2. - Москва, 2003.
      17. Валеева Л. А., Нургалина Э. М., Кулагина И. Г., Годоражи О. Ю. Хронобиологическая организация Н2-рецепторов головного мозга. Медицинский вестник Башкортостана, 2011, т. 6, № 2, с. 296-299.
      18. Шмидт Р., Тевс Г. (ред) Физиология человека. - М.: Мир, 1996.
      19. Климов П. К., Барашкова Г. М. Физиология желудка. Механизмы регуляции. - Л.: Наука, 1991.
      20. Исмайлова Х. Ю., Агаев Т. М., Семенова Т. П. Индивидуальные особенности поведения: (моноаминергические механизмы). - Баку: Нурлан, 2007.
      21. Самонина Г. Е., Копылова Г. Н., Сергеев В. И. и соавт. Коррекция кровотока желудка как один из механизмов противоязвенных эффектов коротких пролинсодержащих пептидов. Российский физиологический журнал им. И. М. Сеченова, 2001, т. 87, № 11, с. 1488-1492.
      22. Byun H. G., Kim S. K. Structure and activity of angiotensin I converting enzyme inhibitory peptides derived from Alaskan Pollack skin. Journal of biochemistry and molecular biolog, 2002, vol. 35, № 2, pp. 239-243.
      23. Ашмарин И. П., Каразеева Е. П. Новые роли высокостабильных олигопептидов, нейротрофинов и иммуномодуляторов в регуляторном континууме. Успехи физиологических наук, 2003, т. 34, № 1, с. 14-19.
      24. Бакаева З. В., Бадмаева К. Е., Сергеев И. Ю., Самонина Г. Е. Влияние глипролинов на норадреналиновый тонус изолированного кольцевого сегмента аорты крысы. Бюллетень экспериментальной биологии и медицины, 2003, т. 135, № 4. с. 390-393.
      25. Asselin S., Knight C. G., Farndale R. W. et al. Monomeric (glycine-proline-hydroxyproline)10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI. Biochemical Journal, 1999, vol. 339, no. 2, pp. 413-418.
      26. Замощина T. A. Лития оксибутират и ритмическая структура активно-поискового поведения и температуры тела крыс в условиях постоянного освещения. Экспериментальная и клиническая фармакология, 2000, т. 63,№ 2, с. 12-15.
      27. Ашофф Ю. Свободнотекущие и захваченные циркадианные ритмы // под ред. Ашоффа Ю. Биологические ритмы. - Москва: Мир, 1984.
      28. Романов Ю. А., Маркина В. В., Антохин А. И. и соавт. Биологические ритмы чувствительности клеток к воздействиям как основа хронобиологического механизма регуляции гомеостаза их функций. Проблемы ритмов в естествознании: матер. 2 междунар. симпоз., Москва, 1-3 марта, 2004, с. 362-363.
     


    Full text is published :
    Tomova T.A., Zamoshchina T.A., Fedorutseva E.Yu., Svetlik M.V. SEASONAL EFF ECT OF GLY-PRO PEPTIDE ON THE SECRETORY FUNCTION OF RATS’ STOMACH WITH DIFF ERENT REACTIVITY OF THE CENTRAL NERVOUS SYSTEM. Experimental and Clinical Gastroenterology Journal. 2017;142(06):66-71
    Read & Download full text

    1. State budgetary institution of Moscow city “The Loginov Moscow clinical research center of the Department of Health” (Moscow, Russian Federation)

    Abstract:The article presents data concerning the determination of acetylcholine (Ah) and cholinesterase activity (HAE) in the serum of patients with PUD, chronic pancreatitis of alcoholic etiology (AKHP) and inflammatory bowel disease (ulcerative colitis, Crohn’s disease), IBD. Established that healthy individuals can be divided into three groups with different levels of the concentration of acetylcholine - low, medium and high. The aim of the research was to identify how the concentration of Oh in response to the disease (primary or secondary). The concentration of Oh is associated with the disease and depends on the localization of the pathological process. The change in concentration of the mediator of the parasympathetic nervous system can influence the course of the disease is prognostically significant factor.

      1. Трубицына И. Е. Биологически активные вещества как факторы агрессии и защиты при язве желудка (экспериментально-клиническое исследование), Автореферат докторской диссертации, 2004, стр. 29, Москва
      2. Трубицына И. Е., Дроздов В. Н., Рудь М. В. Вариации и частота распределения количественного значения ацетилхолина и холинестеразной активности в сыворотке крови у здоровых лиц. //Экспериментальная и клиническая гастроэнтерология, 2007, № 3, с. 78-81.
      3. Винокурова Л. В., Валитова Э. Р., Трубицына И. Е., Шустова С. Г., Яшина Н. И., Ткаченко Е. В. Нарушение гуморальной.регуляции внешнесекреторной функции поджелудочной железы при хроническом панкреатите. Терапевтический архив. 2007. Т. 79. № 2. С. 44-48.
      4. Винокурова Л. В., Трубицына И. Е. Особенности клинического течения и терапии хронического панкреатита в зависимости от стадии заболевания,//Лечащий врач, 2010,№ 2, с. 48-51
      5. Винокурова Л.В., Трубицына И. Е., Губина А. В., Чикунова Б. З. Функциональная недостаточность поджелудочной железы и ее коррекция в зависимости от стадии хронического панкреатита //РМЖ, т. 18, № 13(377), с. 837-841, 2010
      6. Трубицына И. Е., Винокурова Л. В. Дизрегуляция секреторной активности поджелудочной железы при хроническом панкреатите. Научно-практический журнал Патогенез, 2007, 24.
      7. В. Г. Граник «Метаболизм эндогенных соединений» - М.: Вузовская книга, 2006. - 528 с.].
      8. Kruskal W.H, Wallis W. A. Use of ranks in one-criterion variance analysis // Journal of the American Statistical Association, volume 47, issue 260, - 1952 - p. 583-621.
      9. Винокурова Л. В., Трубицына И. Е., Царегородцева Т. М., Яшина Н. И., Хацко И. В., Живаева Н. С. Роль нейромедиаторов и цитокинов в патогенезе хронического алкогольного панкреатита //Тер. Архив., том 80, № 2, 2008, стр. 75-78
      10. Кислякова Е. А. Трибутирин в коррекции послеоперационных нарушений электрической активности тонкой кишки (экспериментальное исследование) Автореферат кандидатской диссертации, 2016, стр. 27, Москва.
     


    Full text is published :
    Trubitsyna I.E., Gulyaev A.S., Vinokurova L.V., Ruchkina I.N. et al. THE CHANGE IN THE CONCENTRATION OF ACETYLCHOLINE IN PEPTIC DUODENAL ULCER DISEASE, CHRONIC ALCOHOLIC PANCREATITIS, INFL AMMATORY BOWEL DISEASES. Experimental and Clinical Gastroenterology Journal. 2017;142(06):72-76
    Read & Download full text

    1. State Research Institute of Highly Pure Biopreparations; North-Western State Medical University named after I. I. Mechnikov (St. Petersburg, Russian Federation)
    2. State Research Institute of Highly Pure Biopreparations (St. Petersburg, Russian Federation)
    3. Kirov Military Medical Academy (St. Petersburg, Russian Federation)
    4. Institute of Experimental Medicine (St. Petersburg, Russian Federation)

    Keywords:calcium butyrate,butyric acid,celiac disease,dysbiosis,Faecalibacterium prausnitzii,gut microbiota,inulin,metabiotics,serum metabolome,ulcerative colitis

    Abstract:Aim: to investigate changes in the composition of fecal microbiota, serum metabolome and some clinical parameters following oral calcium butyrate plus inulin (Zacofalk NMX) in patients with ulcerative colitis (UC) and celiac disease (CD). Methods: 40 mild-to-moderate active left-sided UC patients and 43 CD patients in remission on a gluten-free diet were enrolled in the study. The quantitative real-time polymerase chain reaction (qRT-PCR) was used for fecal microbiota assessment. Serum metabolomic assays were conducted using the GC-MS. Study design: an open, randomized, parallel-group study. UC patients were randomized into A1 and A2 groups and CD patients were randomized into B 1 and B 2 groups. Patients enrolled in the groups A1 (UC) and B 1 (CD) received Zacofalk NMX (Dr. Falk Pharma GmbH, 3 tablets per day) for 28 days as supplement to oral mesalazine (standard treatment) in UC or gluten-free diet (GFD) in CD. Patients from group A2 (UC) received standard treatment for 28 days. Patients from group B 2 (CD) were on a gluten-free diet. Results: Oral butyrate plus inulin (as supplement for 28 days) significantly enhanced fecal butyrate-producing bacteria (with a butyryl coenzyme A: acetate-CoA transferase gene, but) and significantly reduced elevated baseline Bacteroides fragilis / Faecalibacterium prausnitzii ratio in both (A1 and B 1) groups. Significant changes in gut microbiota in both UC and CD were accompanied by changes in serum levels of some microbial metabolites (reduced levels of anti-inflammatory caproate and glycolate, elevated levels of pro-inflammatory metabolites such as lactate, 2-hydroxyisovalerate, succinate, fumarate, benzoate, p-hydroxyphenylacetate and 3-indoleacetate). Butyrate plus inulin significantly lowered serum levels of pro-inflammatory succinic acid (in both UC and CD patients) and 2-hydroxyisovaleric acid (in CD). In total, 85 % of UC patients in group A1 (Zacofalk NMX) demonstrated significant improvement in both rectal bleeding and stool frequency by day 14, compared to 55 % in group A2 (p=0.048; Fisher’s exact test). Consumption of Zacofalk NMX for 28 days in CD patients (group B 1) improved perception of some clinical syndromes (indigestion and abdominal pain) evaluated by the GSRS: there was a significant decrease in related subscores (from 3.8 to 2.1 for indigestion; from 3.2 to 1.7 for abdominal pain; p<0.05 for both). Butyrate plus inulin significantly improved bloating in CD patients (group B 1) compared with those from group B 2 with GFD only (73 % vs. 29 %; p = 0.006; Fisher’s exact test). Conclusions: In addition to anti-inflammatory and immunomodulatory effects, butyric acid is probably able to exert a prebiotic (butyrogenic) effect, restoring butyrate-producing bacteria in patients with gut dysbiosis associated with chronic inflammation (IBD) or in patients with dysbiosis due to a decrease in dietary fiber intake (GFD). A significant reduction in the Bacteroides fragilis / Faecalibacterium prausnitzii ratio and the lowering of serum level of pro-inflammatory microbial metabolites confirm the effectiveness of metabiotics such as butyrate plus inulin in UC- or CD-associated taxonomic/metabolic dysbiosis. Clinical data also support the use of butyrate plus inulin as supplement to standard treatment in UC or gluten-free diet in CD patients to more rapid improvement in gastrointestinal symptoms.

      1. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017 May 16;474(11):1823-1836. doi: 10.1042/BCJ20160510.
      2. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010 Jul;90(3):859-904. doi: 10.1152/physrev.00045.2009.
      3. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003 Feb 8;361(9356):512-9. doi: 10.1016/S 0140-6736(03)12489-0.
      4. Guarnier F. The enteric microbiota. In: Granger DN, Granger J, Morgan & Claypool Life Sciences, eds. Colloquium Series on Integrated Systems Physiology: From Molecule to Function to Disease. USA: Morgan & Clay pool Life Sciences Publishers, 2011: 1-77.
      5. Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics. 2011;5:71-86. doi: 10.2147/BTT.S 19099.
      6. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Therap Adv Gastroenterol. 2013 Jul;6(4):295-308. doi: 10.1177/1756283X13482996.
      7. Philpott H, Gibson P, Thien F. Irritable bowel syndrome - An inflammatory disease involving mast cells. Asia Pac Allergy. 2011 Apr;1(1):36-42. doi: 10.5415/apallergy.2011.1.1.36.
      8. Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, Dinan TG, Cryan JF. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2013 Jun;18(6):666-73. doi: 10.1038/mp.2012.77.
      9. Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? World J Gastroenterol. 2014 Oct 21;20(39):14105-25. doi: 10.3748/wjg.v20.i39.14105.
      10. Ситкин C. И. Воспаление, микробиота, висцеральная гиперчувствительность - новые и «старые» терапевтические мишени при синдроме раздраженного кишечника // Клинические перспективы гастроэнтерологии, гепатологии. - 2014. - № 3. - С. 43-52.
      11. DuPont AW, DuPont HL. The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol. 2011 Aug 16;8(9):523-31. doi: 10.1038/nrgastro.2011.133.
      12. Sartor RB. Gut microbiota: Diet promotes dysbiosis and colitis in susceptible hosts. Nat Rev Gastroenterol Hepatol. 2012 Oct;9(10):561-2. doi: 10.1038/nrgastro.2012.157.
      13. Quigley EM, Monsour HP. The Gut Microbiota and Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2015 Aug;35(3):262-9. doi: 10.1055/s-0035-1562946.
      14. Keren N, Konikoff FM, Paitan Y, Gabay G, Reshef L, Naftali T, Gophna U. Interactions between the intestinal microbiota and bile acids in gallstones patients. Environ Microbiol Rep. 2015 Dec;7(6):874-80. doi: 10.1111/1758-2229.12319.
      15. Verdu EF, Galipeau HJ, Jabri B. Novel players in coeliac disease pathogenesis: role of the gut microbiota. Nat Rev Gastroenterol Hepatol. 2015 Sep;12(9):497-506. doi: 10.1038/nrgastro.2015.90.
      16. Chang C, Lin H. Dysbiosis in gastrointestinal disorders. Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):3-15. doi: 10.1016/j.bpg.2016.02.001.
      17. Marasco G, Di Biase AR, Schiumerini R, Eusebi LH, Iughetti L, Ravaioli F, Scaioli E, Colecchia A, Festi D. Gut Microbiota and Celiac Disease. Dig Dis Sci. 2016 Jun;61(6):1461-72. doi: 10.1007/s10620-015-4020-2.
      18. Kim D, Zeng MY, Núñez G. The interplay between host immune cells and gut microbiota in chronic inflammatory diseases. Exp Mol Med. 2017 May 26;49(5): e339. doi: 10.1038/emm.2017.24.
      19. Miner-Williams WM, Moughan PJ. Intestinal barrier dysfunction: implications for chronic inflammatory conditions of the bowel. Nutr Res Rev. 2016 Jun;29(1):40-59. doi: 10.1017/S 0954422416000019.
      20. Macfarlane S, Furrie E, Cummings JH, Macfarlane GT. Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. Clin Infect Dis. 2004 Jun 15;38(12):1690-9. doi: 10.1086/420823.
      21. Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H, Zhu W, Sartor RB, Boedeker EC, Harpaz N, Pace NR, Li E. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2011 Jan;17(1):179-84. doi: 10.1002/ibd.21339.
      22. Duboc H, Rajca S, Rainteau D, Benarous D, Maubert MA, Quervain E, Thomas G, Barbu V, Humbert L, Despras G, Bridonneau C, Dumetz F, Grill JP, Masliah J, Beaugerie L, Cosnes J, Chazouillères O, Poupon R, Wolf C, Mallet JM, Langella P, Trugnan G, Sokol H, Seksik P. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013 Apr;62(4):531-9. doi: 10.1136/gutjnl-2012-302578.
      23. Kabeerdoss J, Sankaran V, Pugazhendhi S, Ramakrishna BS. Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India. BMC Gastroenterol. 2013 Jan 26;13:20. doi: 10.1186/1471-230X-13-20.
      24. Rajilić-Stojanović M, Shanahan F, Guarner F, de Vos WM. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis. 2013 Mar;19(3):481-8. doi: 10.1097/MIB.0b013e31827fec6d.
      25. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014 May;146(6):1489-99. doi: 10.1053/j.gastro.2014.02.009.
      26. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015 Jan;37(1):47-55. doi: 10.1007/s00281-014-0454-4.
      27. Fukata M, Arditi M. The role of pattern recognition receptors in intestinal inflammation. Mucosal Immunol. 2013 May;6(3):451-63. doi: 10.1038/mi.2013.13.
      28. Quigley EMM. Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet? Nat Rev Gastroenterol Hepatol. 2017 May;14(5):315-320. doi: 10.1038/nrgastro.2017.29.
      29. Swidsinski A, Loening-Baucke V, Herber A. Mucosal flora in Crohn’s disease and ulcerative colitis - an overview. J Physiol Pharmacol. 2009 Dec;60 Suppl 6:61-71.
      30. Chen SJ, Liu XW, Liu JP, Yang XY, Lu FG. Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier. World J Gastroenterol. 2014 Jul 28;20(28):9468-75. doi: 10.3748/wjg.v20.i28.9468.
      31. Sartor RB, Wu GD. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology. 2017 Feb;152(2):327-339.e4. doi: 10.1053/j.gastro.2016.10.012.
      32. Ситкин С. И., Ткаченко Е. И., Вахитов Т. Я. Метаболический дисбиоз кишечника и его биомаркеры // Экспериментальная и клиническая гастроэнтерология. - 2015. - № 12 (124). - С. 6-29.
      33. Huda-Faujan N, Abdulamir AS, Fatimah AB, Anas OM, Shuhaimi M, Yazid AM, Loong YY. The impact of the level of the intestinal short chain fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochem J. 2010 May 13;4:53-8. doi: 10.2174/1874091X01004010053.
      34. Romagnoli PA, Shenk GK, Pham QM, Maher L, Khanna KM. Commensal metabolite indol-3-propionic acid promotes gut barrier function by regulating IL-22 production during intestinal inflammatory conditions. J Immunol. 2016 May 1;196(1) Suppl 67.10.
      35. Корниенко Е. А. Роль кишечной микробиоты в развитии целиакии // Медицинский совет. - 2013. - № 1. - С. 44-51.
      36. De Palma G, Nadal I, Collado MC, Sanz Y. Effects of a gluten-free diet on gut microbiota and immune function in healthy adult human subjects. Br J Nutr. 2009 Oct;102(8):1154-60. doi: 10.1017/S 0007114509371767.
      37. Brown K, DeCoffe D, Molcan E, Gibson DL. Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease. Nutrients. 2012 Aug;4(8):1095-119. doi: 10.3390/nu4081095.
      38. Golfetto L, de Senna FD, Hermes J, Beserra BT, França Fda S, Martinello F. Lower bifidobacteria counts in adult patients with celiac disease on a gluten-free diet. Arq Gastroenterol. 2014 Apr-Jun;51(2):139-43.
      39. Ситкин С. И., Ткаченко Е. И., Вахитов Т. Я., Орешко Л. С., Жигалова Т. Н., Авалуева Е. Б. Метаболом сыворотки крови и микробиота кишечника при язвенном колите и целиакии // Вестник Северо-Западного государственного медицинского университета им. И. И. Мечникова. - 2014. - Том 6, № 3. - С. 12-22.
      40. Lorenzo Pisarello MJ, Vintiñi EO, González SN, Pagani F, Medina MS. Decrease in lactobacilli in the intestinal microbiota of celiac children with a gluten-free diet, and selection of potentially probiotic strains. Can J Microbiol. 2015 Jan;61(1):32-7. doi: 10.1139/cjm-2014-0472.
      41. Ситкин С. И., Вахитов Т. Я., Ткаченко Е. И., Орешко Л. С., Жигалова Т. Н., Радченко В. Г., Селиверстов П. В., Авалуева Е. Б., Суворова М. А., Комличенко Э. В. Микробиота кишечника при язвенном колите и целиакии // Экспериментальная и клиническая гастроэнтерология. - 2017. - № 1 (137). - С. 8-30.
      42. Парфенов А. И., Быкова С. В., Сабельникова Е. А., Маев И. В., Баранов А. А., Бакулин И. Г., Крумс Л. М., Бельмер С. В., Боровик Т. Э., Захарова И. Н., и др. Всероссийский консенсус по диагностике и лечению целиакии у детей и взрослых // Терапевтический архив. - 2017. - Том 89, № 3. - С. 94-107. - DOI: 10.17116/terarkh201789394-107.
      43. Dong F, Zhang L, Hao F, Tang H, Wang Y. Systemic responses of mice to dextran sulfate sodium-induced acute ulcerative colitis using 1H NMR spectroscopy. J Proteome Res. 2013 Jun 7;12(6):2958-66. doi: 10.1021/pr4002383.
      44. Ooi M, Nishiumi S, Yoshie T, Shiomi Y, Kohashi M, Fukunaga K, Nakamura S, Matsumoto T, Hatano N, Shinohara M, Irino Y, Takenawa T, Azuma T, Yoshida M. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res. 2011 Sep;60(9):831-40. doi: 10.1007/s00011-011-0340-7.
      45. Vigsnaes LK, van den Abbeele P, Sulek K, Frandsen HL, Steenholdt C, Brynskov J, Vermeiren J, van de Wiele T, Licht TR. Microbiotas from UC patients display altered metabolism and reduced ability of LAB to colonize mucus. Sci Rep. 2013;3:1110. doi: 10.1038/srep01110.
      46. Novak EA, Mollen KP. Mitochondrial dysfunction in inflammatory bowel disease. Front Cell Dev Biol. 2015 Oct 1;3:62. doi: 10.3389/fcell.2015.00062.
      47. Heller S, Penrose HM, Cable C, Biswas D, Nakhoul H, Baddoo M, Flemington E, Crawford SE, Savkovic SD. Reduced mitochondrial activity in colonocytes facilitates AMPKα2-dependent inflammation. FASEB J. 2017 May;31(5):2013-2025. doi: 10.1096/fj.201600976R.
      48. Bernini P, Bertini I, Calabrò A, la Marca G, Lami G, Luchinat C, Renzi D, Tenori L. Are patients with potential celiac disease really potential? The answer of metabonomics. J Proteome Res. 2011 Feb 4;10(2):714-21. doi: 10.1021/pr100896s.
      49. Calabrò A, Gralka E, Luchinat C, Saccenti E, Tenori L. A metabolomic perspective on coeliac disease. Autoimmune Dis. 2014;2014:756138. doi: 10.1155/2014/756138.
      50. Белобородова Н. В. Интеграция метаболизма человека и его микробиома при критических состояниях // Общая реаниматология. - 2012. - Т. VIII, № 4. - С. 42-54.
      51. Levy M, Thaiss CA, Elinav E. Metabolites: messengers between the microbiota and the immune system. Genes Dev. 2016 Jul 15;30(14):1589-97. doi: 10.1101/gad.284091.116.
      52. Белобородова Н. В., Ходакова А. С., Байрамов И. Т., Оленин А. Ю. Микробный путь образования фенилкарбоновых кислот в организме человека // Биохимия. - 2009. - Т. 74, вып. 12. - С. 1657-1663.
      53. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut microbiota metabolic interactions. Science. 2012 Jun 8;336(6086):1262-7. doi: 10.1126/science.1223813.
      54. Осипов Г. А., Зыбина Н. Н., Родионов Г. Г. Опыт применения масс-спектрометрии микробных маркеров в лабораторной диагностике // Медицинский алфавит. - 2013. - Том 1, № 3 (193). - С. 64-67.
      55. Verbeke KA, Boobis AR, Chiodini A, Edwards CA, Franck A, Kleerebezem M, Nauta A, Raes J, van Tol EA, Tuohy KM. Towards microbial fermentation metabolites as markers for health benefits of prebiotics. Nutr Res Rev. 2015 Jun;28(1):42-66. doi: 10.1017/S 0954422415000037.
      56. Belcheva A, Irrazabal T, Martin A. Gut microbial metabolism and colon cancer: can manipulations of the microbiota be useful in the management of gastrointestinal health? Bioessays. 2015 Apr;37(4):403-12. doi: 10.1002/bies.201400204.
      57. Hold GL. Gastrointestinal Microbiota and Colon Cancer. Dig Dis. 2016;34(3):244-50. doi: 10.1159/000443358.
      58. Cenit MC, Olivares M, Codoñer-Franch P, Sanz Y. Intestinal Microbiota and Celiac Disease: Cause, Consequence or Co-Evolution? Nutrients. 2015 Aug 17;7(8):6900-23. doi: 10.3390/nu7085314.
      59. Prosberg M, Bendtsen F, Vind I, Petersen AM, Gluud LL. The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis. Scand J Gastroenterol. 2016 Dec;51(12):1407-1415. doi: 10.1080/00365521.2016.1216587.
      60. Girbovan A, Sur G, Samasca G, Lupan I. Dysbiosis a risk factor for celiac disease. Med Microbiol Immunol. 2017 Apr;206(2):83-91. doi: 10.1007/s00430-017-0496-z.
      61. de Sousa Moraes LF, Grzeskowiak LM, de Sales Teixeira TF, Gouveia Peluzio Mdo C. Intestinal microbiota and probiotics in celiac disease. Clin Microbiol Rev. 2014 Jul;27(3):482-9. doi: 10.1128/CMR.00106-13.
      62. Schulberg J, De Cruz P. Characterisation and therapeutic manipulation of the gut microbiome in inflammatory bowel disease. Intern Med J. 2016 Mar;46(3):266-73. doi: 10.1111/imj.13003.
      63. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, Krabshuis J, Lemair T, Kaufmann P, de Paula JA, Fedorak R, Shanahan F, Sanders ME, Szajewska H, Ramakrishna BS, Karakan T, Kim N; World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol. 2012 Jul;46(6):468-81. doi: 10.1097/MCG.0b013e3182549092.
      64. Mardini HE, Grigorian AY. Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inflamm Bowel Dis. 2014 Sep;20(9):1562-7. doi: 10.1097/MIB.0000000000000084.
      65. Floch MH, Walker WA, Sanders ME, Nieuwdorp M, Kim AS, Brenner DA, Qamar AA, Miloh TA, Guarino A, Guslandi M, Dieleman LA, Ringel Y, Quigley EM, Brandt LJ. Recommendations for Probiotic Use-2015 Update: Proceedings and Consensus Opinion. J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1: S 69-73. doi: 10.1097/MCG.0000000000000420.
      66. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004 Nov;53(11):1617-23. doi: 10.1136/gut.2003.037747.
      67. Jacobi CA, Malfertheiner P. Escherichia coli Nissle 1917 (Mutaflor): new insights into an old probiotic bacterium. Dig Dis. 2011;29(6):600-7. doi: 10.1159/000333307.
      68. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006 Jun 1;23(11):1567-74. doi: 10.1111/j.1365-2036.2006.02927.x.
      69. Adams SM, Bornemann PH. Ulcerative colitis. Am Fam Physician. 2013 May 15;87(10):699-705.
      70. World Gastroenterology Organisation Global Guidelines ‘Probiotics and prebiotics’. 2017 Feb. Available: http://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english [Accessed 9 April 2017].
      71. Smecuol E, Hwang HJ, Sugai E, Corso L, Cherñavsky AC, Bellavite FP, González A, Vodánovich F, Moreno ML, Vázquez H, Lozano G, Niveloni S, Mazure R, Meddings J, Mauriño E, Bai JC. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease. J Clin Gastroenterol. 2013 Feb;47(2):139-47. doi: 10.1097/MCG.0b013e31827759ac.
      72. Guenther K, Straube E, Pfister W, Guenther A, Huebler A. Sever sepsis after probiotic treatment with Escherichia coli NISSLE 1917. Pediatr Infect Dis J. 2010 Feb;29(2):188-9. doi: 10.1097/INF.0b013e3181c36eb9.
      73. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013 May-Jun;47(5):437-9. doi: 10.1097/MCG.0b013e318279abf0.
      74. Meini S, Laureano R, Fani L, Tascini C, Galano A, Antonelli A, Rossolini GM. Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature. Infection. 2015 Dec;43(6):777-81. doi: 10.1007/s15010-015-0798-2.
      75. Weber E, Reynaud Q, Suy F, Gagneux-Brunon A, Carricajo A, Guillot A, Botelho-Nevers E. Bifidobacterium species bacteremia: risk factors in adults and infants. Clin Infect Dis. 2015 Aug 1;61(3):482-4. doi: 10.1093/cid/civ347.
      76. Laurell A, Sjöberg K. Prebiotics and synbiotics in ulcerative colitis. Scand J Gastroenterol. 2017 Apr;52(4):477-485. doi: 10.1080/00365521.2016.1263680.
      77. Wilson B, Whelan K. Prebiotic inulin-type fructans and galacto-oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders. J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:64-68. doi: 10.1111/jgh.13700.
      78. Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol. 1991 Jul;26(7):747-50. doi: 10.3109/00365529108998594.
      79. Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, González-Huix F, at all. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol. 1999 Feb;94(2):427-33. doi: 10.1111/j.1572-0241.1999.872_a.x.
      80. Capriles VD, Arêas JA. Effects of prebiotic inulin-type fructans on structure, quality, sensory acceptance and glycemic response of gluten-free breads. Food Funct. 2013 Jan 19;4(1):104-10. doi: 10.1039/c2fo10283h.
      81. Лазебник Л. Б., Ткаченко Е. И., Орешко Л. С., Ситкин С. И., Карпов А. А., Немцов В. И., Осипенко М. Ф., Радченко В. Г., Федоров Е. Д., Медведева О. И., Селиверстов П. В., Соловьева Е. А., Шабанова А. А., Журавлева М. С. Рекомендации по диагностике и лечению целиакии взрослых // Экспериментальная и клиническая гастроэнтерология. - 2015. - № 5 (117). - С. 3-12.
      82. World Gastroenterology Organisation Global Guidelines ‘Celiac Disease’. 2016 Jul. Available at: http://www.worldgastroenterology.org/guidelines/global-guidelines/celiac-disease/celiac-disease-english [Accessed 12.08.2016].
      83. Shenderov BA. Metabiotics: novel idea or natural development of probiotic conception. Microb Ecol Health Dis. 2013 Apr 12;24. doi: 10.3402/mehd.v24i0.20399.
      84. De Preter V. Metabolomics in the Clinical Diagnosis of Inflammatory Bowel Disease. Dig Dis. 2015 Sep 14;33 Suppl 1:2-10. doi: 10.1159/000437033.
      85. Sagar NM, Cree IA, Covington JA, Arasaradnam RP. The interplay of the gut microbiome, bile acids, and volatile organic compounds. Gastroenterol Res Pract. 2015;2015:398585. doi: 10.1155/2015/398585.
      86. Ардатская М. Д. Пробиотики, пребиотики и метабиотики в коррекции микроэкологических нарушений кишечника // Медицинский совет. - 2015. - № 13. - С. 94-99.
      87. Ардатская М. Д., Бельмер С. В., Добрица В. П., Захаренко С. М., Лазебник Л. Б., Минушкин О. Н., Орешко Л. С., Ситкин С. И., Ткаченко Е. И., Суворов А. Н., Хавкин А. И., Шендеров Б. А. Дисбиоз (дисбактериоз) кишечника: современное состояние проблемы, комплексная диагностика и лечебная коррекция // Экспериментальная и клиническая гастроэнтерология. - 2015. - № 5 (117). - С. 13-50.
      88. Вахитов Т. Я., Чалисова Н. И., Ситкин С. И., Салль Т. С., Шалаева О. Н., Демьянова Е. В., Моругина А. С., Виноградова А. Ф., Петров А. В., Ноздрачев А. Д. Низкомолекулярные компоненты метаболома крови регулируют пролиферативную активность в клеточных и бактериальных культурах // Доклады Академии наук. - 2017. - Том 472, № 4. - С. 491-493. - DOI: 10.7868/S 0869565217040284.
      89. Vernia P, Monteleone G, Grandinetti G, Villotti G, Di Giulio E, Frieri G, Marcheggiano A, Pallone F, Caprilli R, Torsoli A. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci. 2000 May;45(5):976-81.
      90. Di Sabatino A, Morera R, Ciccocioppo R, Cazzola P, Gotti S, Tinozzi FP, Tinozzi S, Corazza GR. Oral butyrate for mildly to moderately active Crohn’s disease. Aliment Pharmacol Ther. 2005 Nov 1;22(9):789-94. doi: 10.1111/j.1365-2036.2005.02639.x.
      91. Vernia P. Butyrate in the treatment of ulcerative colitis. Digestive and Liver Disease Supplements. 2007 Sep;1(1):27-30. doi: 10.1016/S 1594-5804(08)60008-X.
      92. Assisi RF; GISDI Study Group. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study. Minerva Gastroenterol Dietol. 2008 Sep;54(3):231-8.
      93. Sitkin S., Tkachenko E., Vakhitov T., Oreshko L., Zhigalova T. Oral butyrate plus inulin improve serum metabolomic profile and gut microbiota composition in ulcerative colitis and celiac disease. J Crohns Colitis. 2014;8 (Suppl 1): S 232. doi: 10.1016/S 1873-9946(14)60519-5.
      94. Сарвилина И. Фармакологическое влияние пребиотика Закофальк NMX® на молекулярные механизмы развития целиакии // Врач. - 2014. - № 10. - С. 26-31.
      95. Ивашкин В.Т, Шелыгин Ю. А., Абдулганиева Д. И., Абдулхаков Р. А., Алексеева О. П., Барановский А. Ю., Белоусова Е. А., Головенко О. В., Григорьев Е. Г., и др. Проект клинических рекомендаций по диагностике и лечению взрослых пациентов с язвенным колитом // Колопроктология. - 2013. - № S 3 (45). - С. 4-21.
      96. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625-9. doi: 10.1056/NEJM198712243172603.
      97. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987 Jun;92(6):1894-8.
      98. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989 Jan 14;298(6666):82-6.
      99. D’Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb;132(2):763-86. doi: 10.1053/j.gastro.2006.12.038.
      100. Голофеевский В. Ю., Герасимова А. В., Ситкин С. И., Асанин Ю. Ю. Индекс Масевича: новый подход к оценке клинико-эндоскопической активности язвенного колита // Гастроэнтерология Санкт-Петербурга. - 2004. - № 1. - С. 14-15.
      101. Орешко Л. С. Целиакия взрослых: особенности патогенеза, клинических проявлений, диагностики, лечения и профилактики осложнений: Автореф. дис. … д-ра мед. наук. - СПб., 2008. - 44 с.
      102. Орешко Л. С. Исторические и клинические аспекты целиакии. - СПб.: СПбГМА им. И. И. Мечникова, 2011. - 108 с.
      103. Nachman F, del Campo MP, González A, Corzo L, Vázquez H, Sfoggia C, Smecuol E, Sánchez MI, Niveloni S, Sugai E, Mauriño E, Bai JC. Long-term deterioration of quality of life in adult patients with celiac disease is associated with treatment noncompliance. Dig Liver Dis. 2010 Oct;42(10):685-91. doi: 10.1016/j.dld.2010.03.004.
      104. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, Adams H, van Ree R, Stobberingh EE. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut. 2007 May;56(5):661-7. doi: 10.1136/gut.2006.100164.
      105. Smith B, Li N, Andersen AS, Slotved HC, Krogfelt KA. Optimising bacterial DNA extraction from faecal samples: comparison of three methods. Open Microbiol J. 2011;5:14-7. doi: 10.2174/1874285801105010014.
      106. Liu C, Song Y, McTeague M, Vu AW, Wexler H, Finegold SM. Rapid identification of the species of the Bacteroides fragilis group by multiplex PCR assays using group- and species-specific primers. FEMS Microbiol Lett. 2003 May 16;222(1):9-16. doi: 10.1016/S 0378-1097(03)00296-9.
      107. Rinttilä T., Kassinen A, Malinen E, Krogius L, Palva A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol. 2004;97(6):1166-77. doi: 10.1111/j.1365-2672.2004.02409.x.
      108. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, Stobberingh EE. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006 Aug;118(2):511-21. doi: 10.1542/peds.2005-2824.
      109. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009 Aug;15(8):1183-9. doi: 10.1002/ibd.20903.
      110. Louis P, Flint HJ. Development of a semiquantitative degenerate real-time pcr-based assay for estimation of numbers of butyryl-coenzyme A (CoA) CoA transferase genes in complex bacterial samples. Appl Environ Microbiol. 2007 Mar;73(6):2009-12. doi: 10.1128/AEM.02561-06.
      111. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett. 2009 May;294(1):1-8. doi: 10.1111/j.1574-6968.2009.01514.x.
      112. Лохов П. Г., Арчаков А. И. Масс-спектрометрические методы в метаболомике // Биомедицинская химия. - 2008. - Том 54, № 5. - С. 497-511.
      113. Гладилович В. Д., Подольская Е. П. Возможности применения метода ГХ-МС (обзор) // Научное приборостроение. - 2010. - Том 20, № 4. - C. 36-49.
      114. Lei Z, Huhman DV, Sumner LW. Mass spectrometry strategies in metabolomics. J Biol Chem. 2011 Jul 22;286(29):25435-42. doi: 10.1074/jbc.R 111.238691.
      115. Вирюс Э. Д., Иванов А. В., Лузянин Б. П., Пальцын А. А., Кубатиев А. А. Масс-спектрометрия в биологии и медицине ХХI века // Патологическая физиология и экспериментальная терапия. - 2013. - № 4. - С. 68-75.
      116. Kohashi M., Nishiumi S, Ooi M, Yoshie T, Matsubara A, Suzuki M, Hoshi N, Kamikozuru K, Yokoyama Y, Fukunaga K, Nakamura S, Azuma T, Yoshida M. A novel gas chromatography mass spectrometry-based serum diagnostic and assessment approach to ulcerative colitis. J Crohns Colitis. 2014 Sep;8(9):1010-21. doi: 10.1016/j.crohns.2014.01.024.
      117. van Hees NJ, Giltay EJ, Geleijnse JM, Janssen N, van der Does W. DHA serum levels were significantly higher in celiac disease patients compared to healthy controls and were unrelated to depression. PLoS One. 2014 May 19;9(5): e97778. doi: 10.1371/journal.pone.0097778.
      118. Мороз В. В., Белобородова Н. В., Бедова А. Ю., Ревельский А. И., Гецина М. Л., Осипов А. А., Саршор Ю. Н., Бучинская А. А., Оленин А. Ю. Разработка и адаптация к условиям клинической лаборатории методик газохроматографического определения фенилкарбоновых кислот в сыворотке крови // Журнал аналитической химии. - 2015. - Том 70, № 4. - С. 418-425. - DOI: 10.7868/S 004445021504012X.
      119. Wiese DM, Horst SN, Brown CT, Allaman MM, Hodges ME, Slaughter JC, Druce JP, Beaulieu DB, Schwartz DA, Wilson KT, Coburn LA. Serum Fatty Acids Are Correlated with Inflammatory Cytokines in Ulcerative Colitis. PLoS One. 2016 May 26;11(5): e0156387. doi: 10.1371/journal.pone.0156387.
      120. Zhang A, Sun H, Yan G, Wang P, Wang X. Mass spectrometry-based metabolomics: applications to biomarker and metabolic pathway research. Biomed Chromatogr. 2016 Jan;30(1):7-12. doi: 10.1002/bmc.3453.
      121. Babushok VI, Linstrom PJ, Reed JJ, Zenkevich IG, Brown RL, Mallard WG, Stein SE. Development of a database of gas chromatographic retention properties of organic compounds. J Chromatogr A. 2007 Jul 20;1157(1-2):414-21. doi: 10.1016/j.chroma.2007.05.044.
      122. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, Sinelnikov I, Krishnamurthy R, Eisner R, Gautam B, Young N, Xia J, Knox C, Dong E, Huang P, Hollander Z, Pedersen TL, Smith SR, Bamforth F, Greiner R, McManus B, Newman JW, Goodfriend T, Wishart DS. The human serum metabolome. PLoS One. 2011 Feb 16;6(2): e16957. doi: 10.1371/journal.pone.0016957.
      123. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, Djoumbou Y, Mandal R, Aziat F, Dong E, Bouatra S, Sinelnikov I, Arndt D, Xia J, Liu P, Yallou F, Bjorndahl T, Perez-Pineiro R, Eisner R, Allen F, Neveu V, Greiner R, Scalbert A. HMDB 3.0-The Human Metabolome Database in 2013. Nucleic Acids Res. 2013 Jan;41(Database issue): D 801-7. doi: 10.1093/nar/gks1065.
      124. Osipov GA, Verkhovtseva NV. Study of human microecology by mass spectrometry of microbial markers. Benef Microbes. 2011 Mar;2(1):63-78. doi: 10.3920/BM2010.0017.
      125. Ktsoyan ZA, Beloborodova NV, Sedrakyan AM, Osipov GA, Khachatryan ZA, Kelly D, Manukyan GP, Arakelova KA, Hovhannisyan AI, Olenin AY, Arakelyan AA, Ghazaryan KA, Aminov RI. Profiles of Microbial Fatty Acids in the Human Metabolome are Disease-Specific. Front Microbiol. 2011 Jan 20;1:148. doi: 10.3389/fmicb.2010.00148.
      126. Гржибовский А. М. Типы данных, проверка распределения и описательная статистика // Экология человека. - 2008. - № 1. - С. 52-58.
      127. Банержи A. Медицинская статистка понятным языком: вводный курс / пер. с англ. под ред. В. П. Леонова. - М.: Практическая медицина, 2014. - 287 с.
      128. Гублер Е. В., Генкин А. А. Применение непараметрических критериев статистики в медико-биологических исследованиях. - Л.: Медицина. - 1973. - 141 с.
      129. Гржибовский А. М. Анализ количественных данных для двух независимых групп // Экология человека. - 2008. - № 2. - С. 54-61.
      130. Наследов А. SPSS 19: профессиональный статистический анализ данных. - СПб.: Питер, 2011. - 400 с.
      131. Гржибовский А. М. Анализ трех и более независимых групп количественных данных // Экология человека. - 2008. - № 3. - С. 50-58.
      132. Гржибовский А. М. Одномерный анализ повторных измерений // Экология человека. - 2008. - № 4. - С. 51-60.
      133. Гржибовский А. М. Корреляционный анализ // Экология человека. - 2008. - № 9. - С. 50-60.
      134. Roberfroid MB. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr. 2000 Jun;71(6 Suppl):1682S-7S; discussion 1688S-90S.
      135. Kelly G. Inulin-type prebiotics - a review: part 1. Altern Med Rev. 2008 Dec;13(4):315-29.
      136. Rios-Covian D, Gueimonde M, Duncan SH, Flint HJ, de Los Reyes-Gavilan CG. Enhanced butyrate formation by cross-feeding between Faecalibacterium prausnitzii and Bifidobacterium adolescentis. FEMS Microbiol Lett. 2015 Nov;362(21). pii: fnv176. doi: 10.1093/femsle/fnv176.
      137. Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr. 2009 Feb;101(4):541-50. doi: 10.1017/S 0007114508019880.
      138. Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. MBio. 2014 Apr 22;5(2): e00889. doi: 10.1128/mBio.00889-14.
      139. Fite A, Macfarlane S, Furrie E, Bahrami B, Cummings JH, Steinke DT, Macfarlane GT. Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. J Clin Microbiol. 2013 Mar;51(3):849-56. doi: 10.1128/JCM.02574-12.
      140. Varela E, Manichanh C, Gallart M, Torrejón A, Borruel N, Casellas F, Guarner F, Antolin M. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther. 2013 Jul;38(2):151-61. doi: 10.1111/apt.12365.
      141. Wang W, Chen L, Zhou R, Wang X, Song L, Huang S, Wang G, Xia B. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. J Clin Microbiol. 2014 Feb;52(2):398-406. doi: 10.1128/JCM.01500-13.
      142. Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014 Aug;63(8):1275-83. doi: 10.1136/gutjnl-2013-304833.
      143. Cao Y, Shen J, Ran ZH. Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature. Gastroenterol Res Pract. 2014;2014:872725. doi: 10.1155/2014/872725.
      144. Yao P, Cui M, Wang H, Gao H, Wang L, Yang T, Cheng Y. Quantitative Analysis of Intestinal Flora of Uygur and Han Ethnic Chinese Patients with Ulcerative Colitis. Gastroenterol Res Pract. 2016;2016:9186232. doi: 10.1155/2016/9186232.
      145. Sitkin S., Vakhitov T., Tkachenko E., Zhigalova T., Oreshko L., Suvorova M. Not only butyrate-producing bacteria but possibly also Bacteroides thetaiotaomicron protects against ulcerative colitis. J Crohns Colitis. 2016;10(Suppl 1): S 489. doi: 10.1093/ecco-jcc/jjw019.868.
      146. Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, Zhao L. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012 Feb;6(2):320-9. doi: 10.1038/ismej.2011.109.
      147. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013 Aug 6;8(8): e70803. doi: 10.1371/journal.pone.0070803.
      148. König J, Brummer RJ. Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome. Benef Microbes. 2014 Sep;5(3):247-61. doi: 10.3920/BM2013.0033.
      149. De Palma G, Nadal I, Medina M, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol. 2010 Feb 24;10:63. doi: 10.1186/1471-2180-10-63.
      150. Kumari R, Ahuja V, Paul J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World J Gastroenterol. 2013 Jun 14;19(22):3404-14. doi: 10.3748/wjg.v19.i22.3404.
      151. Boesmans L, Ramakers M, Arijs I, Windey K, Vanhove W, Schuit F, Rutgeerts P, Verbeke K, De Preter V. Inflammation-Induced Downregulation of Butyrate Uptake and Oxidation Is Not Caused by a Reduced Gene Expression. J Cell Physiol. 2015 Feb;230(2):418-26. doi: 10.1002/jcp.24725.
      152. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol. 2002 Apr;34(4):385-96.
      153. Thibault R, Blachier F, Darcy-Vrillon B, de Coppet P, Bourreille A, Segain JP. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm Bowel Dis. 2010 Apr;16(4):684-95. doi: 10.1002/ibd.21108.
      154. Wang A, Si H, Liu D, Jiang H. Butyrate activates the cAMP-protein kinase A-cAMP response element-binding protein signaling pathway in Caco-2 cells. J Nutr. 2012 Jan;142(1):1-6. doi: 10.3945/jn.111.148155.
      155. Diakos C, Prieschl EE, Säemann M, Novotny V, Böhmig G, Csonga R, Baumruker T, Zlabinger GJ. Novel mode of interference with nuclear factor of activated T-cells regulation in T-cells by the bacterial metabolite n-butyrate. J Biol Chem. 2002 Jul 5;277(27):24243-51. doi: 10.1074/jbc.M200191200.
      156. Diakos C, Prieschl EE, Säemann MD, Böhmig GA, Csonga R, Sobanov Y, Baumruker T, Zlabinger GJ. n-Butyrate inhibits Jun NH(2)-terminal kinase activation and cytokine transcription in mast cells. Biochem Biophys Res Commun. 2006 Oct 20;349(2):863-8. doi: 10.1016/j.bbrc.2006.08.117.
      157. Campbell Y, Fantacone ML, Gombart AF. Regulation of antimicrobial peptide gene expression by nutrients and by-products of microbial metabolism. Eur J Nutr. 2012 Dec;51(8):899-907. doi: 10.1007/s00394-012-0415-4.
      158. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, Rudensky AY. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013 Dec 19;504(7480):451-5. doi: 10.1038/nature12726.
      159. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013 Dec 19;504(7480):446-50. doi: 10.1038/nature12721.
      160. Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2247-52. doi: 10.1073/pnas.1322269111.
      161. Dillon SM, Kibbie J, Lee EJ, Guo K, Santiago ML, Austin GL, Gianella S, Landay AL, Donovan AM, Frank DN, McCarter MD, Wilson CC. Low abundance of colonic butyrate-producing bacteria in HIV infection is associated with microbial translocation and immune activation. AIDS. 2017 Feb 20;31(4):511-521. doi: 10.1097/QAD.0000000000001366.
      162. Tamura K, Yamamura M, Satomi M. Effect of butyrate on colonic mucosa. JJPEN Jpn J Parenter Enteral Nutr. 1995;17:481-4.
      163. Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottière HM, Galmiche JP. Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn’s disease. Gut. 2000 Sep;47(3):397-403. doi: 10.1136/gut.47.3.397.
      164. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009 Sep;139(9):1619-25. doi: 10.3945/jn.109.104638.
      165. Vinolo MA, Rodrigues HG, Hatanaka E, Sato FT, Sampaio SC, Curi R. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem. 2011 Sep;22(9):849-55. doi: 10.1016/j.jnutbio.2010.07.009.
      166. Cushing K, Alvarado DM, Ciorba MA. Butyrate and Mucosal Inflammation: New Scientific Evidence Supports Clinical Observation. Clin Transl Gastroenterol. 2015 Aug 27;6: e108. doi: 10.1038/ctg.2015.34.
      167. Lührs H, Kudlich T, Neumann M, Schauber J, Melcher R, Gostner A, Scheppach W, Menzel TP. Butyrate-enhanced TNFα-induced apoptosis is associated with inhibition of NF-κB. Anticancer Res. 2002 May-Jun;22(3):1561-8.
      168. Scharlau D, Borowicki A, Habermann N, Hofmann T, Klenow S, Miene C, Munjal U, Stein K, Glei M. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre. Mutat Res. 2009 Jul-Aug;682(1):39-53. doi: 10.1016/j.mrrev.2009.04.001.
      169. Lazarova DL, Chiaro C, Bordonaro M. Butyrate induced changes in Wnt-signaling specific gene expression in colorectal cancer cells. BMC Res Notes. 2014 Apr 9;7:226. doi: 10.1186/1756-0500-7-226.
      170. Hagland HR, Søreide K. Cellular metabolism in colorectal carcinogenesis: Influence of lifestyle, gut microbiome and metabolic pathways. Cancer Lett. 2015 Jan 28;356(2 Pt A):273-80. doi: 10.1016/j.canlet.2014.02.026.
      171. Zhang T, Ding C, Zhao M, Dai X, Yang J, Li Y, Gu L, Wei Y, Gong J, Zhu W, Li N, Li J. Sodium Butyrate Reduces Colitogenic Immunoglobulin A-Coated Bacteria and Modifies the Composition of Microbiota in IL-10 Deficient Mice. Nutrients. 2016 Nov 24;8(12). pii: E 728. doi: 10.3390/nu8120728.
      172. Zhou D, Pan Q, Xin FZ, Zhang RN, He CX, Chen GY, Liu C, Chen YW, Fan JG. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. World J Gastroenterol. 2017 Jan 7;23(1):60-75. doi: 10.3748/wjg.v23.i1.60.
      173. Xu J, Chen X, Yu S, Su Y, Zhu W. Effects of Early Intervention with Sodium Butyrate on Gut Microbiota and the Expression of Inflammatory Cytokines in Neonatal Piglets. PLoS One. 2016 Sep 9;11(9): e0162461. doi: 10.1371/journal.pone.0162461.
      174. Arpaia N, Rudensky AY. Microbial metabolites control gut inflammatory responses. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2058-9. doi: 10.1073/pnas.1323183111.
      175. Fernando MR, Saxena A, Reyes JL, McKay DM. Butyrate enhances antibacterial effects while suppressing other features of alternative activation in IL-4-induced macrophages. Am J Physiol Gastrointest Liver Physiol. 2016 May 15;310(10): G822-31. doi: 10.1152/ajpgi.00440.2015.
      176. Gantois I, Ducatelle R, Pasmans F, Haesebrouck F, Hautefort I, Thompson A, Hinton JC, Van Immerseel F. Butyrate specifically down-regulates Salmonella pathogenicity island 1 gene expression. Appl Environ Microbiol. 2006 Jan;72(1):946-9. doi: 10.1128/AEM.72.1.946-949.2006.
      177. Vogt SL, Peña-Díaz J, Finlay BB. Chemical communication in the gut: Effects of microbiota-generated metabolites on gastrointestinal bacterial pathogens. Anaerobe. 2015 Aug;34:106-15. doi: 10.1016/j.anaerobe.2015.05.002.
      178. Jung TH, Park JH, Jeon WM, Han KS. Butyrate modulates bacterial adherence on LS 174T human colorectal cells by stimulating mucin secretion and MAPK signaling pathway. Nutr Res Pract. 2015 Aug;9(4):343-9. doi: 10.4162/nrp.2015.9.4.343.
      179. Walker AW, Duncan SH, McWilliam Leitch EC, Child MW, Flint HJ. pH and peptide supply can radically alter bacterial populations and short-chain fatty acid ratios within microbial communities from the human colon. Appl Environ Microbiol. 2005 Jul;71(7):3692-700. doi: 10.1128/AEM.71.7.3692-3700.2005.
      180. Duncan SH, Louis P, Thomson JM, Flint HJ. The role of pH in determining the species composition of the human colonic microbiota. Environ Microbiol. 2009 Aug;11(8):2112-22. doi: 10.1111/j.1462-2920.2009.01931.x.
      181. Chung WS, Walker AW, Louis P, Parkhill J, Vermeiren J, Bosscher D, Duncan SH, Flint HJ. Modulation of the human gut microbiota by dietary fibres occurs at the species level. BMC Biol. 2016 Jan 11;14:3. doi: 10.1186/s12915-015-0224-3.
      182. Zimmerman MA, Singh N, Martin PM, Thangaraju M, Ganapathy V, Waller JL, Shi H, Robertson KD, Munn DH, Liu K. Butyrate suppresses colonic inflammation through HDAC 1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol. 2012 Jun 15;302(12): G1405-15. doi: 10.1152/ajpgi.00543.2011.
      183. Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, Almeida M, Quinquis B, Levenez F, Galleron N, Gougis S, Rizkalla S, Batto JM, at all. Dietary intervention impact on gut microbial gene richness. Nature. 2013 Aug 29;500(7464):585-8. doi: 10.1038/nature12480.
      184. Le Chatelier E., Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T; MetaHIT consortium, Bork P, Wang J, Ehrlich SD, Pedersen O, Guedon E, Delorme C, Layec S, Khaci G, van de Guchte M, Vandemeulebrouck G, Jamet A, Dervyn R, Sanchez N, Maguin E, Haimet F, Winogradski Y, Cultrone A, Leclerc M, Juste C, Blottière H, Pelletier E, LePaslier D, Artiguenave F, Bruls T, Weissenbach J, Turner K, Parkhill J, Antolin M, Manichanh C, Casellas F, Boruel N, Varela E, Torrejon A, Guarner F, Denariaz G, Derrien M, van Hylckama Vlieg JE, Veiga P, Oozeer R, Knol J, Rescigno M, Brechot C, M’Rini C, Mérieux A, Yamada T. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013 Aug 29;500(7464):541-6. doi: 10.1038/nature12506.
      185. Lepage P, Leclerc MC, Joossens M, Mondot S, Blottière HM, Raes J, Ehrlich D, Doré J. A metagenomic insight into our gut’s microbiome. Gut. 2013 Jan;62(1):146-58. doi: 10.1136/gutjnl-2011-301805.
      186. Munukka E, Pekkala S, Wiklund P, Rasool O, Borra R, Kong L, Ojanen X, Cheng SM, Roos C, Tuomela S, Alen M, Lahesmaa R, Cheng S. Gut-adipose tissue axis in hepatic fat accumulation in humans. J Hepatol. 2014 Jul;61(1):132-8. doi: 10.1016/j.jhep.2014.02.020.
      187. Shenderov BA, Midtvedt T. Epigenomic programing: a future way to health? Microb Ecol Health Dis. 2014 May 8;25. doi: 10.3402/mehd.v25.24145.
      188. Sitkin S., Vakhitov T., Tkachenko E., Oreshko L., Zhigalova T. Metabolic dysbiosis concept and its biomarkers in ulcerative colitis and celiac disease. J Crohns Colitis. 2015;9(Suppl 1): S 437. doi: 10.1093/ecco-jcc/jju027.829.
      189. Абдурасулова И. Н., Тарасова Е. А., Ермоленко Е. И., Елисеев А. В., Мацулевич А. В., Бисага Г. Н., Скулябин Д. И., Суворов А. Н., Клименко В. М. При рассеянном склерозе изменяется качественный и количественный состав микробиоты кишечника // Медицинский академический журнал. - 2015. - Том 15, № 3. - С. 55-67.
      190. Tarasova E., Abdurasulova I., Matsulevich A., Skulyabin D., Bisaga G., Ermolenko E., Suvorov A., Klimenko V. Intestinal microbiota composition in patients with Multiple Sclerosis. Abstracts of 26th ECCMID Congress, the European Congress of Clinical Microbiology and Infectious Diseases. Amsterdam, Netherlands, 9-12 April, 2016. ESCMID eLibrary. Abstract 4608. P1001.
      191. Kumps A, Duez P, Mardens Y. Metabolic, nutritional, iatrogenic, and artifactual sources of urinary organic acids: a comprehensive table. Clin Chem. 2002 May;48(5):708-17.
      192. Вахитов Т. Я. Регуляторные функции бактериальных экзометаболитов на внутрипопуляционном и межвидовом уровнях: Автореф. дис. … д-ра биол. наук: 03.00.23 - биотехнология. - СПб., 2007-40 с.
      193. Dai ZL, Wu G, Zhu WY. Amino acid metabolism in intestinal bacteria: links between gut ecology and host health. Front Biosci (Landmark Ed). 2011 Jan 1;16:1768-86.
      194. Белобородова Н. В., Байрамов И. Т., Оленин А. Ю., Федотчева Н. И. Экзометаболиты некоторых анаэробных микроорганизмов микрофлоры человека // Биомедицинская химия. - 2011. - Т. 57, № 1. - С. 95-105.
      195. Russell WR, Hoyles L, Flint HJ, Dumas ME. Colonic bacterial metabolites and human health. Curr Opin Microbiol. 2013 Jun;16(3):246-54. doi: 10.1016/j.mib.2013.07.002.
      196. Захарова Ю. В., Сухих А. С. Хроматографический анализ жирных кислот клеточных стенок бифидобактерий с различной гидрофобностью // Сорбционные и хроматографические процессы. - 2015. - Т. 15, № 6. вып. 6. - С. 776-783.
      197. Richards JL, Yap YA, McLeod KH, Mackay CR, Mariño E. Dietary metabolites and the gut microbiota: an alternative approach to control inflammatory and autoimmune diseases. Clin Transl Immunology. 2016 May 13;5(5): e82. doi: 10.1038/cti.2016.29.
      198. Thota VR, Dacha S, Natarajan A, Nerad J. Eggerthella lenta bacteremia in a Crohn’s disease patient after ileocecal resection. Future Microbiol. 2011 May;6(5):595-7. doi: 10.2217/fmb.11.31.
      199. Venugopal AA, Szpunar S, Johnson LB. Risk and prognostic factors among patients with bacteremia due to Eggerthella lenta. Anaerobe. 2012 Aug;18(4):475-8. doi: 10.1016/j.anaerobe.2012.05.005.
      200. Gardiner BJ, Tai AY, Kotsanas D, Francis MJ, Roberts SA, Ballard SA, Junckerstorff RK, Korman TM. Clinical and microbiological characteristics of Eggerthella lenta bacteremia. J Clin Microbiol. 2015 Feb;53(2):626-35. doi: 10.1128/JCM.02926-14.
      201. Hedberg ME, Israelsson A, Moore ER, Svensson-Stadler L, Wai SN, Pietz G, Sandström O, Hernell O, Hammarström ML, Hammarström S. Prevotella jejuni sp. nov., isolated from the small intestine of a child with coeliac disease. Int J Syst Evol Microbiol. 2013 Nov;63(Pt 11):4218-23. doi: 10.1099/ijs.0.052647-0.
      202. Sjöberg V, Sandström O, Hedberg M, Hammarström S, Hernell O, Hammarström ML. Intestinal T-cell responses in celiac disease - impact of celiac disease associated bacteria. PLoS One. 2013;8(1): e53414. doi: 10.1371/journal.pone.0053414.
      203. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, Frezza C, Bernard NJ, Kelly B, Foley NH, Zheng L, Gardet A, Tong Z, Jany SS, Corr SC, Haneklaus M, Caffrey BE, Pierce K, Walmsley S, Beasley FC, Cummins E, Nizet V, Whyte M, Taylor CT, Lin H, Masters SL, Gottlieb E, Kelly VP, Clish C, Auron PE, Xavier RJ, O’Neill LA. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature. 2013 Apr 11;496(7444):238-42. doi: 10.1038/nature11986.
      204. Mills E, O’Neill LA. Succinate: a metabolic signal in inflammation. Trends Cell Biol. 2014 May;24(5):313-20. doi: 10.1016/j.tcb.2013.11.008.
      205. Curtis MM, Hu Z, Klimko C, Narayanan S, Deberardinis R, Sperandio V. The Gut Commensal Bacteroides thetaiotaomicron Exacerbates Enteric Infection through Modification of the Metabolic Landscape. Cell Host Microbe. 2014 Dec 10;16(6):759-69. doi: 10.1016/j.chom.2014.11.005.
      206. Sharma U, Upadhyay D, Mewar S, Mishra A, Das P, Gupta SD, Dwivedi SN, Makharia GK, Jagannathan NR. Metabolic abnormalities of gastrointestinal mucosa in celiac disease: An in vitro proton nuclear magnetic resonance spectroscopy study. J Gastroenterol Hepatol. 2015 Oct;30(10):1492-8. doi: 10.1111/jgh.12979.
      207. Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva E, Cervantes-Barragan L, Ma X, Huang SC, Griss T, Weinheimer CJ, Khader S, Randolph GJ, Pearce EJ, Jones RG, Diwan A, Diamond MS, Artyomov MN. Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation. Cell Metab. 2016 Jul 12;24(1):158-66. doi: 10.1016/j.cmet.2016.06.004.
      208. Mills EL, Kelly B, Logan A, Costa AS, Varma M, Bryant CE, Tourlomousis P, Däbritz JH, Gottlieb E, Latorre I, Corr SC, McManus G, Ryan D, Jacobs HT, Szibor M, Xavier RJ, Braun T, Frezza C, Murphy MP, O’Neill LA. Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages. Cell. 2016 Oct 6;167(2):457-470.e13. doi: 10.1016/j.cell.2016.08.064.
      209. Russell WR, Duncan SH, Scobbie L, Duncan G, Cantlay L, Calder AG, Anderson SE, Flint HJ. Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein. Mol Nutr Food Res. 2013 Mar;57(3):523-35. doi: 10.1002/mnfr.201200594.
      210. Qiu Y, Cai G, Su M, Chen T, Liu Y, Xu Y, Ni Y, Zhao A, Cai S, Xu LX, Jia W. Urinary metabonomic study on colorectal cancer. J Proteome Res. 2010 Mar 5;9(3):1627-34. doi: 10.1021/pr901081y.
      211. Uchiyama K, Yagi N, Mizushima K, Higashimura Y, Hirai Y, Okayama T, Yoshida N, Katada K, Kamada K, Handa O, Ishikawa T, Takagi T, Konishi H, Kuriu Y, Nakanishi M, Otsuji E, Itoh Y, Naito Y. Serum metabolomics analysis for early detection of colorectal cancer. J Gastroenterol. 2017 Jun;52(6):677-694. doi: 10.1007/s00535-016-1261-6.
      212. Wolf AM, Wolf D, Rumpold H, Moschen AR, Kaser A, Obrist P, Fuchs D, Brandacher G, Winkler C, Geboes K, Rutgeerts P, Tilg H. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol. 2004 Oct;113(1):47-55. doi: 10.1016/j.clim.2004.05.004.
      213. Torres MI, López-Casado MA, Lorite P, Ríos A. Tryptophan metabolism and indoleamine 2,3-dioxygenase expression in coeliac disease. Clin Exp Immunol. 2007 Jun;148(3):419-24. doi: 10.1111/j.1365-2249.2007.03365.x.
      214. Li L, Huang L, Lemos HP, Mautino M, Mellor AL. Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases. Front Immunol. 2012 May 11;3:109. doi: 10.3389/fimmu.2012.00109.
      215. Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, Brot L, Taleb S, Couturier-Maillard A, Nion-Larmurier I, Merabtene F, Seksik P, Bourrier A, Cosnes J, Ryffel B, Beaugerie L, Launay JM, Langella P, Xavier RJ, Sokol H. CARD 9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016 Jun;22(6):598-605. doi: 10.1038/nm.4102.
      216. Etienne-Mesmin L, Chassaing B, Gewirtz AT. Tryptophan: A gut microbiota-derived metabolites regulating inflammation. World J Gastrointest Pharmacol Ther. 2017 Feb 6;8(1):7-9. doi: 10.4292/wjgpt.v8.i1.7.
      217. Assisi RF; GISDI Study Group. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study. Minerva Gastroenterol Dietol. 2008 Sep;54(3):231-8.
     


    Full text is published :
    Sitkin S.I., Vakhitov T.Ya., Tkachenko E.I., Oreshko L.S. et al. DYSBIOSIS IN ULCERATIVE COLITIS AND CELIAC DISEASE AND ITS THERAPEUTIC CORRECTION BY BUTYRIC ACID PLUS INULIN. Experimental and Clinical Gastroenterology Journal. 2017;142(06):77-98
    Read & Download full text

    1. Kyrgyz-Russian Slavic University named after B. N. Yeltsin (Bishkek, Kyrgyzstan)
    2. Kyrgyzstan State Medicine Academy named after I. K. Akhunbaev (Bishkek, Kyrgyzstan)

    Keywords:inflammation,arterial stiffness,insulin resistance,metabolic syndrome,generalized periodontitis

    Abstract:The purpose of the review. To highlight the state of arterial stiffness problem of the metabolic syndrome and generalized periodontitis with clinical, laboratory and instrumental and morphological and functional positions. Recent data on the problem indicate the conjugation of the metabolic syndrome and generalized periodontitis with characteristic changes in arterial stiffness. It is assumed, on the one hand, a fundamental role of generalized periodontitis in the development of immunological processes in the body with the development of atherosclerotic cardiovascular diseases including metabolic disorders with the formation of the insulin resistance syndrome and on the other hand, indicates that hyperinsulinemia, hyperglycemia, dyslipidemia and microcirculatory disturbances increase arterial stiffness. According to the authors, the trigger generalized periodontitis progression of the metabolic syndrome, inflammation appears closely paired with an increase in arterial stiffness. Conclusion. Changes in generalized periodontitis, including vascular stiffness characteristic of the metabolic syndrome, secondary, not only on the background, but also contribute to the progression of the syndrome and the development of complications, closing circle of pathogenesis.

      1. Kornman KS. Mapping the pathogenesis of periodontitis: A new look. // J Periodontol.-2008. -Vol. 79(Suppl. 8). - P. 1560-1568.
      2. Azarpazhooh A., Tenenbaum H. C. Periodontitis: a syndromic condition. // J Can Dent Assoc. - 2012. - Vol.78. - P.27.
      3. Грудянов А. И., Овчинникова В. В. Воспалительные заболевания пародонта как фактор риска развития патологии сердечно-сосудистой системы (обзор литературы) // Стоматология. - 2007. - № 5. - С. 76-78.
      4. Blaizot A, Vergnes JN, Nuwwareh S et al. Periodontal diseases and cardiovascular events: Meta-analysis of observational studies. // Int Dent J. - 2009. -Vol.59. - P. 197-209.
      5. Карпенко И. Н., Булкина Н. В., Понукалина Е. В. Современные представления об этиологии и патогенезе быстропрогрессирующего пародонтита // Архив патологии. - 2009. - № 1. - С. 57-59.
      6. Subramanian S, Emami H, Vucic E et al. High Dose Atorvastatin Reduces Periodontal Inflammation: A Novel Pleiotropic Effect of Statins. // J Am Coll Cardiol. - 2013 Dec 24. -Vol. 62(25). - P. 2382-91.
      7. Vincent E. Friedewald, Kenneth S. Kornman, James D. Beck et al. The American Journal of Cardiology and Journal of Periodontology Editors’ Consensus: Periodontitis and Atherosclerotic Cardiovascular Diseaser. // J Periodontol. - July 2009. - P. 1021-1032.
      8. John Beilby. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. // Clin Biochem Rev. - 2004 Aug. - Vol; 25(3). - P. 195-198.
      9. Кондаков И. К., Коваль С. Н., Снегурская И. А. К проблеме патогенеза метаболического синдрома. Жировая ткань и маркеры острой фазы воспаления // Артериальная гипертензия. - 2009. - № 3 (5). - С. 39-42.
      10. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). // Eur J Cardiovasc Prev Rehabil. - 2007. - Vol. 14 (Suppl 2). - S 1-S 113.
      11. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. // J Am Coll Cardiol. - 2010. - Vol. 55(13). - P. 1318-1327.
      12. Кочкина М. С., Евдокимова М. А., Асейчева О. Ю. и соавторы. Скорость распространения пульсовой волны и риск развития фатальных исходов у больных с артериальной гипертензией, перенесших обострение ишемической болезни сердца. // Кардиология. - 2012. - № 2. - С. 4-11.
      13. Драпкина О. М., Дадаева В. А. Хроническая сердечная недостаточность начинается с периферии? Жесткие сосуды, жесткий миокард. // Российские медицинские вести. - 2014. - Том XIX, № 1. - С. 61-65.
      14. Кочкина М. С. Затейщиков Д. А., Сидоренко Б. А. Измерение жесткости артерий и ее клиническое значение. // Кардиология. - 2005. -№ 1. - С. 63-71.
      15. Максимов Н. И., Ополонский Д. В. Структурные и функциональные изменения артериальных сосудов у больных ишемической болезнью сердца с метаболическим синдромом. // Кардиология. - 2009. - № 6. - С. 10-14.
      16. Викентьев В. В., Сметнева Н. С., Самохина Д. Г. Структурные и функциональные особенности артерий при ультразвуковом исследовании у больных с эндотелиальной дисфункцией, страдающих метаболическим синдромом. // Вестник РУДН, серия Медицина. - 2008. - № 8. - C. 288-292.
      17. Avolio A. P. Pulse wave velocity and hypertension // Arterial and venous systems in essential hypertension / ed. M. Safar. - Boston, Mass: Martinus Nijhoff. - 1991. - Р. 133-152.
      18. Jung YS, Shin MH, Kim IS et al. Relationship between periodontal disease and subclinical atherosclerosis: the Dong-gu Study. // J Clin Periodontol. -2013. - Vol. 41. - P. 262-268.
      19. Orlandi M, Suvan J, Petrie A. et al. Association between periodontal disease and its treatment, flow-mediated dilatation and carotid intima-media thickness: a systematic review and meta-analysis. // Atherosclerosis. - 2014 Sep. - Vol. 236(1). - P. 39-46.
      20. Vlachopous C., Dima I., Aznaouridis K. et al. Acute systemic inflammation icreases arterial stiffness and decreases wave reflections in healthy individuals. // Circulation. - 2005. - Vol.112. - P. 2193-2200.
      21. Schillaci G., Pirro M., Vaudo G. et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension // Hypertension. - 2005. - № 45. - Р. 1078-1082.
      22. Ребров А. П., Никитина Н. М., Кароли Н. А. и соавторы. Жесткость артерий в зависимости от наличия факторов риска развития сердечно-сосудистых заболеваний // Терапевтический архив. - 2009. - № 3. - С. 54-57.
      23. Гударьян А. А. Частота и особенности клинического проявления генерализованного пародонтита при различных компонентах метаболического синдрома // Вестник стоматологии. - 2003. - № 1. - С. 20-25.
      24. Nakanishi N., Shiraishi T., Wada M. Brachial-ankle pulse wave velocity and metabolic syndrome in a Japanese population: the Minoh study // Hypertens Res. - 2005. - № 28 (2). - P. 125-31.
      25. Tomiyama H., Коji Y., Yambe M. et al. Elevated C-reactive protein augments increased arterial stiffness in subjects with the metabolic syndrome // Hypertension. - 2005. - № 45 (5). - Р. 997-1003.
      26. Дружилов М. А., Дружилова О. Ю., Отмахов В. В. и соавторы. Значение оценки артериальной жесткости при метаболическом синдроме. // Российский кардиологический журнал. - 2015. - № 12. - P. 45-49.
      27. Choi K. M., Lee K. W., Seo J. A. et al. Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors of the metabolic syndrome. // Diabetes Res Clin Pract. - 2004. - Oct. 66 (1). - Р. 57-61.
      28. Sutton-Tyrrell K., Newman A., Havlik R. еt al. Aortic stiffness is associated with visceral adiposity in older adults ehrolled in the study of health, aging, and body composition // Hypertension. - 2001. - № 38. - Р. 429.
      29. Sengstock D. M., Vaitkevicius P. V., Supiano M. A. Arterial stiffeness is related to insulin resistance in nondiabetic hypertensive older adults // The J. of Clin Endocrinology and metabolism. - 2004. - Vol. 90 (5). - Р. 2823-2827.
      30. Ройберг Г. Е. - Метаболический синдром / под ред. Г. Е. Ройберга. - М.: МЕДпрессинформ, 2007. - 224 с.
      31. Day K. Metabolic syndrome, or what jou will: definitions and epidemiology // Diab. Vasc. Dis. Res. - 2007. - Vol. 4, № 1. - Р. 32-38
      32. Чазова И. Е., В. Б. Мычка. Метаболический синдром. - М.: Медиа Медика. - 2004. - 113 с.
      33. Соколов, Е. И. Диабетическое сердце. - М.: Медицина, 2002. - 267 с.
      34. Vyssoulis G. P., Pietri P. G., Karpanou E. A. Differential impact of metabolic syndrome on arterial stiffness and wave refl ections: Focus on distinct definitions // Int. J. Cardiol. - 2010. - Vol. 138(2). - P. 119-125.
      35. Saba P. S., Roman M. J., Longhini C. et al. Carotid intimal-medial thickness and stiffness are not affected by hypercholesterolemia in uncomplicated essential hypertension // Arterioscler. Thromb. Vasc. Biol. - 1999. - Vol. 19. - № 11. - P. 2788-2794.
      36. Aznaouridis K., Vlachopoulos C., Dima I. Triglyceride level is associated with wave reflections and arterial stiffness in apparently healthy middle-aged men // Heart. - 2007. - Vol. 93, № 5. - P. 613-614.
      37. Miyaki K, Masaki K, Naito M et al. Periodontal disease and atherosclerosis from the viewpoint of the relationship between community periodontal index of treatment needs and brachial-ankle pulse wave velocity. // BMC Public Health. - 2006. - Vol. 6. - P. 131.
      38. Franek E, Blaschyk R, Kolonko A et al. Chronic periodontitis in hemodialysis patients with chronic kidney disease is associated with elevated serum C-reactive protein concentration and greater intima-media thickness of the carotid artery. // J Nephrol. - 2006. - Vol.19(3). - P. 346-351.
      39. Vieira CL, Cury PR, Miname MH et al. Severe periodontitis is associated with diastolic blood pressure elevation in individuals with heterozygous familial hypercholesterolemia: a pilot study. // J Periodontol. - 2011. - Vol. 82(5). - P. 683-688.
      40. Vidal F, Cordovil I, Figueredo CM, Fischer RG. Non-surgical periodontal treatment reduces cardiovascular risk in refractory hypertensive patients: a pilot study. // J Clin Periodontol. - 2013. - Vol.40(7). - P. 681-687.
      41. Трухан Д. И., Викторова И. В. Изменение органов и тканей полости рта при заболеваниях внутренних органов. / - М.: Практическая медицина, 2012. - 208 с.
      42. Hanaoka Y, Soejima H, Yasuda O et al. Level of serum antibody against a periodontal pathogen is associated with atherosclerosis and hypertension. // Hypertens Res. - 2013. -Vol. 36(9). - P. 829-833.
      43. Jockel-Schneider Y, Harks I, Haubitz I et al. Arterial stiffness and pulse wave reflection are increased in patients suffering from severe periodontitis. // PloS one. - 2014. - Vol. 9(8). - e103449.
      44. Kapellas K, Jamieson LM, Do LG et al. Associations between periodontal disease and cardiovascular surrogate measures among Indigenous Australians. // Int J Cardiol. - 2014. - Vol. 173(2). - P. 190-196.
      45. Shanker J, Setty P, Arvind P et al. Relationship between periodontal disease, Porphyromonas gingivalis, peripheral vascular resistance markers and coronary artery disease in Asian Indians. // Thromb Res. - 2013. - Vol. 132(1). - P. 8-14.
      46. Teeuw WJ, Slot DE, Susanto H et al. Treatment of periodontitis improves the atherosclerotic profile: a systematic review and meta-analysis. // J Clin Periodontol. - 2014. - Vol. 41(1). - P. 70-79.
      47. Seinost G, Wimmer G, Skerget M et al. Periodontal treatment improves endothelial dysfunction in patients with severe periodontitis. // Am Heart J. - 2005. - Vol.149(6). - P. 1050-1054.
      48. Piconi S, Trabattoni D, Luraghi C et al. Treatment of periodontal disease results in improvements in endothelial dysfunction and reduction of the carotid intima-media thickness. // FASEB J. - 2009. - Vol. 23(4). - P. 1196-1204.
      49. W Houcken, W J Teeuw, S Bizzarro et al. Arterial stiffness in periodontitis patients and controls. // Human Hypertension. -2015. -Vol.30. - P. 24-29.
      50. Kapellas K, Maple-Brown LJ, Jamieson LM et al. Effect of periodontal therapy on arterial structure and function among aboriginal Australians: a randomized, controlled trial. // Hypertension. - 2014. - Vol. 64(4). - P. 702-708.
     


    Full text is published :
    Sabirova A.I., Mamytova A.B., Sabirov I.S., Murkamilov I.T. ARTERIAL STIFF NESS IN METABOLIC SYNDROME AND GENERALIZED PERIODONTITIS. Experimental and Clinical Gastroenterology Journal. 2017;142(06):99-104
    Read & Download full text

    1. Moscow state medical and dentistry University n. a. A. I. Evdokimov (Moscow, Russian Federation)

    Keywords:Helicobacter pylori, gastroesophageal reflux disease, Barret esophagus, esophagus adenocarcinoma

    Abstract:The association between gastroesophageal reflux disease (GERD) and Helicobacter pylori infection (H. pylori) has been the subject of discussion for many years. Numerous studies and meta-analyzes conducted up to date have demonstrated an inverse correlation of H. pylori infection (especially CagA-positive strains) with the development of complicated forms of GERD, including Barrett's esophagus and esophageal adenocarcinoma. In fact, the development of H. pylori-associated atrophic pangastritis can have a protective function, reducing the anomalous effect of hydrochloric acid on the mucosa of the distal esophagus. According to several meta-analyzes, successful eradication of H. pylori is a risk factor for the development of GERD in the Asian population, but does not have a significant effect on the population of Western countries.

      1. Лазебник Л. Б., Ткаченко Е. И., Абдулганиева Д. И., и др. VI национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI Московские соглашения). Экспериментальная и клиническая гастроэнтерология. 2017; 2: 3-21.
      2. El-Serag H., Sweet S., Winchester C., Dent J. Update on the epidemiology of gastro- oesophageal reflux disease: a systematic review. Gut 2014; 63:871-80.
      3. Лазебник Л. Б., Машарова А. А., Бордин Д. С. и др. Результаты многоцентрового исследования «Эпидемиология Гастроэзофагеальной РЕфлюксной болезни в России» («МЭГРЕ»). Терапевтический архив. 2011; 1: 45-50.
      4. Richter J. E., Friedenberg F. K. Gastroesophageal reflux disease. In.: Sleisenger and Fordtran’s Gastrointestinaland Liver Disease: Pathophysiology, Diagnosis, Management / edited by Mark Feldman, Lawrence S Friedman, Laurence J Brandt. 10th ed. 2015.
      5. Mansour NM, Groth SS, Anandasabapathy S. Esophageal Adenocarcinoma: Screening, Surveillance, and Management. Annu Rev Med. 2017; 68:213-227.
      6. Маев И. В., Андреев Д. Н., Кучерявый Ю. А., Щегланова М. П. Аденокарцинома пищевода: факторы риска и современные стратегии скрининга. РЖГГК. 2017; 2: 3-8.
      7. Saraggi D, Fassan M, Bornschein J, Farinati F, Realdon S, Valeri N, Rugge M. From Barrett metaplasia to esophageal adenocarcinoma: the molecular background. Histol Histopathol. 2016;31(1):25-32.
      8. Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol. Clin. North Am. 2015; 44(2):203-31
      9. Hampel H, Abraham N, El-Serag H. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Annals of internal medicine. 2005;143(3):199-211.
      10. Jarosz M, Taraszewska A. Risk factors for gastroesophageal reflux disease: the role of diet. Prz Gastroenterol. 2014;9(5):297-301.
      11. Body C, Christie JA. Gastrointestinal Diseases in Pregnancy: Nausea, Vomiting, Hyperemesis Gravidarum, Gastroesophageal Reflux Disease, Constipation, and Diarrhea. Gastroenterol Clin North Am. 2016;45(2):267-83.
      12. Маев И. В., Андреев Д. Н., Кучерявый Ю. А. Инфекция Helicobacter pylori и экстрагастродуоденальные заболевания. Терапевтический архив. 2015; 8: 103-110.
      13. Kyburz A, Müller A. Helicobacter pylori and Extragastric Diseases. Curr Top Microbiol Immunol. 2017;400:325-347.
      14. Маев И. В., Самсонов А. А., Андреев Д. Н. Инфекция Helicobacter pylori. М.: ГЭОТАР-Медиа; 2016.
      15. Morgan D.R, Crowe S. E. Helicobacter pylori infection. In.: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management / edited by Mark Feldman, Lawrence S Friedman, Laurence J Brandt. - 10th ed. 2015.
      16. Маев И. В., Самсонова А. А., Андреев Д. Н., Гречушников В. Б., Коровина В. Б. Клиническое значение инфекции Helicobacter pylori. Клин. мед. 2013; 8: 4-12.
      17. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66(1):6-30
      18. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11(10):628-38.
      19. Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing. Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997;112(5):1442-7.
      20. Kandulski A, Malfertheiner P. Helicobacter pylori and gastroesophageal reflux disease. Curr Opin Gastroenterol. 2014;30(4):402-7.
      21. Konturek PC, Konturek SJ, Brzozowski T. Gastric cancer and Helicobacter pylori infection. J Physiol Pharmacol. 2006;57 Suppl 3:51-65.
      22. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ. 2003;326(7392):737.
      23. O’Connor HJ. Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. Aliment Pharmacol Ther. 1999;13(2):117-27.
      24. Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, Quesenberry C, Buffler P, Parsonnet J. Helicobacter pylori and gastroesophageal reflux disease: a case-control study. Helicobacter. 2008;13(5):352-60.
      25. Nordenstedt H, Nilsson M, Johnsen R, Lagergren J, Hveem K. Helicobacter pylori infection and gastroesophageal reflux in a population-based study (The HUNT Study). Helicobacter. 2007;12(1):16-22.
      26. Rubenstein JH, Inadomi JM, Scheiman J, Schoenfeld P, Appelman H, Zhang M, Metko V, Kao JY. Association between Helicobacter pylori and Barrett’s esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol. 2014;12(2):239-45.
      27. Chung SJ, Lim SH, Choi J, Kim D, Kim YS, Park MJ, Yim JY, Kim JS, Cho SH, Jung HC, Song IS. Helicobacter pylori Serology Inversely Correlated With the Risk and Severity of Reflux Esophagitis in Helicobacter pylori Endemic Area: A Matched Case-Control Study of 5,616 Health Check-Up Koreans. J Neurogastroenterol Motil. 2011;17(3):267-73.
      28. Minatsuki C, Yamamichi N, Shimamoto T, Kakimoto H, Takahashi Y, Fujishiro M, Sakaguchi Y, Nakayama C, Konno-Shimizu M, Matsuda R, Mochizuki S, Asada-Hirayama I, Tsuji Y, Kodashima S, Ono S, Niimi K, Mitsushima T, Koike K. Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan. PLoS One. 2013;8(7): e69891.
      29. Lupu VV, Ignat A, Ciubotariu G, Ciubară A, Moscalu M, Burlea M. Helicobacter pylori infection and gastroesophageal reflux in children. Dis Esophagus. 2016;29(8):1007-1012.
      30. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol. 2007;5(12):1413-7, 1417.e1-2.
      31. Fischbach LA, Nordenstedt H, Kramer JR, Gandhi S, Dick-Onuoha S, Lewis A, El-Serag HB. The association between Barrett’s esophagus and Helicobacter pylori infection: a meta-analysis. Helicobacter. 2012;17(3):163-75.
      32. Xie FJ, Zhang YP, Zheng QQ, Jin HC, Wang FL, Chen M, Shao L, Zou DH, Yu XM, Mao WM. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol. 2013;19(36):6098-107.
      33. Nie S, Chen T, Yang X, Huai P, Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. Dis Esophagus. 2014;27(7):645-53.
      34. Kamada T, Haruma K, Kawaguchi H, Yoshihara M, Sumii K, Kajiyama G. The association between antral G and D cells and mucosal inflammation, atrophy, and Helicobacter pylori infection in subjects with normal mucosa, chronic gastritis, and duodenal ulcer.Am J Gastroenterol. 1998;93(5):748-52.
      35. Ghoshal UC, Chourasia D. Gastroesophageal Reflux Disease and Helicobacter pylori: What May Be the Relationship? J Neurogastroenterol Motil. 2010;16(3):243-50.
      36. Wang F, Xia P, Wu F, Wang D, Wang W, Ward T, Liu Y, Aikhionbare F, Guo Z, Powell M, Liu B, Bi F, Shaw A, Zhu Z, Elmoselhi A, Fan D, Cover TL, Ding X, Yao X. Helicobacter pylori VacA disrupts apical membrane-cytoskeletal interactions in gastric parietal cells. J Biol Chem. 2008; 283(39):26714-25.
      37. Helmer KS, West SD, Vilela R, Chang L, Cui Y, Kone BC, Mercer DW. Lipopolysaccharide-induced changes in rat gastric H/K-ATPase expression. Ann Surg. 2004;239(4):501-9.
      38. Artiko VM, Chebib HY, Ugljesic MB, Petrovic MN, Obradovic VB. Relationship between enterogastric reflux estimated by scintigraphy and the presence of Helicobacter pylori. Hepatogastroenterology. 1999;46(26):1234-7.
      39. Manifold DK, Anggiansah A, Rowe I, Sanderson JD, Chinyama CN, Owen WJ. Gastro-oesophageal reflux and duodenogastric reflux before and after eradication in Helicobacter pylori gastritis. Eur J Gastroenterol Hepatol. 2001;13(5):535-9.
      40. Gall A, Fero J, McCoy C, Claywell BC, Sanchez CA, Blount PL, Li X, Vaughan TL, Matsen FA, Reid BJ, Salama NR. Bacterial Composition of the Human Upper Gastrointestinal Tract Microbiome Is Dynamic and Associated with Genomic Instability in a Barrett’s Esophagus Cohort. PLoS One. 2015;10(6): e0129055.
      41. Fallone CA, Barkun AN, Friedman G, Mayrand S, Loo V, Beech R, Best L, Joseph L. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol. 2000 Apr;95(4):914-20.
      42. Ahmed N, Sechi LA. Helicobacter pylori and gastroduodenal pathology: new threats of the old friend. Ann Clin Microbiol Antimicrob. 2005;4:1.
      43. Tanaka I, Tatsumi Y, Kodama T, Kato K, Fujita S, Mitsufuji S, Kashima K. Effect of Helicobacter pylori eradication on gastroesophageal function. J Gastroenterol Hepatol. 2004;19(3):251-7.
      44. Hamada H, Haruma K, Mihara M, Kamada T, Yoshihara M, Sumii K, Kajiyama G, Kawanishi M. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther. 2000;14(6):729-35.
      45. Nakajima S, Hattori T. Active and inactive gastroesophageal reflux diseases related to Helicobacter pylori therapy. Helicobacter. 2003;8(4):279-93.
      46. Sakata H, Fujimoto K. Barrett’s esophagus and Helicobacter pylori. Nihon Rinsho. 2005;63(8):1383-6.
      47. Hong SJ, Kim SW. Helicobacter pylori Infection in Gastroesophageal Reflux Disease in the Asian Countries. Gastroenterol Res Pract. 2015;2015:985249.
      48. Xie T, Cui X, Zheng H, Chen D, He L, Jiang B. Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol. 2013;25(10):1195-205.
      49. Wang XT, Zhang M, Chen CY, Lyu B. Helicobacter pylori eradication and gastroesophageal reflux disease: a Meta-analysis. Zhonghua Nei Ke Za Zhi. 2016;55(9):710-6.
      50. Yaghoobi M., Farrokhyar F., Yuan Y., Hunt R. H. Is there an increased risk of GERD after Helicobacter pylori eradication: a meta-analysis. The American Journal of Gastroenterology. 2010;105(5):1007-1013.
      51. Qian B., Ma S., Shang L., Qian J., Zhang G. Effects of Helicobacter pylori eradication on gastroesophageal reflux disease. Helicobacter. 2011;16(4):255-265.
      52. Saad A. M., Choudhary A., Bechtold M. L. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scandinavian Journal of Gastroenterology. 2012;47(2):129-135.
      53. Iijima K, Koike T, Shimosegawa T. Reflux esophagitis triggered after Helicobacter pylori eradication: a noteworthy demerit of eradication therapy among the Japanese? Front Microbiol. 2015;6:566.
      54. Rokkas T, Ladas SD, Triantafyllou K, Liatsos C, Petridou E, Papatheodorou G, Karameris A, Raptis SA. The association between CagA status and the development of esophagitis after the eradication of Helicobacter pylori. Am J Med. 2001;110(9):703-7.
      55. Чотчаева А. Р., Пасечников Д. В., Пасечников В. Д. Определение факторов риска и предикторов развитие ГЭРБ после эрадикации бактерии H. pylori у больных язвенной болезнью. РЖГГК. 2008; 5 S 32: 43.
      56. Malfertheiner P., Megraud F., O’Morain C. et al; European Helicobacter Study Group. Management of Helicobacter pylori infection: the Maastricht IV/ Florence Consensus Report. Gut 2012; 61 (7): 646-664.
      57. Kuipers EJ, Uyterlinde AM, Peña AS, Hazenberg HJ, Bloemena E, Lindeman J, Klinkenberg-Knol EC, Meuwissen SG. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol. 1995;90(9):1401-6.
      58. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkman JJ, Festen HP, Dent J, Zeitoun P, Havu N, Lamm M, Walan A. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut. 2004; 53(1):12-20.
      59. Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs JC, Snel P, Luckers AE, Klinkenberg-Knol EC, Festen HP, Viergever PP, Lindeman J, Meuwissen SG. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut. 2000;46(5):615-21.
      60. Андреев Д. Н., Дичева Д. Т., Маев И. В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017; 2: 76-83.
      61. Lee JY, Park KS. Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies. Gastroenterol Res Pract. 2016;2016:9086581.
      62. Desta ZX, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C 19 genetic polymorphism. Clin. Pharmacokinet. 2002; 41(12): 913-958.
      63. Maev I. V., Andreev D. N., Kucheryavyi Yu.A., Dicheva D. T. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014; 30: 134-140.
      64. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C 19: functional and clinical implications of a new variant CYP2C 19*17. Br J Clin Pharmacol. 2010;69(3):222-30.
      65. Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C 19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20(43):16029-36.
      66. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C 19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006;101(7):1467-75. DOI: 10.1111/j.1572-0241.2006.00717.x
      67. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K. CYP2C 19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res. 2001;18(6):721-7.
      68. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C 19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013;8: e62162.
      69. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414-25.
      70. Denisenko NP, Sychev DA, Sizova ZhM, Grachev AV, Velikolug KA. High frequency of CYP2C 19 ultrarapid metabolizers in Russian patients with peptic ulcer. Eksp Klin Gastroenterol. 2015;(6):11-5.
      71. Андреев Д. Н., Дичева Д. Т., Лебедева Е. Г., Парцваниа-Виноградова Е. В. Фармакологические основы применения ингибиторов протонной помп. Фарматека. 2014; 14: 62-69.
      72. Kromer W, Krüger U, Huber R, Hartmann M, Steinijans VW. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology. 1998;56(2):57-70.
      73. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272(36):22438-46.
      74. Pantoflickova D, Dorta G, Jornod P, Ravie M., Blum A. Identification of the characteristics influencing the degree of antisecretory activity of PPIs [abstract]. Gastroenterology. 2000;118: A5895.
      75. Tejura B, Boyce M, Warrington S. Rabeprazole is more potent than esomeprazole in control of gastric pH in healthy volunteers [abstract]. Ninth United European Gastroenterology Week Meeting, Amsterdam, The Netherlands. October 2001.
      76. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009;65(1):19-31.
      77. Ohara T, Goshi S, Taneike I, Tamura Y, Zhang HM, Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter. 2001 Jun;6(2):125-9.
      78. Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol. 2010 Mar 14;16(10):1279-84.
      79. Skoczylas T., Sarosiek I., Sostarich S. et al. Signicant enhancement of gastric mucin content after rabeprazole administration: its potential clinical signicance in acid-related disorders // Dig. Dis. Sci. 2003. Vol. 48. Р. 322-328.
      80. Yasuda S, Ohnishi A, Ogawa T, Tomono Y, Hasegawa J, Nakai H, Shimamura Y, Morishita N. Pharmacokinetic properties of E 3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994;32(9):466-73.
     


    Full text is published :
    Andreev D.N., Maev I.V. GASTROESOPHAGEAL REFL UX DISEASE AND INFECTION HELICOBACTER PYLORI. Experimental and Clinical Gastroenterology Journal. 2017;142(06):105-111
    Read & Download full text

    1. Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow StateMedical University of the Ministry of Health of the Russian Federation (Sechenov University) (Moscow, Russian Federation)

    Keywords:Antibiotic therapy,complications of antibacterial therapy,antibiotic-associated diarrhea,Сlostridium difficile,epidemiology,complications of infection Сlostridium difficile,comorbid diseases

    Abstract:The article contains an overview of modern recommendations for the management of patients with Clostridium difficil infection, one of the urgent and unsolved problems of modern medicine, the risk of developing it increases in elderly patients with various concomitant diseases. The prevalence of this disease in is not known in Russia. The diagnosis of Cd-I is based on a combination of clinical symptoms and the results of microbiological studies confirming the presence of toxins and toxin-producing strains, the absence of another cause or histopathological or colonoscopic signs of pseudomembranous colitis. The choice of the anti-clostridial therapy regimen for patients is based on the severity of the patient’s condition and the probability of relapse.

      1. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению Clostridium difficile-ассоциированной болезни Российский журнал гастроэнтерол гепатол колопроктол 2016;26(5) 56-65An Epidemic, Toxin Gene-Variant Strain of Clostridium difficile
      2. McDonald L. Clifford et al. An Epidemic, Toxin Gene-Variant Strain of Clostridium difficile N Engl J Med 2005; 353:2433-244
      3. Loo VG et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365:1693-703.
      4. Shim JK et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet. 1998;351:633-6.
      5. Longtin Y et al. Effect of Detecting and Isolating Clostridium difficile Carriers at Hospital Admission on the Incidence of C difficile Infections A Quasi-Experimental Controlled Study JAMA Intern Med. 2016;176(6):796-804
      6. Волчкова Е. В., Белоусова Е. А., Макарчук П. А., Русанова Е. В., Великанов Е. В. Частота выявления инфекции Clostridium difficile в больничных условиях // Альманах клинической медицины. 2014. № 33 С. 71-76.
      7. McDonald L. Clifford, Maria Owings, and Daniel B. Jernigan. “Clostridium Difficile Infection in Patients Discharged from US Short-Stay Hospitals, 1996-2003.” Emerging Infectious Diseases 12.3 (2006): 409-415
      8. Pépin JL et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991-2003: a changing pattern disease severity. CMAJ. 2004;17:466-472.
      9. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009. Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality. [Accessed 8 January 2013.]; Statisticalbrief #124.
      10. Elixhauser A, Steiner C, Gould C. Readmissions following hospitalizations with Clostridium difficile infections, 2009. Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality. [Accessed 8 January 2013.]; Statistical brief #145.
      11. Wilcox MH et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. ClinInfectDis. 2012;55:1056-1063.
      12. Davies KA et al. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect. Dis. 14,1208-1219.
      13. Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):206-16.
      14. Cohen SH. et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Infection Control and Hospital Epidemiology; 2010; 31: 431-455
      15. Debast SB, Bauer MP, Kuijper EJ. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20 (Suppl 2):1-26.
      16. Sartelli et al. WSES guidelines for management of Clostridium difficile infection in surgical patients World Journal of Emergency Surgery (2015) 10:38
      17. Zar FA et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-307
      18. Kassam Z et al. Clostridium difficile associated risk of death score (CARDS): a novel severity score to predict mortality among hospitalised patients with C. difficile infection. Aliment Pharmacol Ther. 2016;43:725-33.
      19. Sunkesula VCK, Kundrapu S, Muganda C, Sethi AK, Donskey CJ. Does empirical Clostridium difficile infection (CDI) therapy result in false-negative CDI diagnostic test results? Clin Infect Dis. 2013;57:494-500.
      20. Rokas K, Johnson J, Beardsley J, Ohl C, Luther V, Williamson J. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection. Clin Infect Dis. 2015;61:934-41.
      21. Li R et al. Efficacy and safety of metronidazole monotherapy versus vancomycin monotherapy or combination therapy in patients with Clostridium difficile infection: a systematic review and meta-analysis. PLoS ONE. 2015;10: e0137252.
      22. Goldenberg S et al. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis. 2016;35:251-9.
      23. Biswas JS, Patel A, Otter JA, et al. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin. J Hosp Infect. 2015;90:267-70.
      24. Deshpande A, Hurless K, Cadnum JL, et al. Effect of fidaxomicin versus vancomycin on susceptibility to intestinal colonization with vancomycin-resistant enterococci and Klebsiella pneumoniae in mice. Antimicrob Agents Chemother. 2016
      25. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015 (9) 835-843
      26. Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27-37.
     


    Full text is published :
    Morozova T.E., Andrushchishina T.B., Tsarev I.L. THE INFECTION ASSOCIATED WITH CLOSTRIDIUM DIFFI CILE AS A COMPLICATION OF ANTIBIOTIC THERAPY. REVIEW OF CLINICAL GUIDELINES. Experimental and Clinical Gastroenterology Journal. 2017;142(06):112-119
    Read & Download full text

    1. Central state medical Academy” of Department for presidential Affairs of RF (Moscow, Russian Federation)

    Keywords:cardiovascular disease,antiplatelet agents,prevention of gastrointestinal bleeding

    Abstract: It is well known that in the structure of total mortality in Russia more than 57 % are cardiovascular disease (CVD). From the point of view of pathophysiology the basis of premature cardiovascular death in almost half the cases lies with atherothrombosis: the situation when the tyre is destroyed atherosclerotic plaque is formed thrombus, covering partially or totally the lumen of the vessel, and depending on the location of the lesion, the patient develops a myocardial infarction, ischemic atherothrombotic stroke, or gangrene of the lower extremities. Since the completion of the famous Framingham study, the notion of “risk factor” and therefore the concept of secondary and primary prevention of CVD. Among the drugs that have the ability to reduce CVD risk include antiplatelet agents and statins. It was during the administration of these drugs in some cases can cause serious problems.

      1. Francis K. L. et. al. Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Ulcer Bleeding. N Engl J Med. 2005; 352:238-44.
      2. Kreutz RP, Stanek EJ, Aubert R et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy. 2010 Aug;30(8):787-796.
      3. Бордин Д. С. Что следует учитывать при выборе ингибитора протонной помпы больному ГЭРБ? // Медицинский альманах. 2010. № 1(10) март. - С. 127-130.
      4. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011 Jan;89(1):65-74.
      5. Национальные рекомендации по антитромботической терапии у больных со стабильными проявлениями атеротромбоза. Кардиоваскулярная терапия и профилактика. 2009; 8(6), Приложение 6.
      6. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article: A report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002; 106: 1893-1900.
      7. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011 Jan;89(1):65-74.
      8. Ferreiro JL, Ueno M, Tomasello SD et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. Circ Cardiovasc Interv. 2011 Jun;4(3):273-279.
      9. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article: A report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002; 106: 1893-1900.
      10. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011 Jan; 89(1):65-74.
      11. Fujimori S., Takahashi Y., Gudis K. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a dou ble-blind, randomized, controlled trial evaluated by capsule endoscopy. J. Gastroenterol. 2011; 46 (1): 57-64.
      12. Tozawa K., Oshima T., Okugawa T. et al. Does Rebamipide Prevent Gastric Mucosal Injury in Patients Taking Aspirin and Clopidogrel? Dig. Dis. Sci. 2014. 59: 1671-1673.
      13. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010; 4 (3): 261-270.
      14. Mizukami K., Murakami K., Abe T. et al. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World. J. Gastroenterol. 2011; 17 (46): 5117-5122.
      15. Fujimori S., Takahashi Y., Gudis K. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a dou ble-blind, randomized, controlled trial evaluated by capsule endoscopy. J. Gastroenterol. 2011; 46 (1): 57-64.
      16. Mitsuki Miyata, Toshihiro Konagaya, Shiniti Kakumu, Takeshi Mori. Successful treatment of severe pouchitis with rebamipide refractory to antibiotics and corticosteroids: A case report. World J Gastroenterol. 2006; 12 (4): 656-658.
      17. Maron DJ, Fazio S., Linton MF. Современные перспективы применения статинов. Международный Медицинский Журнал. - 2000 год. - № 6.
      18. Корнеева О. Н., Драпкина О. М., Буеверов А. О., Ивашкин В. Т. Неалкогольная жировая болезнь печени как проявление метаболического синдрома. Клинические перспективы гастроэнтерологии, гепатологии. 2005. № 4.
      19. Ивашкин В. Т., Драпкина О. М., Шульпекова Ю. О. Диагностика и лечение неалкогольной жировой болезни печени. Рос. мед. вести. 2009. Т. XIV. № 3.
      20. Драпкина О. М., Смирин В. И., Ивашкин В. Т. Неалкогольная жировая болезнь печени - современный взгляд на проблему. Лечащий врач. 2010. № 5.
      21. Dima A., Marinescu A. G., Dima A. C. Non-alcoholic Fatty Liver Disease and the Statins Treatment. Rom. J. Intern. Med. 2012. Vol. 50, 1. P. 19-25.
      22. Kivici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003,17:13-18.
      23. Chalasani N., Aljadhey H., Kesterson J. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287-1292.
      24. Athyros V. G., Tziomalos K., Gossios T. D. et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis // Lancet. 2010. Vol. 376. P. 1916-1922.
      25. Драпкина О. М., Дуболазова Ю. В. Статины и печень: тупик или новые горизонты? РМЖ. Человек и лекарство. 2009. № 4.
      26. Argo C. K., Loria P., Caldwell S. H., Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008 Aug;48(2):662-669.
      27. Habeos I. G., Ziros P. G., Chartoumpekis D. et al. Simvastatin activates Keap1/Nrf2 signaling in rat liver. J Mol Med. 2008 Sep 2. [Epub ahead of print].
      28. Dongiovanni P., Petta S., Mannisto V. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015; 63: 705-712.
      29. Драпкина О. М., Фадеева М. В. Статины и печень. Коротко о главном. РМЖ, 2014, № 6. С. 428.
      30. Напалков Д. А. Безопасность статинов: что нужно знать практикующему врачу? Рациональная Фармакотерапия в Кардиологии 2014;10(3) 331-335.
      31. Gastroenterology: manual / ed. by F. I. Komarov, S. I. Rapoport. - M.: Medical informational agency, 2010. 864.
      32. Довженко, Л. И. Пациент с ишемической болезнью сердца и хроническим стеатогепатитом: как проводить гиполипидемическую терапию. Укр. мед. часопис. - 2007. -№ 1. - С. 1-4.
      33. Диагностика и лечение диффузных заболеваний печени / под ред. В. Т. Ивашкина, Н. Д. Ющука. - М., 2003. - 22 с.
      34. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома / под ред. И. Е. Чазовой. - М., 2009. - 32 с.
     


    Full text is published :
    Baryshnikova G.A., Chorbinskaya S.A., Kudryavtseva N.A. PREVENTION OF GASTROINTESTINAL COMPLICATIONS IN THE TREATMENT OF PATIENTS WITH CARDIAC PROFILE. Experimental and Clinical Gastroenterology Journal. 2017;142(06):120-125
    Read & Download full text

    1. Scientific research clinical pediatrician institute by Y. Veltishev (Moscow, Russian Federation)

    Keywords:microbiota,dysbacteriosis (dysbiosis),mucin layer,mucous membrane,short chain fatty acids (SCFA),probiotic

    Abstract: Saccharomyces boulardii CNCM I-745 (Saccharomyces cerevisiae HANSEN CBS 5926) - strain of yeast, used widely in clinical evidence as probiotic. It’s positive effect of immune system, pathogenic agents adsorption and toxins blocking, influence on digestive ferments had proved. As a result S. boulardii allow for microbiota development, provides mucosa caring. Additional, Saccharomyces boulardii action brings stability to microbiota for risk groups patients.

      1. Бухарин О. В., Перунова Н. Б., Иванова Е. В. Бифидофлора при ассоциативном симбиозе человека. - Екатеринбург: УрО РАН, 2014. - 211 с.
      2. Хавкин А. И. Микрофлора пищеварительного тракта. - М.: Фонд социальной педиатрии. - 2006. - 414 с.
      3. Мор М., Свидзинский А. Saccharomyces boulardii CNCM I-745 способствуют восстановлению микробиоты кишечника после дисбактериоза на фоне диареи. Клиническая и экспериментальная гастроэнтерология, 2015, № 8, с. 237-255
      4. Хавкин А. И., Комарова О. Н. Нарушение микробиоценоза кишечника у детей. Пособие для врачей. М: РНИМУ. - 2016. - 48 с.
      5. Хавкин А. И., Комарова О. Н. Эффективность поликомпонентных пробиотических препаратов, включающих штаммы Lactobacillus Acidophilus LA - 14, Lactobacillus reuteri и Bifidobacterium lactis при функциональных нарушениях пищеварения у детей раннего возраста: результаты проспективного, открытого, наблюдательного исследования. Экспериментальная и клиническая гастроэнтерология, 2017, выпуск 141, № 5, с. 57-64
      6. Бухарин О. В. Инфекционная симбиология - новое понимание старых проблем//Вестник Российской академии наук. - 2016. - Т. 86. - № 10. - С. 915-920
      7. Kuwahara A. Contributions of colonic short-chain fatty acid receptors in energy homeostasis. Front Endocrinol. 2014; 5:144.
      8. Abreu M. T. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010;10(2):131-144.
      9. Kim Y. S., Ho S. B. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep. 2010; 12(5): 319-330.
      10. O’Keefe S. J., Ou J., Delany J. P. et al. Effect of fiber supplementation on the microbiota in critically ill patients. World J Gastrointest Pathophysiol. 2011; 2(6):138-145.
      11. Voth D. E., Ballard J. D. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18(2):247-263.
      12. Kimura I., Ozawa K., Inoue D. et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR 43. Nat Commun. 2013;4:1829.
      13. MacKenzie D. A., Defernez M., Dunn W. B. et al. Relatedness of medically important strains of Saccharomyces cerevisiae as revealed by phylogenetics and metabolomics. Yeast. 2008; 25(7): 501-512.
      14. Barc M. C., Charrin-Sarnel C., Rochet V. et al. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: influence of Saccharomyces boulardii. Anaerobe. 2008; 14(4): 229-233.
      15. Graff S., Chaumeil J. C., Boy P., Lai-Kuen R., Charrueau C. Influence of pH conditions on the viability of Saccharomyces boulardii yeast. J Gen Appl Microbiol. 2008; 54(4): 221-227
      16. McFarland L. V. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. BMJ Open. 2014; 4(8): e005047.
      17. Kelesidis T., Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Ther Adv Gastroenterol. 2012; 5(2): 111-125.
      18. Barreto-Bergter E., Figueiredo R. T. Fungal glycans and the innate immune recognition. Front Cell Infect Microbiol. 2014; 4:145.
      19. Samuelsen A. B., Schrezenmeir J., Knutsen S. H. Effects of orally administered yeast-derived β-glucans: a review. Mol Nutr Food Res. 2014; 58(1): 183-193.
      20. Vannucci L., Krizan J., Sima P. et al. Immunostimulatory properties and antitumor activities of glucans (Review). Int J Oncol. 2013; 43(2):357-364.
      21. Goodridge H. S., Reyes C. N., Becker C. A. et al. Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse’. Nature. 2011;472(7344):471-475.
      22. Buccigrossi V., Laudiero G., Russo C. et al. Chloride secretion induced by rotavirus is oxidative stress-dependent and inhibited by Saccharomyces boulardii in human enterocytes. PLoS One. 2014;9(6): e99830.
      23. Oeztuerk H., Schroeder B., Beyerbach M., Breves G. Influence of living and autoclaved yeasts of Saccharomyces boulardii on in vitro ruminal microbial metabolism. J Dairy Sci. 2005; 88(7): 2594-2600.
      24. Buts J. P., De Keyser N., Marandi S. et al. Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut. 1999; 45(1): 89-96.
      25. Czerucka D., Piche T., Rampal P. Review article: yeast as probiotics - Saccharomyces boulardii. Aliment Pharmacol Ther. 2007; 26(6): 767-778.
      26. Buts J. P., Dekeyser N., Stilmant C., Delem E., Smets F., Sokal E. Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr Res. 2006; 60(1): 24-29.
      27. Tiago F. C., Martins F. S., Souza E. L. et al. Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probiotics. J Med Microbiol. 2012; 61(Pt 9): 1194-1207.
      28. Martins F. S., Dalmasso G., Arantes R. M. et al. Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection. PLoS One. 2010; 5(1): e8925.
      29. Gedek B. R. Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses. 1999; 42(4): 261-264.
      30. Zbinden R., Gonczi E.-E., Altwegg M. Inhibition of Saccharomyces boulardii (nom. inval.) on cell invasion of Salmonella typhimurium and Yersinia enterocolitica. Microb Ecol Health Dis. 2011; 11(3). ISSN 1651-2235.
      31. Ducluzeau R., Bensaada M. [Comparative effect of a single or continuous administration of “Saccharomyces boulardii” on the establishment of various strains of “candida” in the digestive tract of gnotobiotic mice]. Ann Microbiol. 1982; 133(3): 491-501. French.
      32. Kamada N., Chen G. Y., Inohara N., Nunez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013;14(7): 685-690.
      33. Everard A., Matamoros S., Geurts L., Delzenne N. M., Cani P. D. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. MBio. 2014; 5(3): e01011-e01014.
      34. Vanhoutte T., De Preter V., De Brandt E., Verbeke K., Swings J., Huys G. Molecular monitoring of the fecal microbiota of healthy human subjects during administration of lactulose and Saccharomyces boulardii. Appl Environ Microbiol. 2006; 72(9): 5990-5997.
      35. Osowska S., Swidsinski A., Kulik Z., Lawinski M., Pertkiewicz M. Impact of saccharomyces boulardii on colonic microbiota and plasma lactate in short bowel syndrome patients on long term parenteral nutrition.Dig Dis Week. 2013; 144(5): s895.
      36. Swidsinski A., Loening-Baucke V., Swidsinski S. Saccharomyces boulardii prevents the antibiotic induced changes in colonic microbiota. Gastroenterology. 2013; 144 (5 Suppl 1): S-824.
      37. Chen S. J., Liu X. W., Liu J. P., Yang X. Y., Lu F. G. Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier. World J Gastroenterol. 2014; 20(28): 9468-9475.
      38. Yutin N., Galperin M. Y. A genomic update on clostridial phylogeny: Gram-negative spore formers and other misplaced clostridia. Environ Microbiol. 2013; 15(10): 2631-2641.
      39. Vital M., Howe A. C., Tiedje J. M. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. MBio. 2014; 5(2): e00889. NCBI Taxomomy Browser. Taxomomy Browser. Available from: http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi. Accessed July 2, 2015.
      40. Kabeerdoss J., Sankaran V., Pugazhendhi S., Ramakrishna B. S. Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India. BMC Gastroenterol. 2013;13:20.
      41. Sokol H., Pigneur B., Watterlot L. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008; 105(43): 16731-16736.
      42. Qiu X., Zhang M., Yang X., Hong N., Yu C. Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J Crohns Colitis. 2013; 7(11): e558-e568
      43. Swidsinski A., Loening-Baucke V., Kruger M., Kirsch S. Central nervous system and the colonic bioreactor: analysis of colonic microbiota in patients with stroke unravels unknown mechanisms of the host defense after brain injury. Intest Res. 2012; 10(4): 332-342.
      44. Staib L., Fuchs T. M. From food to cell: nutrient exploitation strategies of enteropathogens. Microbiology. 2014; 160(Pt 6): 1020-1039.
      45. Dubourg G., Lagier J. C., Armougom F. et al. High-level colonisation of the human gut by Verrucomicrobia following broad-spectrum antibiotic treatment. Int J Antimicrob Agents. 2013; 41(2): 149-155.
      46. Bradlow H. L. Obesity and the gut microbiome: pathophysiological aspects. Hormone Mol Biol Clin Invest. 2014; 17(1): 53-61
     


    Full text is published :
    Khavkin A.I., Komarova O.N. SACCHAROMYCES BOULARDII INFL UENCE OVER HUMAN MICROBIOTA. Literature review. Experimental and Clinical Gastroenterology Journal. 2017;142(06):126-132
    Read & Download full text

    1. Scientific research clinical pediatrician institute by Y. Veltishev (Moscow, Russian Federation)

    Keywords:breakfast,cereal,cognitive developmentsleep disturbance,whole grains

    Abstract: Grain-based products are widely used in nutrition throughout the life of a person, beginning with early childhood. When choosing the first type of complementary foods, priority is given to the cereal, since it has a high energy value and enriches the diet of the baby with vegetable proteins, fats, carbohydrates and other important biologically active compounds. Thus, it has been shown, during the period of active growth and development of the brain, hypoglycemic conditions that can lead to disruption of its functioning are unacceptable. To maintain normoglycemia, especially after an overnight fast, consumption of breakfast, including dishes from cereals, is important. This is important for the maturation of the brain in children and has a long-term effect on cognitive development. Cereals, rich in tryptophan, can be useful for correcting the sleep-wake cycle in children, middle-aged and elderly people, and also having a positive effect on mood. In addition, the consumption of whole grains reduces the risk of cardiovascular diseases, diabetes, obesity and colon cancer in adult patients.

      1. Национальная программа оптимизации вскармливания детей первого года жизни в Российской Федерации. Москва. Союз педиатров России. - 2011. - 68 с.
      2. Okarter N, Liu RH. Health benefits of whole grain phytochemicals. Crit Rev Food Sci Nutr 2010;50:193-208
      3. Digesù A. M., Platani C., Cattivelli L., Mangini G., Blanco A. Genetic variability in yellow pigment components in cultivated and wild tetraploid wheats. J. Cereal Sci. 2009;50:210-218.
      4. Okarter N, Liu RH. Health benefits of whole grain phytochemicals. Crit Rev Food Sci Nutr 2010; 50:193-208
      5. Adom KK, Sorrells ME, Liu RH. Phytochemicals and antioxidant activity of milled fractions of different wheat varieties. J Agric Food Chem 2005;53:2297-306
      6. Borrelli G. M., De Leonardis A. M., Platani C., Troccoli A. Distribution along durum wheat kernel of the components involved in semolina colour. J. Cereal Sci. 2008;48:494-502.
      7. Abdel-Aal E.M.S., Young J. C., Rabalski I., Hucl P., Fregeau-Reid J. Identification and quantification of seed carotenoids in selected wheat species. J. Agric. Food Chem. 2007;55:787-794.
      8. Yeum K. J., Russell R. M. Carotenoid bioavailability and bioconversion. Annu. Rev. Nutr. 2002;22:483-504.
      9. Del Pozo-Insfran D., Brenes C. H., Serna Saldivar S. O., Talcott S. T. Polyphenolic and antioxidant content of white and blue corn (Zea mays L.) products. Food Res. Int. 2006;39:696-703.
      10. Žofajová A., Pšenáková I., Havrlentová M., Piliarová M. Accumulation of total anthocyanins in wheat grain. Agricolture. 2012;58:50-56.
      11. Ficco D. B.M., de Simone V., Colecchia S. A., Pecorella I., Platani C., Nigro F., Finocchiaro F., Papa R., de Vita P. Genetic variability in anthocyanin composition and nutritional properties of blue, purple, and red bread (Triticum aestivum L.) and durum (Triticum turgidum L. ssp. turgidum convar. durum) wheats. J. Agric. Food Chem. 2014;62:8686-8695.
      12. Ranilla L. G., Genovese M. I., Lajolo F. M. Polyphenols and antioxidant capacity of seed coat and cotyledon from Brazilian and Peruvian bean cultivars (Phaseolus vulgaris L.) J. Agric. Food Chem. 2007;55:90-98.
      13. Azuma A., Yakushiji H., Koshita Y., Kobayashi S. Flavonoid biosynthesis-related genes in grape skin are differentially regulated by temperature and light conditions. Planta. 2012;236:1067-1080.
      14. Chen C., Li H., Zhang D., Li P., Ma F. The role of anthocyanin in photoprotection and its relationship with the xanthophyll cycle and the antioxidant system in apple peel depends on the light conditions. Physiol. Plant. 2013;49:354-366.
      15. Shipp J., Abdel-Aal E.-S. Food applications and physiological effects of anthocyanins as functional food ingredients. Open Food Sci. J. 2010;4:7-22.
      16. Bowen-Forbes C.S., Zhang Y., Nair M. G. Anthocyanin content, antioxidant, anti-inflammatory and anticancer properties of blackberry and raspberry fruits. J. Food Compos. Anal. 2010;23:554-560.
      17. Wang L. S., Stoner G. D. Anthocyanins and their role in cancer prevention. Cancer Lett. 2008;269:281-290.
      18. Ghosh D., Konishi T. Anthocyanins and anthocyanin-rich extracts: Role in diabetes and eye function. Asia Pac. J. Clin. Nutr. 2007;16:200-208
      19. De Pascual-Teresa S., Moreno D. A., Darcia-Viguera C. Flavanols and anthocyanins in cardiovascular health. Int. J. Mol. Sci. 2010;11:1679-1703.
      20. Liu RH. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr2004;134: S 3479-85.
      21. Smith MM, Hartley RD. Occurrence and nature of ferulic acid substitution of cell wall polysaccharides in gramineous plants. Carbohydr Res 1983;118:65-80
      22. Klepacka J, Fornal Ł. Ferulic acid and its position among the phenolic compounds of wheat. Crit Rev Food Sci Nutr. 2006;46:639-47
      23. Andreasen MF, Kroon PA, Williamson G, Garcia-Conesa MT. Intestinal release and uptake of phenolic antioxidant diferulic acids. Free Radic Biol Med. 2001;31:304-314.
      24. Adom KK, Liu RH. Antioxidant activity of grains. J Agric Food Chem 2002;50:6182-7
      25. Cordain L., Eaton S. B., Sebastian A., Mann N., Lindeberg S., Watkins B. A., O’Keefe J.H., Brand-Miller J. Origins and evolution of the Western diet: Health implications for the 21st century. Am. J. Clin. Nutr. 2005;81:341-354
      26. Bett-Garber K.L., Lea J. M., Champagne E. T., McClung A. M. Whole-grain rice flavor associated with assorted bran colors. J. Sens. Stud. 2012;27:78-86.
      27. Okarter N., Liu R. H. Health benefits of whole grain phytochemicals. Crit. Rev. Food Sci. Nutr. 2010;50:193-208.
      28. Slavin J. Whole grains and digestive health. Cereal Chem. 2010;87:292-296.
      29. Adom KK, Sorrells ME, Liu RH. Phytochemicals and antioxidant activity of milled fractions of different wheat varieties. J Agric Food Chem 2005;53:2297-306
      30. World Health Organization. Global Strategy on Diet, Physical Activity and Health Worldwide Strategy about “Feeding Regimen, Physical Activity and Health”.
      31. World Health Organization; Washington, DC, USA: 2004.
      32. Alexy U., Zorn C., Kersting M. Whole grain in children’s diet: Intake, food sources and trends. Eur. J. Clin. Nutr. 2010;64:745-751
      33. Fardet A. New hypotheses for the health-protective mechanisms of whole-grain cereals: What is beyond fibre? Nutr. Res. Rev. 2010;23:65-134
      34. Ma X., Tang W. G., Yang Y., Zhang Q. L., Zheng J. L., Xiang Y. B. Association between whole grain intake and all-cause mortality: a meta-analysis of cohort studies. Oncotarget. 2016;7:61996-62005
      35. Slavin J., Tucker M., Harriman C., Jonnalagadda S. S. Whole grains: Definition, dietary recommendations, and health benefits. Cereal Chem. 2016;93:209-216
      36. Ferruzzi M. G., Jonnalagadda S. S., Liu S., Marquart L., McKeown N., Reicks M., Riccardi G., Seal C., Slavin J., Thielecke F., et al. Developing a standard definition of whole-grain foods for dietary recommendations: Summary report of a multidisciplinary expert roundtable discussion. Adv. Nutr. 2014;5:164-176
      37. Signes-Pastor A., Carey M., Meharg A. A. Inorganic arsenic in rice-based products for infants and young children. Food Chem. 2016;191:128-134
      38. WHO. (2008). Worldwide Prevalence of Anaemia 1993-2005: WHO Global Database on Anaemiaeds de Benoist B., McLean E., Egli I., Cogswell M., editors. (Geneva: World Health Organization Press)
      39. Wessells K. R., Brown K. H. (2012). Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting. PLoS ONE 7: e5056810.
      40. Slavin J. L. Whole grains, refined grains and fortified refined grains: What’s the difference? Asia Pac. J. Clin. Nutr. 2000;9: S 23-S 27
      41. Eichler K, Wieser S, Rüthemann I, Brügger I. Effects of micronutrient fortified milk and cereal food for infants and children: a systematic reviewBMC Public Health. 2012; 12: 506
      42. Санитарно-эпидемиологические правила и нормативы 2.3.2.1940-05.
      43. Bubenik GA, Konturek SJ. Melatonin and aging: prospects for human treatment. J Physiol Pharmacol. 2011;62(1):13-19
      44. Cubero J, Narciso D, Terrón MP, Rial R, Esteban S, Rivero M, Parvez H, Rodríguez AB, Barriga C. Chrononutrition applied to formula milks to consolidate infants’ sleep/wake cycle. Neuroendocrinol Lett. 2007;28(4):360-366
      45. Sánchez S, Sánchez CL, Paredes SD, Barriga C, Rodríguez AB. Circadian levels of serotonin in plasma and brain after oral administration of tryptophan in rats. Basic Clin Pharmacol. 2008; 104:52-59
      46. Cubero J, Chanclón B, Sánchez S, Rivero M, Rodríguez AB, Barriga C (2009) Improving the quality of infant sleep through the conclusion at supper of cereals enriched with tryptophan, adenosine-5'-phosphate, and uridine-5'-phosphate. Nutr Neurosci
      47. Porter RJ, Mulder RT, Joyce PR, Luty SE. Trytophan and tyrosine availability and response to antidepressant in major depression. J Affect Disord. 2005
      48. Hussain AM, Mitra AK. Effect of reactive oxygen species on the metabolism of tryptophan in rat brain: influence of age. Mol Cell Biochem. 2004
      49. Cubero J, Otalora BB, Bravo R, Sánchez CL, Franco L, Uguz AC, Rodríguez AB, Barriga C. Distribution of 5-HT receptors in the mammalian brain. Trends Cell Mol Biol. 2011;6:41-46
      50. Bravo R., Matito S.,. Cubero J, Paredes S. D., Franco L., Rivero M., Rodríguez A. B., Barriga C. Tryptophan-enriched cereal intake improves nocturnal sleep, melatonin, serotonin, and total antioxidant capacity levels and mood in elderly humans. Age (Dordr). 2013 Aug; 35(4): 1277-1285
      51. Chugani HT. A critical period of brain development: studies of cerebral glucose utilization with PET. Prev Med. 1998;27:184-8
      52. Huttenlocher PR, Dabholkar AS. Regional differences in synaptogenesis in human cerebral cortex. J Comp Neurol. 1997; 387:167-78
      53. Mata M, Fink DJ, Gainer H, Smith CB, Davidsen L, et al. Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J Neurochem. 1980;34:213-5
      54. Bellisle F. (2004). Effects of diet on behaviour and cognition in children. Br. J. Nutr. 92, S 227-S 232 10.1079/BJN 20041171.
      55. Donin AS, Nightingale CM, Owen CG, Rudnicka AR, Perkin MR, Jebb SA, Stephen AM, Sattar N, Cook DG, Whincup PH. Regular Breakfast Consumption and Type 2 Diabetes Risk Markers in 9- to 10-Year-Old Children in the Child Heart and Health Study in England (CHASE): A Cross-Sectional Analysis.PLoS Med. 2014 Sep; 11(9): e1001703].
      56. Theodore R. F., Thompson J. M. D., Waldie K. E., Wall C., Becroft D. M. O., Robinson E., et al. (2009). Dietary patterns and intelligence in early and middle childhood. Intelligence 37, 506-513.
      57. Taki Y, Hashizume H, Sassa Y, Takeuchi H, Asano M, Asano K, Kawashima R. Breakfast Staple Types Affect Brain Gray Matter Volume and Cognitive Function in Healthy Children. PLoS One. 2010; 5(12): e15213.
      58. Foster-Powell K, Holt SH, Brand-Miller JC. International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr. 2002;76:5-56
      59. Edefonti V, Rosato V, Parpinel M, Nebbia G, Fiorica L, Fossali E, Ferraroni M, Decarli A, Agostoni C. The effect of breakfast composition and energy contribution on cognitive and academic performance: a systematic review.Am J Clin Nutr. 2014 Aug;100(2):626-56].
     


    Full text is published :
    Komarova O.N., Khavkin A.I. PRODUCTS ON CEREAL-BASED DIET IN ADULT AND CHILD: WHAT’S NEW?. Experimental and Clinical Gastroenterology Journal. 2017;142(06):133-140
    Read & Download full text

    1. “Smolensk state medical University” Ministry of healthcare of the Russian Federation (Smolensk, Russian Federation)

    Keywords:chronic erosive gastritis,herpes virus,Helicobacter pylori,cycloferon

    Abstract: The article considers expediency of application of cycloferon in patients with chronic erosive gastritis, associated with Helicobacter pylori and herpes infection.

      1. Литовский И. А., Гордиенко А. В., Ефимов Н. В., Ивашкина Т. Г. Хронический гастрит (дискуссионные вопросы патогенеза, клиники, лечения). Часть 1. Новые Санкт-Петербургские врачебные ведомости. 2016, том 75, № 1, С. 25-35.
      2. Цуканов В. В., Васютин А. В., Тонких Ю. Л., Бичурина Т. Б. Современные аспекты ведения пациентов с гастритом. Фарматека. 2014, № 6, С. 60-63.
      3. Казюлин А. Н., Парцвиниа-Виноградова Е.В., Дичева Д.Т и соавт. Оптимизация антихеликобактерной терапии в современной клинической практике. Consilium medicum. 2016, том 18, С. 32-36.
      4. Чупрынова М. Ю., Потрохова Е. А. Эксхеликобактерный гастрит у детей: возможные механизмы развития. Клинические перспективы гастроэнтерологии, гепатологии. 2014, № 1, С. 26-30.
      5. Крулевский В. А., Петровский А. Н., Аничков Н. М., Новикова В. П. Хронический гастрит и герпетические инфекции у лиц разного возраста. Архив патологии. 2010, № 1, С. 33-35.
      6. Исаков В. А., Архипова Е. И., Исаков Д. К. Герпесвирус инфекция человека. //Руководство для врачей. - СПб.: Спец Лит., 2006. С. 303.
      7. Гомберг М. А., Соловье А. М. Алгоритмы диагностики и лечения наиболее распространенных инфекций, передаваемых половым путем. Трудный пациент. 2004, том 2, № 5, С. 3-5.
      8. Исаков В. А., Рыбалкин С. Б., Романное М. Г. Герпес вирус инфекция. //Рекомендации для врачей. - СПб.: Спец Лит., 2006. С. 96.
      9. Leung D. T., Sacks S. L. Current recommendation ary for the treatment of genital herpes. Drags 2000, vol. 60, no. 6, Р. 1329-1352.
      10. Малашенкова И. К., Дидковский И. А., Девко А. А. К вопросу о роли индивидуального подбора иммунокорректоров. Фарматека. 2004, С. 118-122.
      11. Бажоиово Е. Л. Циклоферон: механизм действия, функции и применение. Экспериментальная клиническая фармакология. 2012, том 75, № 7, С. 40-44.
      12. Исаков В. А., Ермоленко Д. К., Исаков Д. В. Перспективы профилактики и лечения простого герпеса с монотонным типом. Тер. Архив. 2011, том 83, С. 40-44.
      13. MalfertheinerP., MegraudF., O`MorainC. et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report // Gut. - 2007. - Vol. 56, N 6. - P. 772-781
      14. Исаков В. А. Диагностика и лечение инфекции, вызванной Helicobacter pylori: IV Маастрихтское соглашение. Новые рекомендации по диагностике и лечению инфекции H. pylori - Маастрихт IV (Флоренция). Best Clinical Practice. Русское издание. 2012, Вып. 2, с. 4-23.
      15. Ивашкин В. Т., Маев И. В., Лапина Т. Л., Шептулин А. А. Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению инфекции Helicobacter рylori у взрослых. Российский журнал гастроэнтерологии, колопроктологии и гепатологии. 2012, № 1, с. 87-89.
     


    Full text is published :
    Afanasenkova T.E., Dubskaya E.E., Russianow V.V. THE USE OF INTERFERON IN TREATMENT OF PATIENTS WITH CHRONIC EROSIVE GASTRITIS, ASSOCIATED WITH HELICOBACTER PYLORI AND HERPES INFECTION. Experimental and Clinical Gastroenterology Journal. 2017;142(06):141-144
    Read & Download full text

    1. SPb GBUZ children’s hospital No. 4 (St. Petersburg, Russian Federation)
    2. North-Western State Medical University named after I. I. Mechnikov (St. Petersburg, Russian Federation)
    3. Scientific Research Institute of Children's Infections (St. Petersburg, Russian Federation)
    4. St. Petersburg State Pediatric Medical University (St. Petersburg, Russian Federation)

    Abstract: The aim of this work was the demonstration of a clinical case of complications during cystic fibrosis with the development of the syndrome of pseudo-Bartter reflecting the difficulties of differential diagnosis of the disease. Presents a clinical case of late diagnosis of a severe form of cystic fibrosis have an infant with clinical manifestations of congenital herpes virus infection.

      1. Муковисцидоз. Н. И. Капранов, Н. Ю. Каширская (ред). М.: ИД «МЕДПРАКТИКА-М», 2014.
      2. Гончар Н. В., Валетова Л. Г. Случай диагностики легочно-кишечной формы муковисцидоза при первом эпизоде бронхиальной обструкции. Гастроэнтерология Санкт-Петербурга. 2012; № 2-3: М20.
      3. De Oronzo M. A. Hyperechogenic fetal bowel: an ultrasonographic marker for adverse fetal and neonatal outcome? J. Prenat. Med. 2011. Jan-Mar; 5(1): 9-13.
      4. Бойцова Е. В., Гембицкая Т. Е., Иващенко Т. Э. и соавт. Генотипические особенности и фенотипические проявления муковисцидоза у больных Ленинградской области. Педиатрия. 2015; Т. 94 (№ 1): 58-62.
      5. Воронкова А. Ю., Шерман В. Д. Случай поздней диагностики псевдо-Барттера синдрома у ребенка 6 месяцев с муковисцидозом. Педиатрия. 2014; Т. 93 (№ 4): 172-174.
      6. Marah M. A. Pseudo-Bartter as an initial presentation of cystic fibrosis. A case report and review of the literature. East. Mediter. Health J. 2010; Vol. 16 (6): 699-701.
      7. Муковисцидоз. Современные достижения и актуальные проблемы: Методические рекомендации. 4-е изд. Н. И. Капранов, Н. Ю. Каширская (ред.). М.: ИД «МЕДПРАКТИКА-М», 2011.
      8. Kintu B., Brightwell A. Episodic seasonal Pseudo-Bartter syndrome in systic fibrosis. Paed. Resp. Rev. 2014; V. 15 (Suppl. 1): 19-21.
      9. Sinaasappel M., Stern M., Littlewood J. et al. Nutrition in patients with cystic fibrosis: a European Consensus. J. Cyst. Fibr. 2002; V.1: 51-75.
      10. Васильев В. В. Клинические рекомендации по диагностике и лечению врожденных инфекций центральной нервной системы. В кн.: В. В. Васильев, Н. В. Скрипченко, В. И. Гузева. Детская неврология, вып. 3: клинические рекомендации. М.: ООО «МК», 2015.
      11. Masekela R., Zampoli M., Westwood A. T. et al. Phenotypic expression of the 3120+1G>A mutation in non-Caucasian children with cystic fibrosis in South Africa. J. Cyst. Fibr. 2013; V. 12 (Issue 4): 363-366.
      12. Kianifar H.-R., Talebi S., Khazaei M. et al. Predisposing factors for nephrolithiasis and nephrocalcinosis in cystic fibrosis. Iran J. Pediatr. 2011; 21(1): 65-71.
     


    Full text is published :
    Borisenko T.S., Gonchar N.V., Orlov A.V., Konev A.I. LATE DIAGNOSIS OF A SEVERE FORM OF CYSTIC FI BROSIS IN AN INFANT WITH CONGENITAL HERPES VIRUS INFECTION. Experimental and Clinical Gastroenterology Journal. 2017;142(06):145-149
    Read & Download full text

    1. Perm State Medical University. Acad. E. A. Wagner (Perm, Russian Federation)
    2. Perm National Research Polytechnic University (Perm, Russian Federation)

    Keywords:Obstructive jaundice,pathological physiology,intraoperative cholangiography,hepatocyte,hyperbilirubinemia,percutaneous transhepatic cholangiography

    Abstract: The purpose of the study. To present the history of differential diagnosis of jaundice in the Perm region. Materials and methods. The study used narrative, historical-genetic, comparative and structural methods. Results. The number of patients with diseases of the liver and biliary tract, manifested by obstructive jaundice syndrome is steadily increasing. Indirect methods of contrast enhancement turned out to be untenable in the presence of hypertension in the biliary tract. Direct opacification of the biliary tract originally performed by intraoperative cholangiography via the cystic duct stump. The method of percutaneous transhepatic cholangiography (transparietal cholangiography), promoted in the 60-ies of the several hospitals of the Soviet Union, is not widely spread due to the lack of imaging punchthrough ducts. Head of Department of hospital surgery, Perm medical Institute Professor S. Y. Minkin on 27m all-Union Congress of surgeons in 1960 first reported cholestatic jaundice without mechanical barriers to the outflow of bile. The use of electron microscopy made it possible to develop universally accepted diagram of the structure of the biliary tract. On the basis of the pathogenetic classification of Professor E. N. Ter-Grigorova algorithm of differential diagnosis, which can be used for computer calculation of the characteristics manually, or simply in the form of visual diagrams (L. F. Pulatova, 1977). In order to diagnose the functional state of the liver was applied isotope hepatography. Significantly advanced diagnosis using endoscopic techniques, laparoscopic cholecystocholangiography, endoscopic retrograde cholangiopancreatography. Distal levels of obstruction of the biliary tract were identified using the relaxation of duodenography, ultrasound and endomicroscope research. Computer and magnetic resonance imaging, especially magnetic resonance-cholangiography has virtually solved the problem. Invasive methods are mainly used for diabeticheskoi techniques, the research also serves as the first stage of surgical treatment for relief of biliary tree and the elimination of biliary hypertension. Advances in diagnosis have led to the progress in surgical treatment. If in the middle of the twentieth century, the most frequent operation was palliative cholecystojejunostomy, and high tumor - tunnelization of the tumor, it is now in daily clinical practice included pancreatoduodenectomy, liver resection for tumors of the gate as a portal, and navalnyj. Wide application of mini-invasive methods (endoscopic cholangiopancreatography, percutaneous transhepatic cholangiography, mini-accesses, puncture under ultrasound control) allows to reduce operational risk and prevent the development or progression of liver failure, which greatly improves treatment results Conclusion. Evolution of morphological and clinical methods for differential diagnosis of jaundice has enabled the optimization of surgical tactics, which currently contains a whole spectrum of interventions, from minimally invasive diabeticheskoi methods to extensive radical surgery.

      1. Бетшев П. С. Механическая желтуха: причины и диагностические подходы (лекция) /Анналы хирургической гепатологии, 2011, том 16, № 3, с. 50-57
      2. Гальперин Э. И. Диагностика и лечение больных механической желтухой/Советская медицина, 1972, № 8. С. 46-51
      3. Гальперин Э. И., Момунова О. Н. Классификация тяжести механической желтухи/Хирургия, 2014, № 1, с. 5-9
      4. Котельникова Л. П. Состояние печени и желчных путей в оценке хирургической тактики при желчнокаменной болезни /автореф. Докт дисс., Пермь, 1995
      5. Майстренко Н. А. Стукалов В. В., Прядко А. С. и др. Диагностика и лечение синдрома механической желтухи доброкачественного генеза /Анналы хирургической гепатологии, 2011, том 16, № 3, с. 26-34
      6. Мансурова И. Д. Биохимия печени больных гепатитами и циррозом/Автореф. Дисс. Докт., Душанбе, 1966.
      7. Натальский А. А. Современные принципы диагностики и лечения синдрома механической желтухи /автореф. Докт. Дисс., Рязань, 2015
      8. Палатова Л. Ф. Хирургические заболевания желчных путей, сопровождающиеся желтухой, их взаимосвязь с патологией печени /автореф. Докт. Дисс., Пермь, 1977.
      9. Савельев В. С., Кириенко А. И. Клиническая хирургия. / Национальное руководство, том 2, 2008.
      10. Семендяева М. Е. Холангиолитический гепатит / Советская медицина, 1961, № 5, с. 52-60
      11. Смирнов Е. В. К хирургическому лечению обтурационной желтухи/Советская медицина, 1972, № 8, с. 62-66
      12. Тер-Григорова Е.Н., Тер-Григоров В. С. Врожденный вирусный гепатит / М. Медицина, 1967
      13. Шерлок Ш. Заболевания печени и желчных путей/ Ш. Шерлок, Дж. Дули, М. Гэотар-Медицина, 1999.
     


    Full text is published :
    Palatova L.F., Nechaev O.I. EVOLUTION PROBLEMS OF DIFF ERENTIAL DIAGNOSIS OF JAUNDICE IN THE WESTERN URALS. Experimental and Clinical Gastroenterology Journal. 2017;142(06):150-154
    Read & Download full text

    1. North-Western State Medical University named after I. I. Mechnikov (St. Petersburg, Russian Federation)

    Abstract: The report about The XVII Congress of the Scientific Society of Gastroenterology of Russia and the 19th International Slavic-Baltic Scientific Forum "St. Petersburg - Gastro-2017". About 2000 delegates from more than 20 countries of the world took part in the work of the Congress, the scientific program of which covered a wide range of issues of diagnosis, treatment, and prevention of the most important diseases of the digestive organs and associated pathology.

     


    Full text is published :
    Sitkin S.I. REPORT ON THE WORK OF THE XVII GSSR CONGRESS. Experimental and Clinical Gastroenterology Journal. 2017;142(06):155-156
    Read & Download full text

      1. State budgetary institution of Moscow city “The Moscow clinical research center of the Department of Health” (Moscow, Russian Federation)

      Abstract: Famous physician - gastroenterologist Professor, Doctor of Medical Sciences work at the Central Research Institute of Gastroenterology since August 1968, three years after the graduation of the 2nd Moscow State Medical Institute n.a. N.I. Pirogov. It was the time of birth of a new, little-known method of endoscopic examination of the upper sections of the digestive tract, which later became the basic procedure of diagnostic search. Yury Vasilyevich was among the first in the country who mastered this technique and transferred it to the younger generation. The article is in Russian. L.Yu. Firsova, PhD, MD

       


      Full text is published :
      Firsova L.D. IN MEMORY OF YURI VASILEV. Experimental and Clinical Gastroenterology Journal. 2017;142(06):157-158
      Read & Download full text